nctid,status,why_stop,label,phase,diseases,icdcodes,drugs,smiless,criteria
NCT00561418,completed,,1,phase 1,"['lymphoma', 'small intestine cancer']","[""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['C17.9', 'C78.4', 'D37.2', 'C17.8', 'D13.30', 'D13.39', 'Z12.13']""]",['vorinostat'],['Status: 503'],"
        DISEASE CHARACTERISTICS:

          -  Must have received a BEAM (cytarabine, etoposide, melphalan, carmustine)-conditioned
             autologous stem cell transplantation for any of the following high-risk lymphomas:

               -  Diffuse large B-cell lymphoma as defined by:

                    -  Induction failure but with response to salvage therapy

                    -  Relapse less than one year after completion of induction therapy

                    -  Elevated lactate dehydrogenase (LDH) at relapse

                    -  Stage III/IV disease at relapse

                    -  Positive PET scan after induction or salvage therapy

                    -  Age ≤ 75 and ≥ 60 years

               -  Follicular lymphoma as defined by:

                    -  Progressive disease after two or more prior regimens

                    -  Transformed to aggressive lymphoma but still chemotherapy sensitive

                    -  Not felt to be a good candidate for an allogeneic transplantation

               -  Hodgkin lymphoma as defined by:

                    -  Primary refractory disease

                    -  Relapse less than one year after completion of induction therapy

                    -  Relapse with PET-positive disease after salvage therapy

                    -  Relapsed refractory and not felt to be a good candidate for an allogeneic
                       transplantation

               -  Mantle cell lymphoma

                    -  Chemotherapy-sensitive disease after induction therapy

                    -  Chemotherapy-sensitive relapsed disease and not felt to be a good candidate
                       for an allogeneic transplantation

               -  T-cell non-Hodgkin lymphoma (NHL)

                    -  Peripheral T-cell lymphoma not otherwise specified and one or more of the
                       following at diagnosis:

                         -  High LDH

                         -  Marrow involvement

                         -  Age > 60 years

                         -  Low platelet count

                         -  Relapsed chemotherapy-sensitive disease

                    -  Angioimmunoblastic lymphadenopathy with dysproteinemia

                    -  Anaplastic lymphoma kinase-negative anaplastic NHL

                    -  Enteropathy-associated T-cell NHL

                    -  Natural killer (NK)/T-cell NHL and stage III/IV disease at diagnosis

                    -  NK blastic NHL

        PATIENT CHARACTERISTICS:

          -  ECOG (Eastern Cooperative Oncology Group) /WHO performance status 0-2

          -  ANC (absolute neutrophil count) ≥ 1,000/μL

          -  Platelet count ≥ 75,000/μL

          -  Total bilirubin ≤ 1.5 mg/dL

          -  AST (aspartate aminotransferase)/ALT (Alanine transaminase) ≤ 2 x upper limit of
             normal (ULN)

          -  Serum creatinine ≤ 1.5 x ULN OR creatinine clearance ≥ 50 mL/min

          -  No severe or uncontrolled systemic illness

          -  Patients must be able to swallow capsules

          -  Negative pregnancy test

          -  Not pregnant or nursing

          -  Fertile patients must use at least two adequate barrier methods of contraception
             during study and for 90 days after completion of study therapy

          -  No other malignancy within the past 5 years other than nonmelanoma skin cancer,
             carcinoma in situ of the cervix, or a malignancy considered by their physician to be
             at less than 30% risk of relapse

          -  No congenital long QT syndrome

          -  No significant history of uncontrolled cardiac disease (i.e., uncontrolled
             hypertension, unstable angina, myocardial infarction within the past 6 months, or
             uncontrolled congestive heart failure)

          -  No active bacterial, fungal, or viral infection

          -  No known HIV infection

          -  No active hepatitis B and/or hepatitis C infection

          -  No other medical condition, including mental illness or substance abuse, deemed by the
             Investigator(s) to interfere with a patient's ability to sign informed consent,
             cooperate and participate in the study, or interfere with the interpretation of the
             results

        PRIOR CONCURRENT THERAPY:

          -  Recovered from the majority of the toxicities from the autologous transplantation
             (must have returned to their pretransplant baseline or have no greater than grade I
             extramedullary toxicity Common Toxicity Criteria for Adverse Effects[CTCAE 3.0])

          -  No prior treatment with a histone deacetylase (HDAC) inhibitor (e.g., depsipeptide,
             MS-275, LAQ-824, belinostat, valproic acid)

          -  More than 4 weeks since prior and no concurrent class Ia, Ib, or Ic antiarrhythmic
             drugs

          -  No other concurrent antineoplastic chemotherapy or biologic therapy

          -  No concurrent radiotherapy, unless for local control of bone pain

               -  Irradiated area for pain management should be as small as possible and lesions
                  within the irradiated field cannot be used for response

          -  No concurrent use of complementary or alternative medicines that would confound the
             interpretation of toxicities and antitumor activity of vorinostat (SAHA)
      "
NCT00487786,completed,,1,phase 1,['neoplasms'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['ogx-427', 'docetaxel']","['CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=S)(O)OC3CC(OC3COP(=S)(O)OC4CC(OC4COP(=S)(O)OC5CC(OC5COP(=S)(O)OC6CC(OC6COP(=S)(O)OC7CC(OC7COP(=S)(O)OC8CC(OC8COP(=S)(O)OC9CC(OC9COP(=S)(O)OC1CC(OC1COP(=S)(O)OC1C(OC(C1OCCOC)N1C=NC2=C(N=CN=C21)N)COP(=S)(O)OC1C(OC(C1OCCOC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)OC1C(OC(C1OCCOC)N1C=NC2=C1N=C(NC2=O)N)COP(=S)(O)OC1C(OC(C1OCCOC)N1C=NC2=C1N=C(NC2=O)N)CO)N1C=C(C(=NC1=O)N)C)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=NC1=O)N)C)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=NC1=O)N)C)N1C=NC2=C1N=C(NC2=O)N)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OCC1C(CC(O1)N1C=C(C(=NC1=O)N)C)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=NC1=O)N)C)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=NC2=C1N=CNC2=N)OCCOC)OP(=S)(O)OCC1C(C(C(O1)N1C=C(C(=O)NC1=O)C)OCCOC)O', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O']","
        Inclusion Criteria

          -  Age ≥ 18 years at time of consent.

          -  Histologically or cytologically confirmed diagnosis of one of the following:
             adenocarcinoma of the breast, ovary, or prostate, any NSCLC or bladder cancer.

          -  Must have metastatic disease. Prostate cancer patients must be hormone refractory.

          -  Must have failed therapies that are potentially curative; failed/refused standard
             therapy known to prolong survival or progression-free survival; or failed/refused
             therapy, that in the view of the investigator, would be beneficial in improvement of
             symptoms

          -  Patients enrolled into Cohorts 6 and 7 (OGX 427 in combination with docetaxel) must
             have disease that has a possibility of responding to docetaxel.

          -  A minimum of 28 days must have elapsed between any major surgery, the last dose of
             chemotherapy, radiotherapy (except limited fields-see #7 below), radioisotope,
             immunotherapy or experimental agent and enrollment onto the study. Note: Patients on
             hormone or estrogen therapy and steroids for treatment of their disease may remain on
             therapy.

          -  A minimum of 7 days must have elapsed between a single fraction of ≤ 800 cGy to a
             limited field or conventional radiotherapy to a limited non marrow-bearing field such
             as an extremity or orbit and enrollment onto the study.

          -  Recovery from all toxicities of prior therapy including chemotherapy, radiation
             therapy, immunotherapy and experimental agents to ≤ grade 2 by NCI CTCAE, version 3.0.

          -  If not treated with bilateral orchiectomy, patients with HRPC must be willing to
             continue luteinizing hormone releasing hormone (LHRH) analogues throughout the study.

          -  If taking opioid medication, patient must be willing to continue on the same opioid
             medication that they are on at enrollment through the PK/ECG evaluations during Cycle
             1.

          -  Karnofsky score of ≥60%.

          -  Various laboratory requirements.

          -  Must be willing to use effective contraception during and for 3 months following
             treatment if of child bearing potential.

          -  Must be willing to undergo pharmacokinetic blood draws and frequent ECG monitoring on
             Days 1 and 2 of Cycle 1.

          -  Must provide written, informed consent.

        Exclusion Criteria

          -  More than three cytotoxic chemotherapy regimens.

          -  Current treatment with any anticancer agent including but not limited to trastuzumab,
             aromatase inhibitors, or tamoxifen. Steroids, bisphosphonates and female hormone
             replacement therapy are allowed.

          -  Documented central nervous system (CNS) metastasis or carcinomatous meningitis.

          -  For patients in Cohorts 6 and 7, prior history of a serious allergic reaction to
             docetaxel; any chemotherapy containing Cremophor EL (used in drugs such as
             cyclosporine, etoposide, teniposide); or polysorbate 80 (the diluent for docetaxel).

          -  Current pregnancy or lactation.

          -  Current second malignancy except for non melanoma skin cancers, superficial bladder
             cancer, early cervical cancer or early prostate cancer not requiring treatment.

          -  Uncontrolled and/or serious medical conditions such as, but not limited to, active
             infection, symptomatic congestive heart failure, unstable angina, significant cardiac
             arrhythmia, significant neurological dysfunction, history of myocardial infarction or
             stroke within the 3 months prior to enrollment or any other condition which the
             Investigator feels would preclude protocol therapy.

          -  Concomitant participation in another clinical trial of an experimental drug, vaccine
             or device.

          -  Prior high dose chemotherapy requiring stem cell rescue.

          -  Atrial fibrillation, left bundle branch block, or obligatory use of a cardiac
             pacemaker.

          -  Currently on a drug known to increase the QTc duration.
      "
NCT00031044,completed,,0,phase 1/phase 2,['hiv infections'],"[""['Z21']""]","['enfuvirtide', 'amdoxovir']","['Status: 503', 'C1C(OC(O1)CO)N2C=NC3=C(N=C(N=C32)N)N']","
        Note: Enrollment into this study was permanently closed on 02/09/04.

        Inclusion Criteria:

          -  HIV infected

          -  Taken at least two combination anti-HIV treatments containing three or more drugs. In
             total, the treatments must have lasted at least 24 months and must have included at
             least two nucleoside reverse transcriptase inhibitors (NRTIs), two protease inhibitors
             (PIs), and one nonnucleoside reverse transcriptase inhibitor (NNRTI).

          -  Failed two previous combination treatments of three or more drugs

          -  Viral load of more than 5000 copies/ml on stable (at least 8 weeks) antiretroviral
             regimen, within 60 days prior to study entry

          -  Willing to stay on the current failing anti-HIV treatment until starting study
             treatment; may have to remain on failing regimen for an additional 60 days after study
             screening

          -  Willing to use acceptable methods of contraception

          -  Access to optimized background (OB) regimen drugs

          -  Ability to bring OB regimen drugs to screening visit

        Exclusion Criteria:

          -  Prior use of DAPD or ENF

          -  Drug or alcohol use which, in the opinion of the investigator, would interfere with
             the study

          -  History of any illness that, in the opinion of the investigator, would interfere with
             study participation

          -  Single kidney or history of two or more episodes of kidney stones

          -  Pregnant or breastfeeding

          -  Experimental anti-HIV drug use or use of any agent that acts on the immune system
             within 60 days prior to entry

          -  Active immunization within 21 days prior to study entry

          -  Acute therapy for a serious infection or illness

          -  Active AIDS-defining opportunistic infection requiring acute treatment

          -  Unexplained fever within 7 days prior to study entry

          -  Cancer that requires chemotherapy

          -  Prior HIV vaccination, except for subunit vaccines that contained only gp120

          -  Certain mutations in HIV-1 reverse transcriptase

          -  Measurable loss of vision due to lens opacity

          -  Posterior subcapsular cataract

          -  Cortical cataract of Grade C3 or higher on the Lens Opacities Classification System
             III (LOCS III) scale

          -  Nuclear opalescence Grade NO3 (LOCS III) or higher

          -  Best corrected vision worse than 20/200

          -  Diabetes mellitus. Gestational diabetes is not excluded.
      "
NCT01160926,terminated,"
    2 dlts had been reported from first 4 patients on lowest possible dose cohort.
  ",0,phase 1,['rectal cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['azd6244', 'cediranib (azd2171)']","['CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO', 'CC1=CC2=C(N1)C=CC(=C2F)OC3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCC5']","
        Inc Criteria:

          -  Histologically confirmed rectal adenocarcinoma

          -  MRI (magnetic resonance imaging) and triphasic CT (computerised tomography) defined
             locally advanced rectal cancer:

               -  Mesorectal fascia involved or

               -  Mesorectal fascia threatened or

               -  Any T3 tumours < 5cm from the anal verge

          -  Primary resection unlikely to achieve clear margins

          -  No previous chemotherapy or radiotherapy for rectal cancer

          -  Bone marrow function: absolute neutrophil count ≥1.5 x109/l and platelet count >100
             x109/l

          -  Hepatobiliary function: serum bilirubin <1.5 x upper limit of normal (ULN); serum ALP
             <5 x ULN; serum transaminase (AST or ALT) <2.5 x ULN

          -  Renal function: Serum creatinine clearance >50mL/min by either Cockcroft-Gault formula
             or EDTA (ethylenediaminetetraacetic acid) clearance

          -  ECOG PS(Eastern Cooperative Oncology Group Performance Status) 0-1

          -  Disease can be encompassed within a radical radiotherapy treatment volume

          -  No pre-existing condition which would deter radiotherapy, e.g. fistulas, severe
             ulcerative colitis, Crohn's disease, prior adhesions

          -  For women of child-bearing potential a negative pregnancy test is required and
             adequate contraceptive precautions such as a condom for their partner must be used.
             For men - adequate contraception must be used.

          -  Fit to receive all study treatments

          -  Able to comply with oral medication and protocol

          -  Signed, written and dated informed consent.

          -  Life expectancy ≥ 3 months.

        Exc Criteria:

          -  Concurrent uncontrolled medical illness, or other previous/current malignant disease
             likely to interfere with protocol treatments

          -  Age<18

          -  Any pregnant, lactating women or potentially childbearing patients not using adequate
             contraception

          -  Previous chemotherapy or radiotherapy for rectal cancer

          -  Metastatic disease

          -  ECOG PS>1

          -  Patients who have very significant small bowel delineated within the radiation fields.

          -  Current or impending rectal obstruction (unless defunctioning stoma present), metallic
             colonic rectal stent in situ

          -  Pelvic sepsis.

          -  Uncontrolled cardiac, respiratory or other disease, or any serious medical or
             psychiatric disorder that would preclude trial therapy or informed consent.

          -  Cardiac conditions as follows:

               -  Uncontrolled hypertension (resting BP ≥150/95mmHg despite optimal therapy)

               -  Heart failure NYHA Class II or above

               -  Prior or current cardiomyopathy

               -  Atrial fibrillation with heart rate >100 bpm

               -  Unstable ischaemic heart disease

          -  Refractory nausea and vomiting, chronic gastrointestinal diseases, or significant
             bowel resection that would preclude adequate absorption of trial drug

          -  Patients who are deemed unsuitable for surgery because of co-morbidity or coagulation
             problems.

          -  Recent (<14 days) major thoracic or abdominal surgery prior to entry into the study or
             a surgical incision that is not fully healed which would prevent administration of
             study treatment

          -  Known DPD (dihydropyrimidine dehydrogenase)deficiency

          -  Patients suffering from any condition that may affect the absorption of capecitabine
             or IMP (investigational medical product)

          -  Any evidence of severe or uncontrolled systemic disease, active infection, active
             bleeding diatheses or renal transplant, including any patient known to have Hep B, Hep
             C or HIV

          -  Mean QTc with Bazetts correction >470msec in screening ECG or history of familial long
             QT syndrome

        EXC CRITERIA (AZD6244 cohorts)

          -  KRAS (Kirsten ras sarcoma viral oncogene) wild-type

          -  Prior treatment with a MEK inhibitor

          -  Baseline LVEF (left ventricular ejection fraction) ≤50%

        EXC CRITERIA (Cediranib cohorts)

          -  Known hypersensitivity to Cediranib or any of its excipients

          -  Greater than +1 proteinuria on two consecutive dipsticks taken no less than 1 week
             apart unless urinary protein < 1.5g in a 24 hr period or protein/creatinine ratio <
             1.5.

          -  Significant haemorrhage (>30mL bleeding/episode in previous 3 months) or haemoptysis
             (>5mL fresh blood in previous 4 weeks)

          -  APTT ratio > 1.5 x ULN

          -  Arterial thromboembolic event (including ischemic attack) in the previous 12 months
      "
NCT00093613,completed,,1,phase 1,"['adult anaplastic astrocytoma', 'adult anaplastic oligodendroglioma', 'adult giant cell glioblastoma', 'adult gliosarcoma', 'recurrent adult brain tumor']","[""['C84.67', 'C84.77', 'C84.7A', 'C84.60', 'C84.70', 'C84.62', 'C84.66']"", ""['C84.67', 'C84.77', 'C84.7A', 'C84.60', 'C84.70', 'C84.62', 'C84.66']"", ""['G47.13', 'J01.41', 'K11.22', 'K12.0', 'N96', 'F33.8', 'G03.2']""]",['sorafenib tosylate'],['CC1=CC=C(C=C1)S(=O)(=O)O.CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F'],"
        Inclusion Criteria:

          -  Patients must have histologically proven malignant glioma (anaplastic astrocytoma,
             anaplastic oligodendroglioma or glioblastoma multiforme) which is progressive or
             recurrent after radiation therapy ± chemotherapy; patients with previous low grade
             glioma who progressed after radiotherapy ± chemotherapy and are biopsied and found to
             have a high grade glioma are eligible

          -  Patients must have measurable progressive or recurrent malignant glioma by MRI or CT
             imaging; (Within 14 days before starting treatment)

          -  Patients must have recovered from toxicity of prior therapy; an interval of at least 3
             months must have elapsed since the completion of the most recent course of radiation
             therapy, while at least 3 weeks must have elapsed since the completion of a
             non-nitrosourea containing chemotherapy regimen, and at least 6 weeks since the
             completion of a nitrosourea containing chemotherapy regimen

          -  Patients must have a Karnofsky performance status >= 60% (i.e. the patient must be
             able to care for himself/herself with occasional help from others)

          -  Absolute Neutrophil Count >= 1500/mm^3

          -  Platelets >= 100,000/mm^3

          -  Creatinine =< 1.7mg/dl

          -  Total Bilirubin =< 1.5mg/dl

          -  Transaminases =< 4 times above the upper limits of the institutional norm

          -  PT, PTT, INR within institutional norm

          -  Patients must be able to provide written informed consent

          -  Patients with the potential for pregnancy or impregnating their partner must agree to
             follow acceptable birth control methods to avoid conception; women of childbearing
             potential must have a negative serum pregnancy test; (The anti-proliferative activity
             of this experimental drug may be harmful to the developing fetus or nursing infant)

          -  Patients must have a Mini Mental State Exam score >= 15

        Exclusion Criteria:

          -  Patients with serious concurrent infection or medical illness which would jeopardize
             the ability of the patient to receive the treatment outlined in this protocol with
             reasonable safety; (Examples of medical illnesses are [but not limited to] the
             following: uncontrolled hypertension, symptomatic congestive heart failure, unstable
             angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that
             would limit compliance with study requirements)

          -  Patients who are pregnant or breast-feeding; (The anti-proliferative activity of this
             experimental drug may be harmful to the developing fetus or nursing infant)

          -  Patients who have received more than two prior treatments

          -  Patients receiving concurrent therapy for their tumor (with the exception of steroids)

          -  Patients with a concurrent malignancy are ineligible unless they are patients with
             curatively treated carcinoma-in-situ or basal cell carcinoma of the skin; patients
             with a prior malignancy are ineligible unless they have been free of disease for >=
             five years

          -  Patients must not have any evidence of bleeding diathesis

          -  Patients must not be on therapeutic anticoagulation; prophylactic anticoagulation
             (i.e. low dose warfarin) of venous or arterial access devices is allowed provided that
             the requirements for PT, INR or PTT are met; (Patients will be taken off treatment if
             they require therapeutic anticoagulation during BAY 43-9006 treatment)
      "
NCT00346229,terminated,"
    funding
  ",1,phase 1,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]",['lyso-thermosensitive liposomal doxorubicin(thermodox)'],['Status: 503'],"
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the breast

               -  Locally recurrent disease involving the chest wall and/or its overlying skin

                    -  Clinically and biopsy proven disease on the chest wall area measuring ≥ 1 cm

                    -  Overall surface extent of tumor ≤ two 16 x 16 cm fields

                    -  Tumor thickness ≤ 3 cm by clinical exam and CT scan or MRI

                    -  Disease extent on the chest wall that exceeds the above criteria allowed
                       provided no other local therapies are available

                    -  Patients with axillary disease involvement only must meet the above criteria
                       in order to be eligible

                    -  Prior skin changes consistent with inflammatory breast cancer are allowed

          -  Distant metastasis (excluding known brain metastases) allowed

               -  No resectable chest wall recurrence as the only site of metastatic disease

               -  No refractory pain secondary to metastatic disease

          -  Must have undergone prior local radiotherapy to the chest wall or breast in the
             adjuvant or metastatic setting

          -  Must have progressed on ≥ 1 course of hormonal therapy for metastatic disease (if
             tumor is estrogen receptor positive or progesterone receptor positive) AND ≥ 1 course
             of chemotherapy

          -  Prior contralateral breast malignancy allowed provided not previously treated with
             chemotherapy

          -  Hormone receptor status not specified

        PATIENT CHARACTERISTICS:

          -  Female

          -  Menopausal status not specified

          -  Zubrod performance status 0-1 OR Karnofsky performance status 90-100%

          -  Not pregnant

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Granulocyte count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 9 g/dL

          -  Bilirubin normal

          -  alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times upper
             limit of normal (ULN)

          -  Creatinine ≤ 1.5 times ULN

          -  left ventricular ejection fraction (LVEF) ≥ 50% by multiple gated acquisition scan
             (MUGA) or echocardiogram

          -  No nonhealing wounds or active infection in the area of the chest wall

          -  No clinically significant findings on baseline evaluations, including laboratory and
             physical examinations, vital signs, and ECG

          -  No prior sensitivity (e.g., rash, dyspnea, wheezing, urticaria, or other symptoms)
             attributed to anthracyclines or other liposomally encapsulated drugs

          -  No other prior or concurrent primary malignancy except for melanoma in situ,
             nonmelanoma skin cancer, squamous cell carcinoma, or noninvasive cervical carcinoma

          -  No history of any of the following:

               -  Cardiac ischemia or acute coronary artery syndrome, myocardial infarction (MI),
                  cerebral vascular accident, or abnormal cardiac stress testing within the last 6
                  months

               -  Coronary artery disease (including non-Q wave MI)

               -  Uncontrolled hypertension or cardiomyopathy

               -  Cardiac valvular surgery or open heart surgery

               -  Known structural heart disease

          -  No other serious medical illness including, but not limited to, the following:

               -  Congestive heart failure

               -  Life-threatening cardiac arrhythmias

               -  Acute or chronic liver disease

          -  No major psychiatric illness that required inpatient treatment within the past 3
             months or that would preclude obtaining informed consent

          -  No concurrent devices or conditions that might interfere with the hyperthermia portion
             of the trial, including any of the following:

               -  Functioning cardiac pacemaker

               -  Metal plates, rods, or prosthesis of the chest wall

               -  Severe numbness and/or tingling of the chest wall or breast

               -  Skin grafts and/or flaps on the breast or chest wall

               -  Unstable cardiovascular or pulmonary status

          -  No known allergy to eggs or egg products

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  More than 3 months since prior major surgery

          -  No prior therapy with anthracyclines exceeding the following doses:

               -  Doxorubicin hydrochloride > 450 mg/m^2

               -  Epirubicin hydrochloride > 900 mg/m^2

          -  More than 42 days since prior trastuzumab (Herceptin®)

          -  More than 90 days since prior radiotherapy to the involved chest wall area

          -  No other concurrent systemic anticancer therapy, including hormonal therapy,
             chemotherapy, or investigational anticancer therapy

          -  No concurrent radiotherapy, including radiotherapy for pain control

          -  No concurrent administration of any of the following drugs:

               -  Amphotericin B by injection

               -  Antithyroid agents

               -  Azathioprine

               -  Chloramphenicol

               -  Colchicine

               -  Flucytosine

               -  Ganciclovir

               -  Interferon

               -  Plicamycin

               -  Zidovudine

               -  Sulfinpyrazone

               -  Probenecid

               -  Cyclosporine

               -  Phenobarbital

               -  Phenytoin

               -  Streptozocin

               -  Live vaccines

          -  Concurrent bisphosphonates for palliation of bony metastasis allowed
      "
NCT00390156,completed,,1,phase 1,['unspecified adult solid tumor'],"[""['H01.009', 'H02.209', 'H02.009', 'H02.109', 'H04.209', 'H05.409', 'H10.509']""]","['cyclophosphamide', 'imatinib']","['C1CNP(=O)(OC1)N(CCCl)CCCl', 'CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5']","
        DISEASE CHARACTERISTICS:

          -  Diagnosis of solid tumor

               -  Advanced or metastatic disease* NOTE: *With the exception of colorectal and lung
                  cancer patients, all patients must receive approval from the insurance carrier
                  that allows for coverage/payment of the study drug bevacizumab

          -  Refractory to standard therapy OR no standard therapy exists

          -  No advanced ovarian cancer or peritoneal carcinomatosis

          -  No metastases from any cancer causing significant ascites

          -  No lung malignancy with any of the following characteristics:

               -  In close proximity to a major vessel

               -  Centrally located

               -  Cavitary

               -  Squamous histology

               -  Hemoptysis > ½ teaspoon per day

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  Platelet count ≥ 100,000/mm^3

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Bilirubin < 2 mg/dL

          -  AST or ALT < 3 times upper limit of normal

          -  Creatinine < 2 mg/dL

          -  Urine protein:creatinine ratio ≤ 1.0

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  Able to tolerate oral therapy

          -  No bleeding diatheses or coagulopathy

          -  No impairment of gastrointestinal (GI) function or GI disease that may affect or alter
             absorption of imatinib mesylate and/or cyclophosphamide (e.g., malabsorption syndrome,
             history of total gastrectomy/significant small bowel resection)

          -  No abdominal fistula, GI perforation, or intra-abdominal abscess within the past 6
             months

          -  No uncontrolled hypertension (i.e., blood pressure > 150/100 mm Hg)

          -  No uncontrolled cardiovascular disease, including any of the following:

               -  Coronary artery disease

               -  Uncontrolled cardiac arrhythmia

               -  Symptomatic congestive heart failure (i.e., New York Heart Association class
                  II-IV)

               -  Unstable angina pectoris

               -  Clinically significant peripheral vascular disease

          -  No arterial thromboses within the past year, including any of the following:

               -  Transient ischemic attack

               -  Myocardial infarction

               -  Cerebrovascular event

               -  Unstable angina

               -  Angina requiring medical or surgical intervention

               -  Clinically significant peripheral artery disease

               -  Any other arterial thromboembolic event

          -  No interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the
             lung

          -  No serious nonhealing wound, ulcer, or bone fracture

          -  No other active second malignancy except nonmelanoma skin cancer or cervical carcinoma
             in situ unless therapy has been completed and < 30% risk for relapse exists

          -  No active infection or known HIV infection

          -  No history of allergic reactions (≥ grade 3 or 4) to compounds of similar chemical or
             biologic composition to cyclophosphamide (i.e., alkylating agents)

          -  No history of noncompliance with medical regimens

          -  No known intolerance or hypersensitivity reaction to bevacizumab, imatinib mesylate,
             or cyclophosphamide

          -  No other significant medical illness, psychiatric illness, or social situation that,
             in the opinion of the investigator, would limit compliance with study requirements

          -  No inability to grant reliable informed consent

        PRIOR CONCURRENT THERAPY:

          -  No major surgical procedure within the past 28 days or anticipated major surgery
             during study treatment except for placement of a venous access device or surgery for a
             diagnostic study
      "
NCT02251873,completed,,0,phase 1,['healthy'],"[""['Z76.3', 'Z76.2']""]","['tpv + rtv (low dose)', 'tpv + rtv (high dose)', 'ddl']","['Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Healthy male or female subjects as determined by results of screening

          -  Female subjects were not lactating and not of child bearing potential as defined by
             surgically sterile or post menopausal (no periods for at least 12 months and elevated
             follicle stimulating hormone (FSH) with low estradiol and no estrogen
             supplementation). Females were to use barrier contraception (e.g. condoms) for at
             least one month prior to administration of study medication, during the study and at
             least one month after release from the study. Women were to have negative pregnancy
             tests

          -  Signed written informed consent in accordance with Good Clinical Practice (GCP) and
             local legislation

          -  Age >=18 and <=60 years

          -  Body mass index (BMI) >=18.5 and <=29.9 kg/m2

        Exclusion Criteria:

          -  Any finding of the medical examination (including blood pressure, pulse rate and ECG)
             deviating from normal and of clinical relevance

          -  History or current gastrointestinal, hepatic, renal, respiratory, cardiovascular,
             metabolic, immunologic, hormonal disorders, including a clinical history of viral
             hepatitis, or serological evidence of active Hepatitis B, Hepatitis C, or HIV
             infection

          -  History of orthostatic hypotension, fainting spells and blackouts

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          -  Chronic or relevant acute infections

          -  History of allergy/hypersensitivity (including drug allergy) which was deemed relevant
             to the trial as judged by the investigator including study drugs

          -  Intake of drugs with a long half-life (> 24 hours) or enzyme altering drug within 1
             month prior to administration of study drugs

          -  Use of any drugs that might have influenced the results of the trial within 10 days
             prior to administration or during the trial (in addition to specific medication
             prohibitions mentioned in exclusion criteria above)

          -  Use of grapefruit or grapefruit juice, alcohol, green tea, methylxanthine-containing
             products or tobacco within one week of study drug administration

          -  Participation in another trial with an investigational drug within 2 months prior to
             administration or during the trial

          -  Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from
             smoking on trial days

          -  Alcohol abuse (> 60 g/day)

          -  Drug abuse

          -  Blood or plasma donation within 1 month prior to administration or during the trial

          -  Excessive physical activities within 5 days prior to administration or during the
             trial

          -  Following specific laboratory findings: activated partial thromboplastin time (aPTT),
             prothrombin time international normalised ratio (INR), aspartate transaminase (AST),
             alanine transaminase (ALT), gamma-glutamyl-transferase (GGT), amylase, lipase, or
             triglyceride above the normal range

          -  Any other laboratory value outside the clinically accepted reference range and of
             clinical relevance

          -  History of any familial bleeding disorder

          -  Inability to swallow multiple large capsules

          -  Inability to comply with dietary regimen of study centre

          -  Inability to comply with investigator's instructions
      "
NCT01391117,terminated,"
    antiviral activity was considered insufficient to warrant further clinical development of
    tmc649128.
  ",0,phase 1,['hepatitis c virus'],"[""['B00.81', 'B25.1', 'B26.81', 'B58.1', 'K75.4', 'A51.45', 'B17.2']""]","['placebo.', 'placebo.', 'tmc649128.', 'placebo.', 'placebo', 'tmc649128', 'tmc649128.', 'tmc649128', 'tmc649128.', 'placebo.']","['CC1C(C(OC1N2C=CC(=NC2=O)N)(COC(=O)C(C)C)N=[N+]=[N-])OC(=O)C(C)C', 'CC1C(C(OC1N2C=CC(=NC2=O)N)(COC(=O)C(C)C)N=[N+]=[N-])OC(=O)C(C)C']","
        Inclusion Criteria:

          -  Documented chronic (> 6 months) genotype 1a or 1b Hepatitis C virus (HCV) infection

          -  Treatment-naive volunteer, meaning never received (Peg)IFN, RBV or any other approved
             or investigational treatment for chronic HCV infection (Panels 1, 2, 3 or 4) OR
             volunteer is a documented prior non-responder or relapser subject to previous
             treatment regimens (IFN/RBV or pegylated IFN/RBV) but has stopped this treatment at
             least 6 months before screening

          -  volunteer has never received a HCV polymerase inhibitor and HCV protease inhibitor
             treatment was stopped since at least one year (Panels 1, 2 or 3)

          -  Volunteer with HCV plasma RNA levels of > 100,000 IU/mL at screening

          -  Body Mass Index of 18.0 to 35.0 kg/m2

          -  Healthy based on a medical evaluation including medical history, physical examination,
             blood tests, vital signs, and electrocardiogram.

        Exclusion Criteria:

          -  Evidence of liver cirrhosis

          -  Historical liver biopsy graded as liver cirrhosis or evidence for the presence of
             oesophageal varices or a transient elastography (Fibroscan) result of more than 14.6
             kPa within 2 years prior to screening

          -  Evidence of decompensated liver disease defined as prior history or current evidence
             of ascites, hepatic encephalopathy, bleeding oesophageal or gastric varices

          -  Evidence of renal dysfunction, documented by an estimated creatinine clearance below
             70 mL/min

          -  Evidence of any other cause of significant liver disease in addition to hepatitis C,
             this may include but is not limited to hepatitis B, drug- or alcohol-related
             cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, non-alcoholic
             steatohepatitis, or primary biliary cirrhosis

          -  Volunteer with diagnosed or suspected hepatocellular carcinoma

          -  Volunteer receiving or having received any treatment for HCV during the 6 months
             before screening

          -  Volunteer coinfected with Human Immunodeficiency Virus-1 (HIV-1) or HIV-2, or
             hepatitis A or B virus infection, or clinically active tuberculosis at study
             screening.
      "
NCT01187836,completed,,1,phase 1/phase 2,['heart failure'],"[""['I50.814', 'I09.81', 'I50.82', 'I50.89', 'I50.9', 'T86.22', 'I11.0']""]","['trv120027', 'placebo']","['Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Diagnosis of congestive heart failure made at least 3 months prior to screening

          -  NYHA Class III or IV heart failure, ejection fraction </= 35% and , and in the opinion
             of the investigator, right-heart catheterization is clinically indicated.

          -  Baseline mean PCWP >/= 20 mmHg

          -  Systolic blood pressure at screening must be >/= 100 mmHg. Heart rate at screening
             must be </= 90 bpm.

        Exclusion Criteria:

          -  Any significant disease or condition that would interfere with the interpretation of
             safety or efficacy in this study as determined by the Investigator based on medical
             history, physical examination or laboratory tests.

          -  Significant valve disease

          -  Current signs or symptoms of acute myocardial ischemia or acute coronary syndrome
             (ACS) or coronary revascularization in the past 3 months.

          -  Sustained or uncontrolled ventricular arrhythmia. Inclusion of patients with atrial
             fibrillation with a heart rate ≤ 90 bpm is permitted.
      "
NCT01089062,completed,,0,phase 1,['healthy'],"[""['Z76.3', 'Z76.2']""]","['map0004', 'iv placebo (saline)', 'placebo inhaler', 'iv dihydroergotamine mesylate (dhe)']",['CC1(C(=O)N2C(C(=O)N3CCCC3C2(O1)O)CC4=CC=CC=C4)NC(=O)C5CC6C(CC7=CNC8=CC=CC6=C78)N(C5)C'],"
        Inclusion Criteria:

          1. Able to provide a signed, executed written informed consent

          2. Healthy non-smoking adult volunteers: Male or Female subjects 18 to 45 years old

          3. Female subjects who are practicing adequate contraception

          4. Stable cardiac status

          5. Normal hemoglobin values

          6. Normal Echocardiogram

          7. Normal or not clinically significant 12-lead Electrocardiogram

          8. Demonstrated ability to properly use the Tempo® Inhaler

          9. Subject has not donated blood in the last 56 days

        Exclusion Criteria:

          1. Contraindication to dihydroergotamine mesylate (DHE)

          2. Use of any excluded concomitant medications within the 10 days prior to Visit 1

          3. History of hemiplegic or basilar migraine

          4. Participation in another investigational trial during the 30 days prior to Visit 1
      "
NCT00701298,terminated,,0,phase 1,"['unspecified adult solid tumor, protocol specific']","[""['H01.009', 'H02.209', 'H02.009', 'H02.109', 'H04.209', 'H05.409', 'H10.509']""]",['decitabine'],['Status: 503'],"
        Inclusion Criteria:

          -  Biopsy-proven solid tumor

               -  Metastatic or unresectable disease

          -  Tumor amenable to biopsy

          -  No curative or more effective treatment for this disease exists, in the opinion of the
             investigator

          -  Measurable disease by scans as assessed by RECIST criteria

          -  No untreated brain metastasis

               -  No longer receiving steroid therapy for previously treated brain metastasis

          -  Zubrod performance status of 0-2

          -  Bilirubin ≤ 1.5 times upper limit normal (ULN)

          -  SGOT or SGPT ≤ 2.5 times ULN (≤ 5 ULN if hepatic metastases present)

          -  Serum creatinine ≤ 1.5 times ULN

          -  Creatinine clearance ≥ 50 mL/min

          -  ANC > 1,500/μL

          -  Platelet count > 100,000/μL

          -  Hemoglobin > 9 g/dL (transfusion allowed)

          -  No NYHA class III-IV cardiac problems (e.g., congestive heart failure or myocardial
             infarction within the past 2 months)

          -  No severe and/or uncontrolled concurrent medical disease (e.g., uncontrolled diabetes,
             uncontrolled chronic renal or liver disease, or active uncontrolled infection [e.g.,
             HIV])

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective barrier contraception during and for 3 months
             after completion of study therapy

          -  Willing to undergo biopsies

          -  No medical or psychological conditions that, in the opinion of the investigator, may
             preclude the patient's ability to tolerate or complete the treatment, or to grant
             reliable informed consent

          -  No other prior malignancy except for adequately treated basal cell or squamous cell
             skin cancer, in situ cervical cancer, adequately treated stage I, II, or III cancer
             from which the patient is currently in complete remission, or any other cancer from
             which the patient has been disease-free for 5 years

          -  No prior extensive pelvic irradiation or prolonged nucleoside analogue pretreatment

          -  At least 28 days since prior and no concurrent chemotherapy, radiotherapy, surgery,
             biological therapy, anticancer agent, or other investigational drug
      "
NCT00074022,completed,,0,phase 1/phase 2,"['recurrent non-small cell lung cancer', 'recurrent prostate cancer', 'stage iii prostate cancer', 'stage iiia non-small cell lung cancer', 'stage iiib non-small cell lung cancer', 'stage iv non-small cell lung cancer', 'stage iv prostate cancer', 'unspecified adult solid tumor, protocol specific']","[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']"", ""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']"", ""['H01.009', 'H02.209', 'H02.009', 'H02.109', 'H04.209', 'H05.409', 'H10.509']""]",['docetaxel'],['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O'],"
        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of 1 of the following:

               -  Solid tumor malignancy (phase I only)*

               -  Prostate cancer (phase I only)*

               -  Non-small cell lung cancer (phase I and II)*

          -  Recurrent, metastatic, locally advanced unresectable, or treatment-refractory disease

          -  Measurable disease

               -  At least 1 unidimensionally measurable lesion at least 20 mm by conventional
                  techniques OR at least 10 mm by spiral CT scan

               -  Previously irradiated lesions are considered measurable provided they have
                  demonstrated progression before study entry

               -  No bone-only disease

                    -  Must have measurable disease other than bone lesions

          -  No stage IIIA or IIIB non-small cell lung cancer without a malignant pleural or
             pericardial effusion that is eligible for first-line radical combined chemotherapy and
             radiotherapy

          -  No known progressive or symptomatic brain metastases

               -  Asymptomatic brain metastases allowed

          -  Performance status - ECOG 0-2

          -  Performance status - Karnofsky 60-100%

          -  More than 3 months

          -  WBC at least 3,000/mm^3

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  No history of coagulopathy

          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)

          -  AST/ALT no greater than 2 times ULN (3.5 times ULN if liver metastases are present)

          -  INR no greater than 1.3

          -  APTT no greater than 1.25 times ULN

          -  Creatinine no greater than 1.5 times ULN

          -  Creatinine clearance at least 50 mL/min

          -  No symptomatic congestive heart failure

          -  No evidence of cardiac dysfunction

          -  No unstable angina pectoris

          -  No cardiac arrhythmia

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No active peptic ulcer disease

          -  No poorly controlled diabetes mellitus

          -  No pre-existing grade 2 or greater neuropathy

          -  No ongoing or active infection

          -  No contraindication to corticosteroids

          -  No psychiatric illness or social situation that would limit compliance with study
             requirements

          -  No prior allergic reaction attributed to compounds of similar chemical or biological
             composition to study drugs

          -  No other concurrent uncontrolled illness

          -  One, and only one, prior chemotherapy regimen for advanced disease (not including
             adjuvant therapy) allowed

               -  Neoadjuvant/adjuvant chemotherapy allowed

          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin)
             and recovered

          -  Prior multiple lines of endocrine therapy for advanced solid tumors allowed

          -  More than 4 weeks since prior endocrine therapy and recovered

          -  Concurrent steroids allowed

          -  See Disease Characteristics

          -  More than 4 weeks since prior radiotherapy and recovered

          -  No concurrent radiotherapy to sole site of measurable disease

          -  Prior surgery allowed

          -  No concurrent anticoagulant therapy

               -  Concurrent low-dose warfarin for central line thrombosis prophylaxis allowed

          -  No concurrent combination antiretroviral therapy for HIV-positive patients

          -  No other concurrent investigational or commercial agents or therapies intended to
             treat the malignancy

          -  Concurrent bisphosphonates allowed
      "
NCT01867866,completed,,1,phase 1,['advanced solid tumors'],"[""['K74.02', 'G47.22', 'H35.3133', 'H35.3134', 'H35.3113', 'H35.3114', 'H35.3123']""]","['tas-102', 'trifluridine']",['C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O'],"
        Inclusion Criteria:

          1. Has provided written informed consent

          2. Has advanced solid tumors (excluding breast cancer) for which no standard therapy
             exists

          3. ECOG performance status of 0 or 1

          4. Is able to take medications orally

          5. Has adequate organ function (bone marrow, kidney and liver)

          6. Women of childbearing potential must have a negative pregnancy test and must agree to
             adequate birth control if conception is possible. Males must agree to adequate birth
             control.

        Exclusion Criteria:

          1. Has had certain other recent treatment e.g. anticancer therapy, received
             investigational agent, within the specified time frames prior to study drug
             administration

          2. Certain serious illnesses or medical condition(s)

          3. Has had either partial or total gastrectomy

          4. Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any
             prior therapies

          5. Known sensitivity to TAS-102 or its components

          6. Is a pregnant or lactating female

          7. Refuses to use an adequate means of contraception (including male patients)
      "
NCT00372619,completed,,0,phase 1/phase 2,['leukemia'],"[""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']""]","['clofarabine', 'cytarabine', 'methotrexate']","['C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)F)Cl)N', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O', 'CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O']","
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed diagnosis of 1 of the following:

               -  Acute myeloid leukemia (AML) with ≥ 5% blasts in the bone marrow (M2/M3 bone
                  marrow) with or without extramedullary disease

               -  Acute lymphoblastic leukemia (ALL) with > 25% blasts in the bone marrow (M3 bone
                  marrow) with or without extramedullary disease

               -  Acute leukemia of ambiguous lineage with ≥ 5% blasts in the bone marrow (M2/M3
                  bone marrow) with or without extramedullary disease

          -  Disease must have relapsed after or be refractory to prior induction therapy

               -  Patients with AML or acute leukemia of ambiguous lineage must be in first relapse
                  OR refractory to first induction therapy with ≤ 1 attempt at remission induction

                    -  Patients with AML who enroll on the phase I portion of the study must have
                       received prior mitoxantrone hydrochloride and cytarabine for newly diagnosed
                       AML (phase I closed to accrual as of 09/16/09)

               -  Patients with ALL must be in second or third relapse (≤ 3 prior induction
                  regimens) OR refractory to reinduction in first relapse

                    -  Patients with ALL refractory to first induction therapy are not eligible

          -  No acute promyelocytic leukemia

          -  No CNS 3 involvement (i.e., WBC ≥ 5/μL in the cerebrospinal fluid with blasts present
             on cytospin)

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status (PS) 50-100% (> 16 years of age) OR Lansky PS 50-100% (≤
             16 years of age) OR ECOG PS 0-2

          -  Life expectancy ≥ 8 weeks

          -  Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min

          -  Direct bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  ALT < 2.5 times ULN (unless it is related to leukemic involvement)

          -  Shortening fraction ≥ 27% by echocardiogram OR ejection fraction ≥ 45% by gated
             radionuclide study

          -  No evidence of dyspnea at rest or exercise intolerance

          -  Pulse oximetry > 94% at room air

          -  Amylase ≤ 1.5 times ULN

          -  Lipase < 1.5 times ULN

          -  No active, uncontrolled grade 3 or 4 infection

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for ≥ 3 months after
             completion of study treatment

          -  No known hepatitis B or C infection or history of cirrhosis

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Recovered from all prior therapy*

          -  At least 14 days since prior cytotoxic therapy (except hydroxyurea and intrathecal
             chemotherapy)*

          -  At least 7 days since prior biologic agent*

          -  At least 14 days since prior monoclonal antibody therapy*

          -  No more than 1 prior autologous or allogeneic hematopoietic stem cell transplantation

               -  No evidence of active graft-vs-host disease

               -  At least 4 months since transplantation

          -  No other concurrent chemotherapy or immunomodulating agents

          -  No other concurrent investigational therapy NOTE: *Patients who relapse during ALL
             maintenance therapy do not require a waiting period.
      "
NCT00724568,completed,,1,phase 1/phase 2,['multiple myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]","['lenalidomide', 'bortezomib', 'dexamethasone', 'doxil']","['C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N', 'B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O', 'CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C', 'CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O']","
        Inclusion Criteria

          -  At least 18 years of age at the time of consent

          -  Measurable disease

          -  All necessary baseline studies completed

          -  LVEF (left ventricular ejection fraction) greater than or equal to 50 percent by MUGA
             (multigated acquisition scan) or ECHO (echocardiogram)

          -  Must be able to adhere to study visit schedule

        Exclusion

          -  Greater than or equal to grade 2 peripheral neuropathy on clinical examination within
             14 days of enrollment

          -  Renal insufficiency

          -  Evidence of mucosal or internal bleeding and/ or platelet refractory.

          -  Absolute neutrophil count less than 1000 cells/mm^2 within 14 days of enrollment.

          -  Acceptable labs

          -  Concomitant medications that include corticosteroids

          -  Myocardial infarction within 6 months prior to enrollment, uncontrolled angina, severe
             uncontrolled ventricular arrhythmias

          -  Clinically relevant active infection or serious medical condition that places the
             subject at unacceptable risk

          -  Any condition, including laboratory values that places the subject at an unacceptable
             risk

          -  Another malignancy within 3 years of enrollment, with the exception of the complete
             resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ
             malignancy, or low risk prostate cancer after curative therapy

          -  Hypersensitivity to bortezomib, boron, or mannitol or any of the components of DOXIL

          -  Female subject that is pregnant or breastfeeding.

          -  Can not have received any other investigational drugs within 14 days of enrollment

          -  Serious medical or psychiatric illness

          -  Uncontrolled diabetes mellitus

          -  Hypersensitivity to acyclovir or similar antiviral drug

          -  POEMS (plasma cell dyscrasia with polyneuropathy)

          -  Known HIV

          -  Known hepatitis B or C

          -  Known intolerance to steroid therapy

          -  Known hypersensitivity to required prophylactic mediations
      "
NCT00943293,terminated,"
    poor accrual; did not enter phase 2
  ",0,phase 1,"['preleukemia', 'myeloproliferative disorders', 'lymphoma', 'myeloma', 'graft versus host disease']","[""['D47.1']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['C90.01', 'C90.02', 'C90.00']"", ""['D89.810', 'D89.811', 'D89.813', 'D89.812']""]","['fludarabine', 'melphalan', 'campath']","['C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N', 'C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl']","
        Inclusion Criteria:

          -  Relapsed or refractory acute myelogenous or lymphoid leukemia.

          -  Acute myeloid or lymphocytic leukemia in first remission at high-risk for recurrence.

          -  Chronic myelogenous leukemia in accelerated phase or blast-crisis.

          -  Chronic myelogenous leukemia in second or subsequent chronic phase

          -  Recurrent or refractory malignant lymphoma or Hodgkin's disease

          -  Multiple myeloma at high risk for disease recurrence.

          -  Chronic lymphocytic leukemia, relapsed or with poor prognostic features.

          -  Myeloproliferative disorder (polycythemia vera, myelofibrosis) with poor prognostic
             features.

        Exclusion Criteria:

          -  Clinical progression.

          -  Contra-indications for vaccination.
      "
NCT00610194,completed,,1,phase 1,['advanced cancer'],"[""['K74.02', 'G47.22', 'H35.3133', 'H35.3134', 'H35.3113', 'H35.3114', 'H35.3123']""]",['rdea119'],['COC1=CC(=C(C(=C1NS(=O)(=O)C2(CC2)CC(CO)O)NC3=C(C=C(C=C3)I)F)F)F'],"
        Inclusion Criteria: - Histological or cytological confirmed solid tumor. - Advanced
        metastatic or locally recurrent disease for which no proven effective therapy exists. - In
        the expanded MTD cohort, a minimum of 10 patients must have an accessible tumor that is
        amendable to biopsy (cut or needle) at the start and during the study. For patients not in
        the biopsy group, a block from the patient's original diagnostic biopsy/excision, if
        available, may be used for genotype analysis. - ECOG performance status of 0-1. - Life
        expectancy of > or equal to 3 months. - Acceptable hematology, clinical chemistry, and
        coagulation laboratory values. - Patient must be acceptable for treatment and follow up
        according to the Investigator. - Patent must have agreed to and signed the Informed
        Consent. - Patient has within normal range cardiac function as measured by echocardiogram
        or MUGA scan. Exclusion Criteria: - Use of investigational agents or devices within the
        last 28 days. - Major surgery within 30 days of start of study. - Patients with documented
        CNS metastasis who are not off steroids and other CNS therapies - Evidence of uncontrolled
        active infections. - Other serious medical or psychiatric illness. - Significant cardiac
        dysfunction including congestive heart failure (NYHA Class III or IV); myocardial
        infarction or ventricular tachyarrhythmia within the last 6 months; major conduction
        abnormalities unless corrected with a cardiac pacemaker; prolonged QTc >460msec. - Patients
        with known hypersensitivity to any of the drugs or components given in this protocol. -
        Pregnancy. - Women or men of childbearing potential not willing to use effective
        contraception, including barrier protection. - Patients with abdominal fistula, GI
        perforation, intra-abdominal abscess, or small bowel resection, any of which is within 6
        months of study entry. - Patients with abdominal radiation resulting in chronic diarrhea. -
        Because RDEA119 is primarily metabolized by CYP3A4 and CYP2C19, inhibitors and inducers of
        these enzymes should be avoided. - Patients with known HIV infection will be excluded.
      "
NCT00554827,completed,,1,phase 1,['cutaneous t-cell lymphoma'],"[""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']""]",['pralatrexate'],['Status: 503'],"
        Inclusion Criteria:

          -  Confirmed relapsed or refractory cutaneous T-cell lymphoma (CTCL):

               1. Mycosis fungoides Stage IB or higher

               2. Sézary syndrome

               3. Primary cutaneous anaplastic large cell

          -  No curative treatment options.

          -  Progression of disease (PD) or relapse of disease after at least 1 previous systemic
             therapy, PD after last prior treatment regimen, and recovered from the toxic effects
             of prior therapy.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.

          -  Life expectancy ≥ 3 months.

          -  Adequate blood, liver, and kidney function as determined by laboratory tests.

          -  Methylmalonic acide (MMA) serum concentration < 200 nmol/L and homocysteine (Hcy)
             concentration < 10 μmol/L at screening, or receipt of 1 mg daily oral folic acid for
             at least 10 days prior to the planned start of pralatrexate and 1 mg intramuscular
             vitamin B12 within 10 weeks of the planned start of pralatrexate.

          -  Women of childbearing potential must use a medically acceptable contraceptive regimen
             from study treatment initiation until at least 30 days after the last dose of
             pralatrexate and must have a negative serum pregnancy test within 14 days prior to the
             first day of study treatment. Serum pregnancy test not required for patients who are
             postmenopausal (greater than 12 months since last menses) or are surgically
             sterilized.

          -  Women who are breastfeeding.

          -  Men who are not surgically sterile must use a medically acceptable contraceptive
             regimen from start of pralatrexate until at least 90 days after the last
             administration of pralatrexate.

          -  Written informed consent and privacy authorization.

        Exclusion Criteria:

          -  Active concurrent malignancy (except non-melanoma skin cancer or carcinoma in situ of
             the cervix). If there is a history of prior malignancy, the patient must be
             disease-free for ≥ 5 years. Patients with other prior malignancies < 5 years before
             study entry may be enrolled if treatment resulted in complete resolution of the cancer
             and currently have no clinical, radiologic, or laboratory evidence of active or
             recurrent disease.

          -  Congestive heart failure Class III/IV per the New York Heart Association Heart Failure
             Guidelines.

          -  Uncontrolled hypertension.

          -  Human immunodeficiency virus (HIV)-positive diagnosis with a CD4 count of <100 mm3 or
             detectable viral load within the past 3 months, and is receiving combination
             anti-retroviral therapy.

          -  Symptomatic central nervous system metastases or lesions for which treatment is
             required.

          -  Active uncontrolled infection, underlying medical condition that would impair ability
             to receive protocol treatment.

          -  Major surgery within 2 weeks of planned start of treatment.

          -  Receipt of any conventional chemotherapy or radiation therapy (RT) encompassing >10%
             of bone marrow within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study
             treatment or planned use during the study.

          -  Receipt of systemic corticosteroids within 3 weeks of study treatment, unless on a
             continuous dose of ≤10 mg/day of prednisone for at least 1 month.

          -  Initiation of or change in dosage of topical corticosteroids within 3 weeks of study
             treatment (topical steroid use within 3 weeks is allowed if strength/use has been
             stable for at least 1 month; topical corticosteroids cannot be started during the
             study).

          -  Use of investigational drugs, biologics, or devices within 4 weeks prior to study
             treatment or planned use during the study.

          -  Receipt of a monoclonal antibody within 3 months without evidence of progression.

          -  Use of oral retinoids within 4 weeks of study treatment or high-dose vitamin A.

          -  Previous exposure to pralatrexate, unless the patient was on this study, achieved a
             complete or partial response, and was taken off study treatment because of
             investigator decision, and subsequently experienced disease recurrence or progressive
             disease.

          -  Re-entering patients: must not have received subsequent therapy for CTCL during the
             time off initial study treatment.
      "
NCT01200004,terminated,"
    slow accrual.
  ",0,phase 1,['advanced cancers'],"[""['K74.02', 'G47.22', 'H35.3133', 'H35.3134', 'H35.3113', 'H35.3114', 'H35.3123']""]","['azacitidine', 'lenalidomide', 'grifola frondosa']","['C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N', 'C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N']","
        Inclusion Criteria:

          1. Patients must have histologically or cytologically confirmed diagnosis of an advanced
             solid tumor refractory to standard treatment or for which no standard therapy is
             available.

          2. Patients must have ECOG performance status 2 or better (0-2).

          3. Patients must have normal organ and marrow function as defined: Absolute lymphocyte
             count > 1,000 /uL, Absolute neutrophil count > 1,500 /uL, Platelets > 75,000 /uL,
             Bilirubin </= 1.5 * ULN and AST and/or ALT </= 2.5 * the institutional upper limit of
             normal (ULN), </= 5 * ULN for patients with liver metastases, Serum creatinine within
             normal limits; if abnormal, then a calculated creatinine clearance >/= 50 mL/min

          4. Patients must be able to understand and be willing to sign an IRB-approved written
             informed consent document.

          5. Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy
             test with a sensitivity of at least 50 mlU/mL within 10-14 days prior to and again
             within 24 hours of prescribing lenalidomide (prescriptions must be filled within 7
             days) and must either commit to continued abstinence from heterosexual intercourse or
             begin TWO acceptable methods of birth control, one highly effective method and one
             additional effective method AT THE SAME TIME, at least 28 days before she starts
             taking lenalidomide.FCBP must also agree to ongoing pregnancy testing. Men must agree
             to use a latex condom during sexual contact with a FCBP even if they have had a
             successful vasectomy. A female of childbearing potential is a sexually mature woman
             who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been
             naturally postmenopausal for at least 24 consecutive months (ie, has had menses at any
             time in the preceding 24 consecutive months).

          6. Patients must be 18 years of age or older since the safety and dosages of these study
             drugs has not been demonstrated in the pediatric population. Exception: patients who
             are 13 years old or older and have more than 50 kg of body weight will be eligible
             after consultation with their pediatric attending.

          7. Life expectancy greater than 3 months based on the attending physician's discretion.

          8. All study participants must be registered in the mandatory RevAssist program, and be
             willing and able to comply with the requirements of RevAssist.

        Exclusion Criteria:

          1. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure (NYHA Class III or IV), unstable
             angina pectoris, symptomatic cardiac arrhythmia, active bleeding, active thrombosis,
             or psychiatric illness/social situations that would limit compliance with study
             requirements.

          2. History of stroke or transient ischemic attack within 6 months prior to study
             enrollment and significant vascular disease (e.g., aortic aneurysm, aortic dissection)
             and symptomatic peripheral vascular disease.

          3. History of allergic reactions to the study drugs or their analogs.

          4. Patients that have had any treatment specific for tumor control within 3 weeks of
             study drug treatment or: a. within 2 weeks if cytotoxic agents were given weekly b.
             within 6 weeks for nitrosoureas or mitomycin C c. within 4 half-lives for targeted
             agents with half lives and pharmacodynamic effects lasting less than 5 days (that
             includes, but is not limited to, erlotinib, sorafenib, sunitinib, bortezomib, and
             other similar agents) d. failed to recover from toxic effects of any therapy prior to
             study entry

          5. Concurrent known immunosuppressors.

          6. Inability to swallow oral medication.

          7. Pregnant or breastfeeding women.

          8. Concurrent enrollment on another research study.

          9. Known hepatitis B and C infection, HIV infection and autoimmune disorders.

         10. Subjects with known moderate or severe renal impairment will be excluded if creatinine
             clearance < 60 ml/min.
      "
NCT01232439,completed,,1,phase 1,['alcohol dependence'],"[""['F10.20', 'F10.24', 'F10.27', 'F10.280', 'F10.281', 'F10.282', 'F10.288']""]",['opioid receptor kappa antagonist'],['Status: 503'],"
        Inclusion Criteria:

          -  Healthy male or female

          -  Have clinical laboratory tests within normal reference ranges

          -  Have arterial and venous access sufficient to allow blood sampling

        Exclusion Criteria:

          -  Currently enrolled in, or discontinued within the last 30 days from a clinical trial

          -  History of severe allergies or multiple adverse drug reactions

          -  Have an abnormal ECG at screening visit

          -  Have abnormal sitting blood pressure

          -  Have an increased risk of seizures

          -  Current suicidal ideation

          -  Positive test for HIV, hepatitis C, or hepatitis B

          -  Women who are breast feeding

          -  Smoke more than 10 cigarettes per day, or equivalent

          -  Drink more than 5 cups of coffee per day, or equivalent

          -  Have a history of head injury

          -  Unable to undergo a MRI

          -  Suffer from claustrophobia
      "
NCT01684969,withdrawn,"
    lack of accrual and funding is about to expire.
  ",0,early phase 1,"['nausea', 'vomiting']","[""['R11.0', 'R11.11', 'R11.2']"", ""['R11.10', 'R11.12', 'R11.14', 'R11.11', 'K91.0', 'O21.2', 'O21.8']""]","['haloperidol', 'placebo']",['C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F'],"
        Inclusion Criteria

          -  Age: patient must be 18 years or older and less than 70 years of age.

          -  Provision of informed consent

          -  No previous adverse reaction to haloperidol

          -  No current use of haloperidol

          -  Good health

          -  No alcohol within 24 hours of the study

          -  No significant cardiovascular, gastrointestinal, hematologic, neurologic, renal,
             hepatic or pulmonary disease.

          -  Normal neurologic exam

        Exclusionary Criteria

          -  Evidence of any other significant clinical disorder or laboratory finding that makes
             it undesirable for the patient to participate in the study

          -  Recent cerebral trauma

          -  Study will exclude women who are pregnant and/or nursing

          -  Women who are of child bearing potential must have a negative urine pregnancy test.

          -  History of seizures

          -  Taking medications that can interact with haloperidol

          -  Subjects with significant cardiovascular (cardiac conduction deficits),
             gastrointestinal, hematologic, neurologic, renal, hepatic or pulmonary disease.
      "
NCT00045708,completed,,0,phase 1/phase 2,"['adult anaplastic astrocytoma', 'adult giant cell glioblastoma', 'adult gliosarcoma', 'recurrent adult brain tumor']","[""['C84.67', 'C84.77', 'C84.7A', 'C84.60', 'C84.70', 'C84.62', 'C84.66']"", ""['G47.13', 'J01.41', 'K11.22', 'K12.0', 'N96', 'F33.8', 'G03.2']""]","['ixabepilone', 'anticonvulsant']",['CC1CCCC2(C(O2)CC(NC(=O)CC(C(C(=O)C(C1O)C)(C)C)O)C(=CC3=CSC(=N3)C)C)C'],"
        Inclusion Criteria:

          -  Patients must have histologically proven malignant glioma (anaplastic astrocytoma or
             glioblastoma multiforme) which is progressive or recurrent following radiation therapy
             +/- chemotherapy; patients with previous low grade glioma who progressed after
             radiotherapy +/- chemotherapy and are biopsied and found to have a high grade glioma
             are eligible

          -  Patients must have measurable progressive or recurrent malignant glioma by MRI or CT
             imaging

          -  Patients must have recovered from severe toxicity of prior therapy; an interval of at
             least 3 months must have elapsed since the completion of the most recent course of
             radiation therapy while at least 3 weeks must have elapsed since the completion of a
             non-nitrosourea containing chemotherapy regimen and at least 6 weeks since the
             completion of a nitrosourea containing chemotherapy regimen

          -  Patients must have a Karnofsky performance status >= 60% (i.e. the patient must be
             able to care for himself/herself with occasional help from others)

          -  Absolute neutrophil count >= 1500/mm^3

          -  Platelets >= 100,000/mm^3

          -  HgB > 9 g/dl

          -  Creatinine =< 1.5mg/dl

          -  Total Bilirubin =< 1.5mg/dl

          -  Transaminases =< 2.5 times above the upper limits of the institutional norm)

          -  Patients must be able to provide written informed consent

          -  Patients must have =< 2 prior chemotherapy regimens

          -  Patients with the potential for pregnancy or impregnating their partner must agree to
             follow acceptable birth control methods to avoid conception; the anti-proliferative
             activity of this experimental drug may be harmful to the developing fetus or nursing
             infant; female patients of child-bearing potential must have a negative pregnancy test

          -  Patients must have no concurrent malignancy except curatively treated basal or
             squamous cell carcinoma of the skin or carcinoma in situ of the cervix and breast;
             patients with prior malignancies must be disease-free for >= five years

          -  Patients must be maintained on a stable corticosteroid regimen from the time of their
             baseline scan until the start of treatment

          -  Patients must have a Mini Mental State Exam score of >= 15

        Exclusion Criteria:

          -  Patients with serious concurrent infection or medical illness, which would jeopardize
             the ability of the patient to receive the treatment outlined in this protocol with
             reasonable safety

          -  Patients who are pregnant or breast-feeding

          -  Patients with more than 2 prior chemotherapy regimens

          -  Patients receiving concurrent investigational agents

          -  Patients receiving any of the following medications which are known to be moderate to
             significant inhibitors of CYP3A4 are not eligible:

               -  Antibiotics: clarithromycin, erythromycin, troleandomycin

               -  Anti-HIV agents: delavirdine, nelfinavir, amprenavir, ritonavir, indinavir,
                  saquinavir, lopinavir

               -  Antifungals: itraconazole, ketoconazole, fluconazole (doses > 200mg/day),
                  voriconazole

               -  Antidepressants: nefazodone, fluvoxamine

               -  Calcium channel blockers: verapamil, diltiazem

               -  Miscellaneous: amiodarone NOTE: The above list of agents was provided by the
                  National Cancer Institute as moderate to significant inhibitors of CYP3A4 that
                  should not be administered with BMS; there may be other agents that have similar
                  activities on CYP3A4, however these are currently unspecified; if investigators
                  are concerned about a particular medication's inhibitory effect on CYP3A4, they
                  are encouraged to consult local pharmacy services for more information and to
                  contact the principal investigator to discuss the situation further
      "
NCT01432951,completed,,1,phase 1,"['solid tumor', 'lymphoma, malignant']","[""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']""]",['enzastaurin'],['CN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CN(C5=CC=CC=C54)C6CCN(CC6)CC7=CC=CC=N7'],"
        Inclusion Criteria:

          -  Have given written informed consent

          -  Have a histologic or cytologic diagnosis of cancer (solid tumor or lymphoma) with
             clinical or radiologic evidence of locally advanced and/or metastatic disease for
             which no life-prolonging therapy exists. (Note: participants with glioblastoma, and
             other hematologic malignancies [except lymphoma] are excluded from this study.)

          -  Male and female participants with reproductive potential must use an approved
             contraceptive method, if appropriate (for example, intrauterine device, birth control
             pills, or barrier device) during and for 3 months after discontinuation of study
             treatment. Women with childbearing potential must have a negative serum pregnancy test
             within 7 days prior to study enrollment.

          -  Have a performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG)
             scale and, in the investigator's opinion, are suitable for participation in the study

          -  Have discontinued all previous therapies for cancer, including chemotherapy,
             radiotherapy, anticancer hormone therapy, or other investigational therapy for at
             least 30 days prior to study entry (6 weeks for mitomycin-C or nitrosoureas), and have
             recovered from the acute effects of therapy

          -  If the participants have hormone-refractory prostate cancer, the study doctor will
             discuss with the participants what drugs they would be allowed to continue to receive
             during the study

          -  Have adequate organ function, including:

               -  Bone Marrow Reserve: absolute neutrophil count (ANC) greater than or equal to 1.5
                  × 10^9/Liter (L) prior to treatment, platelets greater than or equal to 100 ×
                  10^9/L, and hemoglobin greater than or equal to 10 gram/deciliter (g/dL).
                  Participants may receive erythrocyte transfusions to achieve this hemoglobin
                  level at the discretion of the investigator. Participants may be allowed
                  erythropoietin of choice as per standard of care.

               -  Hepatic: bilirubin within 1.5 times the upper limit of normal (ULN), alanine
                  transaminase, and aspartate transaminase less than or equal to 2.5 times ULN or
                  less than or equal to 5 times ULN when liver metastases are known

               -  Renal: serum creatinine less than or equal to 1.5 milligram/deciliter (mg/dL)

          -  Electrolytes: Participants may be entered into the study if, in the investigator's
             opinion, any electrolyte disorders, including potassium less than 3.4
             milliequivalents/liter (mEq/L), calcium less than 8.4 mg/dL, or magnesium less than
             1.2 (mEq/L), may be appropriately managed and stabilized by the time of the laboratory
             evaluation on the lead-in day. If electrolytes have not been stabilized during this
             time, the participant will be discontinued from the study. Participants with
             hypercalcemia are excluded.

          -  Have an estimated life expectancy, in the judgment of the investigator, that will
             permit the participant to complete the PK phase and at least 1 cycle of the safety
             extension phase (if the participant were to participate in the safety extension phase)

        Exclusion Criteria:

          -  Have received treatment within 28 days of the first dose of study drug with an
             experimental agent for non cancer indications that has not received regulatory
             approval for any indication

          -  Participants with glioblastoma or hematologic malignancies other than lymphoma are
             excluded from this study. Participants who have central nervous system (CNS)
             metastases (unless the participant has completed successful local therapy.

        for CNS metastases and has been off of corticosteroids for at least 4 weeks before starting
        study therapy) are excluded. In the absence of a clinical suspicion of brain metastases, no
        screening computed tomography (CT) or magnetic resonance imaging (MRI) scan before
        enrollment is required.

          -  Serious concomitant systemic disorder, including active infection, that is
             incompatible with the study (at the discretion of the investigator)

          -  Have a history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
             infections

          -  Have a serious cardiac condition

          -  Have abnormal electrocardiogram (ECG) findings, at the discretion of the investigator

          -  Use medications that are known to cause certain changes in electrocardiogram (ECG)
             readings

          -  Have a history of unexplained syncope (fainting or passing out) within the last year,
             or have a known family history of unexplained sudden death

          -  Have had a complete gastrectomy or other significant gastrointestinal diseases that,
             in the investigator's opinion, may significantly impact drug absorption

          -  Are receiving total parenteral nutrition

          -  Are not able to swallow tablets

          -  Are a woman who is breast feeding, lactating, or pregnant

          -  Are allergic to enzastaurin

          -  Are receiving herbal regimens

          -  Drugs and herbal supplements that are known to be potent or moderate inhibitors or
             inducers of cytochrome P450 (CYP)3A are specifically excluded. Foods that are known to
             be potent or moderate inhibitors of CYP3A (for example, grapefruit, grapefruit juice,
             Seville oranges, or Seville orange juice) are also specifically excluded during the
             study. In addition, starfruit and starfruit juice are excluded during the PK phase of
             the study.

          -  Drugs with narrow therapeutic windows that are also known substrates of CYP2C9,
             CYP2C8, CYP2C19, and CYP3A are excluded

          -  Have an average weekly alcohol intake that exceeds 21 units per week (men) and 14
             units per week (women) or are unwilling to stop alcohol consumption from the lead-in
             day through the completion of collecting samples for study drug measurement (1 unit =
             12 oz or 360 milliliter (mL) of beer; 5 ounces (oz) or 150 mL of wine; 1.5 oz or 45 mL
             of distilled spirits)

          -  Use of drugs of abuse, as evidenced by history and/or positive findings on urinary
             drug screening, unless prescribed by a physician (for example, narcotic pain
             medication)

          -  The investigator thinks you should not participate for any reason
      "
NCT01268059,terminated,"
    in conjunction with the overall risk-benefit assessment, study was terminated prematurely due
    to safety concerns.
  ",0,phase 1/phase 2,['non-small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['carboplatin', 'paclitaxel', 'medi-575']","['C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C']","
        Inclusion Criteria:

          -  Histologically confirmed inoperable Stage IIIB or Stage IV non-small cell lung cancer
             according to the Seventh Edition of the American Joint Committee on Cancer (AJCC)
             Tumor Node Metastases (TNM) staging system (only participants with squamous cell
             carcinoma will be enrolled)

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Life expectancy of greater than or equal to (>=) 3 months

          -  Prothrombin time elevation less than or equal to (<=) Grade 2 by National Cancer
             Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) criteria (Version
             4.0) is acceptable for participants on anticoagulant therapy

          -  Adequate hematologic function

          -  Adequate organ function

          -  Suitable candidates for therapy with carboplatin/paclitaxel

          -  Participants must have at least 1 lesion that is measurable using Response Evaluation
             Criteria for Solid Tumors

          -  Participants must be willing to consent to allow collection of archived NSCLC tumor
             samples

          -  Negative serum beta-human chorionic gonadotropin (beta-hCG) test (women of
             childbearing potential only)

          -  Females of childbearing potential, unless surgically sterile has a sterile male
             partner, is premenarchal or at least 2 years postmenopausal, or practices abstinence,
             must use 2 effective methods of avoiding pregnancy (including oral, transdermal, or
             implanted contraceptives, intrauterine device, female condom with spermicide,
             diaphragm with spermicide, cervical cap, or use of a condom with spermicide by the
             sexual partner) from screening, and must agree to continue using such precautions for
             90 days after the final dose of treatment; cessation of birth control after this point
             should be discussed with a responsible physician

          -  Males, unless surgically sterile, must use 2 effective methods of birth control with a
             female partner and must agree to continue using such contraceptive precautions from
             screening through 90 days after the final dose of treatment

        Exclusion Criteria:

          -  At discretion of the investigator regarding safety of the participants

          -  Concurrent enrollment in another clinical study

          -  Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic, or hormonal
             therapy for treatment of cancer

          -  Previous monoclonal antibody (mAb) treatment specifically directed against
             platelet-derived growth factor (PDGF) or PDGF receptors

          -  History of serious allergy or reaction to any component of the MEDI-575 formulation

          -  Receipt of any previous systemic anticancer therapies for advanced or metastatic
             disease

          -  Previous adjuvant/neoadjuvant radiotherapy or chemotherapy for treatment of previous
             nonmetastatic disease is allowed provided that 6 months have elapsed from the end of
             such therapies to the time of enrollment

          -  New York Heart Association >= Class II congestive heart failure

          -  History of myocardial infarction, unstable angina, transient ischemic attack or stroke
             within the previous 6 months prior to enrollment

          -  History of other invasive malignancy within 5 years except for cervical carcinoma in
             situ (CIS), non-melanomatous carcinoma of the skin or ductal carcinoma in situ (DCIS)
             of the breast that have been surgically cured

          -  Evidence of active infection requiring the use of systemic antimicrobial treatment
             within 72 hours prior to initial treatment with MEDI-575

          -  Use of immunosuppressive medication (inhaled and topical corticosteroids are
             permitted) within 7 days prior to enrollment

          -  Systemic immunosuppressive steroid therapy

          -  Participants may take replacement doses of steroids if on a stable dose for at least 2
             weeks prior to enrollment

          -  History of active human immunodeficiency virus (HIV) or active hepatitis B virus (HBV)
             or hepatitis C virus (HCV) infection

          -  Pregnancy or lactation

          -  Previous medical history or evidence of an inter-current illness

          -  Any physical, social, or psychiatric condition which would prevent effective
             cooperation or participation in the study
      "
NCT01565928,completed,,1,phase 1,['prostate cancer'],"[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]",['mdv3100'],['CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C'],"
        Inclusion Criteria:

          -  Willing and able to provide informed consent;

          -  Men, 18 years of age or older;

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate;

          -  Ongoing androgen deprivation therapy

        Exclusion Criteria:

          -  Severe concurrent disease;

          -  Known or suspected brain metastasis;

          -  History of another malignancy within the previous 5 years;

          -  Prior treatment with docetaxel-based chemotherapy
      "
NCT01010542,terminated,"
    see termination reason in detailed description.
  ",0,phase 1,['plaque psoriasis'],"[""['L40.0', 'L40.4', 'L40.8', 'L40.9', 'L40.1', 'L40.50']""]","['ilv-095 300 mg in a 4 to 1 ratio', 'ilv-095 300 mg in a 4 to 1 ratio']",['Status: 503'],"
        Inclusion Criteria:

          -  Sexually active men or women must agree to use a medically acceptable form of
             contraception during the study and continue it for 16 weeks after investigational
             product administration.

          -  Negative urine pregnancy test result for all women.

          -  Body mass index (BMI) >=18 kg/m2 and body weight >=50 kg. BMI is calculated by taking
             the subject's weight, in kilograms, divided by the square of the subject's height, in
             meters, at screening: BMI = weight (kg)/(height [m]).

          -  Must meet the following criteria for disease activity, at screening and/or at study
             entry (subjects who washout from prior therapy may not meet this level of disease
             activity at screening but must before being entered into the study).

          -  Must have stable moderate to severe chronic plaque psoriasis covering >=15% of body
             surface area and be a candidate for systemic therapy or phototherapy.

          -  Psoriasis Area Severity Index (PASI) score of >11.

          -  Physician Global Assessment (PGA) of psoriasis score >=3.

          -  Target lesion score >=6 based on the physician rating of selected sites for erythema,
             plaque elevation and scaling, with a minimum of 2 on the plaque elevation score.
             A-12-point score will be used with a 1-4 scale for each domain. Target lesions should
             not be on the scalp, axillae, face, or groin.

        Exclusion Criteria:

          -  Presence or history of any disorder that may prevent the successful completion of the
             study.

          -  Evidence of unstable clinically significant disease (eg, unstable cardiovascular,
             renal, respiratory, or psychiatric disease or any serious disorder that currently
             requires physician care).

          -  Acute disease state (eg, nausea, vomiting, fever, or diarrhea) within 7 days before
             study day 1.

          -  Evidence of skin conditions (eg, eczema) other than psoriasis that would interfere
             with evaluations of the effect of study medication on psoriasis.

          -  Presence of guttate, erythrodermic, or pustular psoriasis.

          -  Active severe infections within 4 weeks before study day 1.

          -  Systemic malignancy within the past 5 years including melanoma. Treated skin cancer
             (basal cell carcinoma or squamous cell carcinoma) is excluded.

        Evidence of latent tuberculosis by purified protein derivative (PPD) screening. PPD
        screening should be performed according to local standards using the tuberculin skin test
        (TST). Any result >5mm is considered positive. Prior Bacillus Calmette-Guerin (BCG) should
        not be taken into account when interpreting a TST result. TST must be performed during the
        screening period unless one has been performed within the previous 3 months and the results
        are available.
      "
NCT00456833,completed,,0,phase 1,['non small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['rad001', 'erlotinib']","['CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC', 'COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC']","
        Inclusion criteria:

          -  Age over 18 years

          -  Advanced Non Small Cell Lung Cancer which is not responding to chemotherapy treatment
             including either cisplatin or carboplatin

          -  Only 1-2 previous chemotherapy regimens for advanced disease

          -  More than 2 weeks from previous surgery, radiation or chemotherapy

          -  Ability to perform normal daily functions

        Exclusion criteria:

          -  Chronic steroid treatment

          -  Prior treatment with EGFR inhibitors

          -  Active bleeding conditions, skin conditions, gastrointestinal disorders, mouth ulcers,
             eye conditions or other severe medical conditions

          -  Other cancers within the past 2 years

          -  Pregnant or breastfeeding women Other protocol-defined inclusion/exclusion criteria
             may apply
      "
NCT01145014,terminated,,0,phase 1,"['pain', 'healthy']","[""['N50.82', 'R07.2', 'R07.82', 'R10.13', 'R10.33', 'R14.1', 'R52']"", ""['Z76.3', 'Z76.2']""]","['bi 660848', 'bi 660848', 'bi 660848', 'bi 660848', 'bi 660848', 'bi 660848', 'bi 660848', 'bi 660848', 'bi 660848', 'bi 660848', 'bi 660848', 'placebo']","['Status: 503', 'Status: 503', 'Status: 503', 'Status: 503', 'Status: 503', 'Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion criteria

          1. Healthy male based upon a complete medical history, including the physical
             examination, regarding vital signs (BP, PR), 12 lead ECG measurement, and clinical
             laboratory tests. There is no finding deviating from normal and of clinical relevance.
             There is no evidence of a clinically relevant concomitant disease.

          2. Age 21 and 50 years

          3. BMI 18.5 and <30 kg/m2 (Body Mass Index)

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and the local legislation

        Exclusion criteria

          1. Any finding of the medical examination (including BP, PR, and ECG measurements)
             deviating from normal and of clinical relevance

          2. Evidence of a clinically relevant concomitant disease

          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          5. History of relevant orthostatic hypotension, fainting spells or blackouts

          6. Chronic or relevant acute infections

          7. History of relevant allergy/hypersensitivity (including allergy to the drug or its
             excipients) as judged clinically relevant by the investigator

          8. Intake of drugs with a long half-life (24 hours) within at least 1 month or less than
             10 half-lives of the respective drug prior to randomisation

          9. Use of drugs which might reasonably influence the results of the trial based on the
             knowledge at the time of protocol preparation within 10 days prior to randomisation

         10. Participation in another trial with an investigational drug within 2 months prior to
             randomisation

         11. Smoker (>10 cigarettes or >3 cigars or >3 pipes/day)

         12. Inability to refrain from smoking on trial days as judged by the investigator

         13. Alcohol abuse (more than 30 g alcohol a day)

         14. Drug abuse

         15. Blood donation (more than 100 mL blood within 4 weeks prior to randomisation or during
             the trial)

         16. Excessive physical activities within 1 week prior to randomisation or during the trial

         17. Any laboratory value outside the reference range that is of clinical relevance

         18. Inability to comply with dietary regimen of the study centre
      "
NCT02273388,completed,,1,phase 1,['neoplasms'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]",['bi 6727'],['CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C'],"
        Inclusion criteria:

          1. Patients with confirmed diagnosis of advanced, non resectable and / or metastatic
             solid tumours, who have failed conventional treatment, or for whom no therapy of
             proven efficacy exists, or who are not amenable to established forms of treatment

          2. Age 18 years or older

          3. Written informed consent consistent with ICH-GCP and local legislation

          4. Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score ¿ 2

          5. Recovery from CTCAE Grade 2 - 4 therapy-related toxicities from previous chemo-,
             hormone-, immuno-, or radiotherapies (except alopecia)

             The 18 additional patients recruited at the MTD must also meet the following
             criterion:

          6. Measurable tumour deposits (RECIST) by one or more techniques (CT, MRI)

        Exclusion criteria:

          1. Serious illness or concomitant non-oncological disease considered by the investigator
             to be incompatible with the protocol

          2. Pregnancy or breastfeeding

          3. Active infectious disease or known chronic Hepatitis B/Hepatitis C infection

          4. Clinical evidence of active brain or leptomeningeal disease during the past 12 months

          5. Second malignancy currently requiring active therapy

          6. Absolute neutrophil count less than 1500 / mm3

          7. Platelet count less than 100 000 / mm3

          8. Bilirubin greater than 1.5 mg / dl (> 26 ¿mol / L, SI unit equivalent)

          9. Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater
             than 2.5 times the upper limit of normal (if related to liver metastases greater than
             five times the upper limit of normal)

         10. Serum creatinine greater than 1.5 mg / dl (> 132 ¿mol / L, SI unit equivalent)

         11. Known history of relevant QT-prolongation, e.g. long QT-syndrome

         12. Women and men who are sexually active and unwilling to use a medically acceptable
             method of contraception

         13. Treatment with other investigational drugs or participation in another clinical trial
             within the past four weeks before start of therapy or concomitantly with this trial
             (except for present trial drug)

         14. Chemo-, radio or immunotherapy within the past four weeks before start of therapy or
             concomitantly with this trial. This restriction does not apply to steroids and
             bisphosphonates.

         15. Patients unable to comply with the protocol

         16. Active alcohol or drug abuse
      "
NCT00532090,completed,,1,phase 1,['neoplasms'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['rg4733', 'rg4733', 'rg4733']","['CC(C)(C(=O)NCC(C(F)(F)F)(F)F)C(=O)NC1C2=CC=CC=C2C3=CC=CC=C3NC1=O', 'CC(C)(C(=O)NCC(C(F)(F)F)(F)F)C(=O)NC1C2=CC=CC=C2C3=CC=CC=C3NC1=O', 'CC(C)(C(=O)NCC(C(F)(F)F)(F)F)C(=O)NC1C2=CC=CC=C2C3=CC=CC=C3NC1=O']","
        Inclusion Criteria:

          -  adult patients, >=18 years of age;

          -  advanced and/or metastatic solid tumor malignancy;

          -  measurable or evaluable disease;

          -  ECOG performance status 0 or 1.

        Exclusion Criteria:

          -  prior chemotherapy, radiotherapy or immunotherapy within 28 days of first receipt of
             study drug;

          -  prior corticosteroids as anti-cancer therapy within a minimum of 14 days of first
             receipt of study drug. Dexamethasone may be allowed only as part of the supportive
             care measures;

          -  major surgery within 28 days of first receipt of study drug.
      "
NCT01181310,completed,,0,phase 1,['dementia'],"[""['F01.A11', 'F01.A4', 'F01.B11', 'F01.B4', 'F01.C11', 'F01.C4', 'F03.A11']""]","['a: placebo to match donepezil and mk-3134 + placebo to match scopolamine', 'b: placebo to match donepezil and mk-3134 + scopolamine 0.5 mg', 'c: mk-3134 25 mg + scopolamine 0.5 mg', 'd: donepezil 10 mg + scopolamine 0.5 mg', 'e: combo: donepezil 10 mg + mk-3134 25 mg + scopolamine 0.5 mg']","['Status: 503', 'Status: 503']","
        Participants were eligible for inclusion in the study who were:

          -  Male between 18 and 40 years of age.

          -  Non-smokers, in good health (as defined in protocol), and were willing to follow
             study-related procedures.

        Participants were not eligible for inclusion in the study if they:

          -  Had a history of illness that, in the opinion of the study investigator or as
             specified in protocol, might confound the results of the study or posed an potential,
             additional risk to the participant if they were to participate in the study.

          -  Were taking any medication (prescription, nonprescription, vitamin supplements or
             herbal, illicit or legitimate) except for acetaminophen.

          -  Had a history of any significant head injury/trauma.
      "
NCT00246012,completed,,0,phase 1/phase 2,['melanoma'],"[""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']""]","['intetumumab', 'dacarbazine', 'placebo']",['CN(C)N=NC1=C(NC=N1)C(=O)N'],"
        Inclusion Criteria:

          -  Histologically confirmed melanoma including ocular and mucosal

          -  Documented AJCC (American Joint Committee on Cancer) Stage 3 unresectable or Stage 4
             melanoma (Phase 1); AJCC Stage 4 melanoma (Phase 2)

          -  Radiographically measurable disease or measurable skin lesions

          -  Prior chemotherapy for metastatic melanoma will be allowed for Phase 1, while
             previously untreated for melanoma by chemotherapy will be allowed for Phase 2

          -  Agrees to protocol-defined use of effective contraception

        Exclusion Criteria:

          -  History of receiving murine or human/murine recombination products of human αν
             integrins

          -  Known human immunodeficiency virus (HIV) positivity and clinically important active
             infection

          -  Presence of bone metastases or malignant effusions (non-measurable lesions) and
             central nervous system metastases

          -  Prior radiation to target lesions

          -  Concurrent immunotherapy, biotherapy, radiotherapy, chemotherapy, or investigational
             therapy and therapeutic use of anticoagulation
      "
NCT00062127,completed,,0,phase 1,"['unspecified adult solid tumor, protocol specific']","[""['H01.009', 'H02.209', 'H02.009', 'H02.109', 'H04.209', 'H05.409', 'H10.509']""]","['irinotecan hydrochloride', 'thalidomide']","['CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7.Cl', 'C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O']","
        Inclusion Criteria:

          -  Histologically confirmed malignant solid tumor

               -  Metastatic or unresectable

               -  Standard curative or palliative therapy is no longer effective or does not exist

          -  Measurable or assessable disease

          -  No uncontrolled brain metastases

               -  Patients with brain metastases are eligible provided the following are true:

                    -  Stable neurologic status

                    -  At least 4 weeks since prior steroids or anticonvulsants

                    -  No neurologic dysfunction that would confound evaluation

          -  Performance status - Karnofsky 70-100%

          -  More than 12 weeks

          -  WBC at least 3,000/mm^3

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Bilirubin normal

          -  AST and ALT no greater than 2.5 times upper limit of normal

          -  Creatinine normal

          -  Creatinine clearance at least 60 mL/min

          -  No symptomatic congestive heart failure

          -  No unstable angina pectoris

          -  No cardiac arrhythmia

          -  No history of inflammatory bowel disease requiring therapy

          -  No chronic diarrhea syndromes

          -  No paralytic ileus

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile female patients must use 2 forms of effective contraception, including 1
             highly effective method, for at least 4 weeks before, during, and for 4 weeks after
             study participation

          -  Male patients must use effective barrier contraception during and for 4 weeks after
             study participation

          -  No prior allergic reaction attributed to compounds of similar chemical or biological
             composition to study drugs

          -  No uncontrolled seizure disorder

          -  No other concurrent uncontrolled illness that would preclude study participation

          -  No psychiatric illness or social situation that would preclude study compliance

          -  No ongoing or active infection

          -  No significant traumatic injury within the past 28 days

          -  No serious, nonhealing wounds or ulcers

          -  No bone fractures

          -  No preexisting peripheral neuropathy grade 2 or greater

          -  At least 4 weeks since prior biologic therapy

          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)

          -  See Disease Characteristics

          -  At least 4 weeks since prior radiotherapy

          -  More than 28 days since prior major surgical procedure or open biopsy

          -  At least 4 weeks since prior investigational therapy

          -  No concurrent combination antiretroviral therapy for HIV-positive patients

          -  No other concurrent investigational or commercial agents or therapies for the
             malignancy
      "
NCT01725802,completed,,1,phase 1/phase 2,"[""parkinson's disease""]","[""['G20']""]","['levodopa and carbidopa solution for sc administration', 'placebo']","['Status: 503', 'Status: 503']","
        Main Inclusion Criteria:

          -  Men and women with idiopathic Parkinson's disease

          -  Subjects must experience motor fluctuations associated with LD/CD dosing

          -  Modified Hoehn and Yahr stage < 5

          -  Subjects must be taking optimized and stable levodopa/dopa decarboxylase inhibitor
             therapy

          -  Women must be postmenopausal, surgically sterilized, or using adequate birth control.
             Women of childbearing potential must have a negative pregnancy test (serum beta-HCG)
             at screening.

          -  Subjects must be age 30 or older.

          -  Subjects must be willing and able to give informed consent.

        Main Exclusion Criteria:

          -  Subjects with a clinically significant or unstable medical or surgical condition

          -  Subjects with clinically significant psychiatric illness.

          -  Pre-menopausal women, not using birth control method.

          -  Subjects who have taken experimental medications within 60 days prior to baseline.

          -  Subject who have undergone a neurosurgical intervention for Parkinson's disease (e.g.,
             pallidotomy, thalamotomy, transplantation and deep brain stimulation).
      "
NCT00514306,completed,,1,phase 1,['advanced solid tumors'],"[""['K74.02', 'G47.22', 'H35.3133', 'H35.3134', 'H35.3113', 'H35.3114', 'H35.3123']""]",['osi-906'],['Status: 503'],"
        Inclusion Criteria:

          -  Histologically or cytologically documented malignancy that is now advanced and/or
             metastatic and refractory to established forms of therapy or for which no effective
             therapy exists

          -  Patients with Eastern Cooperative Oncology Group (ECOG) performance status </= 2

          -  Predicted life expectancy ≥ 12 weeks

          -  Patients may have had prior therapy, providing the following conditions are met:

               -  Chemotherapy: A minimum of 3 weeks (4 weeks for carboplatin or investigational
                  anticancer agents and 6 weeks for nitrosoureas and mitomycin C) must have elapsed
                  between the end of treatment and registration into this study. Prior tyrosine
                  kinase inhibitor therapy is permitted. Patients must have recovered from any
                  treatment-related toxicities (except for alopecia, fatigue, and grade 1
                  neurotoxicity) prior to registration

               -  Hormonal therapy: Patients may have had prior anticancer hormonal therapy
                  provided it is discontinued prior to registration into this study. However,
                  patients with prostate cancer with evidence of progressive disease may continue
                  on therapy that produces medical castration (eg, goserelin or leuprorelin),
                  provided this therapy was commenced at least 3 months earlier

               -  Radiation: Patients may have had prior radiation therapy provided they have
                  recovered from the acute, toxic effects of radiotherapy prior to registration. A
                  minimum of 21 days must have elapsed between the end of radiotherapy and
                  registration into the study unless the radiotherapy was palliative and
                  nonmyelosuppressive

               -  Surgery: Previous surgery is permitted provided that wound healing has occurred
                  prior to registration

          -  Fasting glucose ≤ 125 mg/dL (7 mmol/L) at baseline

          -  Potassium, calcium, and magnesium must be within normal limits (WNL). Electrolyte
             abnormalities will be permitted if they are not clinically significant and if
             treatment for the abnormality is initiated prior to Day 1

          -  Adequate hematopoietic, hepatic, and renal function defined as follows:

               -  Neutrophil count ≥ 1.5 x 10^9/L and platelet count ≥ 100 x 10^9/L

               -  Bilirubin ≤ 1.5 x ULN or ≤ 3 x ULN if patient has Gilbert's disease

               -  AST and/or ALT ≤ 2.5 x ULN or ≤ 5 x UNL if patient has documented liver
                  metastases

               -  Serum creatinine ≤ 1.5 x ULN

          -  Patients must be accessible for repeat dosing and follow-up, including pharmacokinetic
             sampling

          -  Patients - both males and females - with reproductive potential (ie, menopausal for
             less than 1 year and not surgically sterilized) must practice effective contraceptive
             measures (ie, barrier methods, eg, condom or diaphragm, with spermicide) throughout
             the study. Women of childbearing potential must provide a negative pregnancy test
             (serum or urine) within 14 days prior to registration

          -  Patients must provide written informed consent to participate in the study

        Exclusion Criteria:

          -  Documented history of diabetes mellitus

          -  History of significant cardiac disease unless the disease is well-controlled.
             Significant cardiac diseases includes second/third degree heart block; significant
             ischemic heart disease; QTc interval > 450 msec at baseline; poorly controlled
             hypertension; congestive heart failure of New York Heart Association (NYHA)Class II or
             worse (slight limitation of physical activity; comfortable at rest, but ordinary
             physical activity results in fatigue, palpitation, or dyspnea)

          -  Any type of active seizure disorder

          -  Concurrent anticancer therapy (with the exception of hormonal therapy as described
             above)

          -  Use of drugs with a risk of causing QT interval prolongation within 14 days prior to
             Day 1 and while on study

          -  Use of glucocorticoids within 14 days prior to Day 1 dosing and while on study, with
             the exception of hormone replacement therapy or inhalers

          -  History of any kind of stroke

          -  Previously diagnosed brain metastases (includes active brain metastases)

          -  Active or uncontrolled infections or serious illnesses or medical conditions that
             could interfere with the patient's ongoing participation in the study

          -  History of any psychiatric condition that might impair the patient's ability to
             understand or to comply with the requirements of the study or to provide informed
             consent

          -  Pregnant or breast-feeding females

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to the study drug
      "
NCT01314885,completed,,1,phase 1,['chronic obstructive pulmonary disease (copd)'],"[""['G91.1', 'I42.1', 'N11.1', 'J05.0', 'P28.42', 'G47.33', 'J44.9']""]","['pf-03715455', 'ph-797804', 'placebo for pf-03715455', 'placebo for ph-797804']","['CC(C)(C)C1=NN(C(=C1)NC(=O)NCC2=CC=CC=C2SC3=CN4C(=NN=C4C5=CC=CC=C5SCCO)C=C3)C6=CC(=C(C=C6)O)Cl', 'Status: 503', 'Status: 503']","
        Inclusion Criteria:

          -  Male or female (of non-child bearing potential) subjects, aged 18-50 years.

          -  Subjects whose FEV1 and FVC at screening are both greater than or equal to 80% of
             their predicted value for age, race, sex and height.

          -  Subjects who have normoresponsive airways.

          -  Subjects who are able to successfully complete screening sputum inductions.

        Exclusion Criteria:

          -  Subjects who have evidence, on review of pre-study laboratory data and full physical
             examination, or history of any clinically significant hematological, renal, endocrine,
             gastrointestinal, dermatological, hepatic, psychiatric, neurologic diseases.
             Specifically liver function tests and CRP must be within the reference range.

          -  Subjects with a medical history of asthma symptomatology (ie, wheeze and/or dyspnea at
             rest).

          -  Subjects who have experienced a respiratory tract infection within the previous 4
             weeks or any other infection within 1 week of dosing
      "
NCT00765765,terminated,"
    slow accrual
  ",0,phase 1/phase 2,['breast cancer'],"[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['hydroxychloroquine', 'ixabepilone']","['CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO', 'CC1CCCC2(C(O2)CC(NC(=O)CC(C(C(=O)C(C1O)C)(C)C)O)C(=CC3=CSC(=N3)C)C)C']","
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed breast cancer

               -  Histologic or cytologic elements can be established on metastatic tumor aspirate
                  or biopsy

               -  Metastatic disease

               -  Measurable disease according to RECIST criteria

          -  Must have received 2 prior chemotherapy regimens for metastatic breast cancer

          -  Anthracycline-resistant (or treated with minimum cumulative doxorubicin dose of 240
             mg/m^2 or epirubicin dose of 360 mg/m^2) and taxane-resistant disease

               -  Anthracycline resistance is defined as progression while on therapy or within 6
                  months in the adjuvant/neoadjuvant setting or 3 months in the metastatic setting

               -  Taxane resistance is defined as progression while on therapy or within 12 months
                  in the adjuvant/neoadjuvant setting or 4 months in the metastatic setting

          -  Hormone receptor status known

          -  No known CNS metastases or previously treated and now stable CNS metastases

        PATIENT CHARACTERISTICS:

          -  Menopausal status not specified

          -  ECOG performance status 0-2

          -  ANC ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 9 g/dL

          -  Total bilirubin ≤ upper limit of normal (ULN)

               -  If patient has Gilbert's disease, then patient must have isolated
                  hyperbilirubinemia (e.g., no other liver function test abnormality), with maximum
                  bilirubin ≤ 2 times ULN

          -  AST and ALT ≤ 2.5 times ULN, independently of liver metastases

          -  Alkaline phosphatase ≤ 2.5 times ULN

          -  Creatinine ≤ 1.5 times ULN OR calculated creatinine clearance ≥ 60 mL/min

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other active malignancy

               -  History of basal cell or squamous cell carcinoma of the skin or carcinoma in situ
                  of the cervix within the past 3 years allowed provided patient has been treated
                  with curative intent

               -  History of prior malignancy allowed provided patient has been treated with
                  curative intent and has been disease free > 3 years

          -  None of the following conditions within the past 6 months:

               -  Myocardial infarction

               -  Stroke

               -  Symptomatic peripheral vascular disease

          -  No unstable angina or NYHA class II-IV congestive heart failure

          -  No history of psoriasis or porphyria

          -  No history of hypersensitivity to 4-aminoquinoline compound

          -  No retinal or visual field changes from prior 4-aminoquinoline-compound use

          -  No history of G6PD deficiency

          -  No GI pathology that would interfere with drug bioavailability

          -  No motor or sensory neuropathy ≥ grade 2 (NCI CTCAE) at study entry

          -  No serious uncontrolled medical disorder or active infection at study entry

          -  No rheumatoid arthritis or systemic lupus erythematosus requiring active treatment

          -  No history of HIV

          -  No history of any condition (social or medical) that, in the opinion of the
             investigator, might interfere with the patient's ability to comply with the protocol
             or pose additional or unacceptable risk to the patient

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Prior radiation to tumor sites allowed provided:

               -  Radiation was completed ≥ 3 weeks prior to study treatment

               -  All radiation-related toxicities have resolved to ≤ grade 1

          -  No more than 3 prior chemotherapy regimens in the metastatic setting

          -  No prior ixabepilone or another epothilone

          -  No concurrent highly active antiretroviral therapy

          -  No other concurrent hydroxychloroquine for treatment or prophylaxis of malaria

          -  No other concurrent anticancer investigational or commercial agents or therapies
      "
NCT00480987,terminated,"
    lack of support.
  ",0,phase 1/phase 2,"['myelodysplastic syndromes', 'acute myeloid leukemia', 'leukemia']","[""['D46.9', 'D46.C', 'D46.Z']"", ""['C92.A1', 'C92.A2', 'C92.61', 'C92.62', 'C92.A0', 'C92.60']"", ""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']""]","['oxaliplatin', 'fludarabine', 'cytarabine']","['C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]', 'C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O']","
        Inclusion Criteria:

          -  Histologically or cytologically confirmed relapsed or refractory acute myeloid
             leukemia (AML) or high-risk myelodysplastic syndrome.

          -  Performance status 0-2 (Zubrod scale).

          -  Serum creatinine equal or less than 1.3 mg/dL or creatinine clearance > 40 mL/min.

          -  Bilirubin </= 2 mg/dL; serum glutamic oxaloacetic transaminase (SGOT) or Serum
             glutamic pyruvic transaminase (SGPT) </= 3 times the Upper Limit of Normal (ULN) for
             the reference lab unless due to leukemia or congenital hemolytic disorder (for
             bilirubin).

          -  Written informed consent.

        Exclusion Criteria:

          -  No untreated or uncontrolled life-threatening infection.

          -  No oxaliplatin, fludarabine, or cytarabine intolerance.

          -  No pregnancy or lactation. Female patients of childbearing potential (including those
             < 1 year post-menopausal) and male patients must agree to use contraception.

          -  No chemotherapy or radiation therapy within 4 weeks of study entry. Hydroxyurea is
             allowed prior to starting therapy in the setting of rapidly proliferating disease.

          -  No other medical condition, including mental illness or substance abuse, deemed by the
             Investigator to be likely to interfere with a patient's ability to sign informed
             consent or cooperate and participate in the study or to interfere with the
             interpretation of the results.
      "
NCT00508365,completed,,1,phase 1,['hypertension'],"[""['I15.0', 'I97.3', 'K76.6', 'P29.2', 'G93.2', 'H40.053', 'I10']""]","['carvedilol cr capsules', 'placebo', 'lisinopril']",['C1CC(N(C1)C(=O)C(CCCCN)NC(CCC2=CC=CC=C2)C(=O)O)C(=O)O'],"
        Inclusion Criteria:

          -  Males or females who are ≥ 65 years of age

          -  Body mass index (BMI) between 24 and 37 kg/m2 where: BMI = (weight in kg)/ (height in
             meters)2

          -  Subjects must have a documented history of essential hypertension and must be stable
             on treatment with an ACE inhibitor or angiotensin II receptor antagonist or renin
             antagonist and no more than one other antihypertensive medication at least 3 months
             before screening with a sitting SBP<180 mmHg and DBP<110 mmHg.

          -  All subjects must be able to be safely (in the opinion of the Investigator) withdrawn
             or down-titrated from all antihypertensive treatment(s) and transitioned to lisinopril
             10 mg OD for the two-week run-in phase.

        Exclusion Criteria:

          -  Any clinically relevant abnormality identified on the screening history, physical or
             laboratory examination, or any other medical condition or circumstance making the
             volunteer unsuitable for participation in the study

          -  Subject who metabolizes carvedilol poorly based on CYP2D6 genotype as determined at
             screening

          -  Subject has persistent hyperkalemia or history of hyperkalemia resulting from either
             Type IV RTA (renal tubular acidosis) or previous treatment with an ACE inhibitor, ARB
             or renin inhibitor.

          -  Subject has malignant (accelerated) hypertension, history of malignant hypertension,
             or history of secondary forms of hypertension

          -  Subject has advanced hypertensive retinopathy (Keith Wagner Grade IV)

          -  Subject has a history of hepatic impairment (characterized by prolonged prothrombin
             time/low concentrations of albumin) and/or renal insufficiency (subjects with an
             estimated CrCl ≤ 30 mL/min by Cockroft-Gault must be excluded). CrCL =
             [140-ageCr][weight/70] x 0.85 (if female); Cr in mg/dL; Weight in kg

          -  Subject is being treated for diabetes mellitus

          -  Subject has a history of angioedema

          -  Subject has been under treatment with 3 or more antihypertensive medications. (NOTE: A
             combination drug containing two antihypertensive agents represents two
             antihypertensive medications.)

          -  Subject has been under treatment with HCTZ > 12.5 mg/day

          -  Subject is receiving ongoing treatment or is anticipated to receive treatment with any
             of the following medications during the study:

               -  monoamine oxidase inhibitors (MAO)

               -  any Class I or III antiarrhythmic

               -  alpha-adrenergic receptor blockers

               -  beta-2-adrenergic agonists

               -  all antidepressants including SSRIs

               -  lithium

               -  medications known to be inhibitors/inducers of cytochrome P-450 2D6 should be
                  discontinued for at least 14 days or 5 half-lives [which ever is longer] prior to
                  the first day of the run-in period

          -  Treatment with any over-the-counter medications , herbal and dietary supplements, as
             well as grapefruit-containing products within 7 days or 5 half-lives (whichever is
             longer) prior to first day of run-in period through the end of the study unless
             approved by the PI and GSK medical monitor. Standard vitamins and/or daily
             multi-vitamins are permitted, however herbal vitamins should be excluded.

          -  Treatment with an investigational drug within 30 days or 5 half-lives (whichever is
             longer) preceding the run-in period

          -  Subject has mean sitting SBP ≥ 180 mmHg at the screening assessment (one set of repeat
             measurement is permitted as per approval by the medical monitor).

          -  Documented history of low blood pressure within six months of screening visit (average
             sitting SBP < 110 mm Hg and/or DBP /< 50 mm Hg) or blood pressure below these values
             at time of screening (one set of repeat measurement is permitted as per approval by
             the medical monitor).

          -  Orthostatic hypotension diagnosed at screening (orthostatic hypotension is defined as
             a reduction in systolic blood pressure of 20 mmHg or more and/or a reduction in
             diastolic blood pressure of 10 mmHg or more for standing vs. supine measurements)

          -  Subject has any of the following conditions:

               -  uncontrollable or symptomatic arrhythmias; unstable angina

               -  sick sinus syndrome or second or third degree heart block (unless treated with a
                  permanent, functioning pacemaker)

               -  bradycardia (seated heart rate <55 bpm) (one repeat measurement is permitted as
                  per approval by the medical monitor) ; history of myocardial infarction, or
                  history of stroke within 1 year of screening.

               -  subject is in, or has a history of atrial fibrillation

          -  Any of the following abnormalities on 12-lead ECG during screening:

               -  complete RBBB or LBBB

               -  evidence of second- or third-degree AV block

               -  pathological Q-waves (Q-wave wider than 0.04 sec or depth greater than 0.4-0.5
                  mV)

               -  any other abnormalities that investigator feels could be of concern when patient
                  is taking a β-adrenergic blocking agent

          -  Donation of blood in excess of 500 mL within a 56-day period including the estimated
             150 mL of blood to be drawn during this study

          -  History of asthma, COPD and/or hypersensitivity to β -adrenergic blocking agents

          -  History of sensitivity to carvedilol, lisinopril, alpha-blockers, beta-blockers or ACE
             inhibitors

          -  History of sensitivity to any of the study medications or components thereof

          -  History of anaphylaxis or anaphylactoid reactions or severe allergic responses to
             drugs

          -  History of regular alcohol consumption exceeding 7 drinks/week for women or 14
             drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of
             hard liquor) within 6 months of screening

          -  Unanticipated positive urine drug screen (UDS) at screening. Note: If the subject is
             taking a drug known to give a positive on the UDS, then this should be discussed with
             the medical monitor prior to sending the UDS. In this situation, with prior approval,
             a positive finding on the UDS will not be considered an exclusion

          -  Positive for Hepatitis B surface antigen or HIV

          -  Unwillingness or inability to follow the procedures outlined in the protocol or
             inability to provide written informed consent
      "
NCT00516165,completed,,0,phase 1/phase 2,['hepatocellular carcinoma'],"[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]",['rad001'],['Status: 503'],"
        Inclusion Criteria:

          -  Unresectable of metastatic HCC. Patients must have prior core biopsy to confirm the
             diagnosis of HCC and have archived tissues available for correlative studies

          -  At least one measurable site of disease according to RECIST criteria that has not been
             previously irradiated. If it has had previous radiation to teh marker lesion(s), there
             must be evidence of progression since the radiation

          -  0-2 prior systemic chemotherapy and biologic regimens for hepatocellular carcinoma

          -  Patients with prior chemoembolization history can participate in the study if the
             chemoembolization was performed more than 4 weeks ago and patients must have
             measurable disease outside of prior chemoembolization field

          -  18 years of age or older

          -  Minimum of 4 weeks since any major surgery or completion of radiation

          -  Minimum of 4 weeks since completion of all prior systemic anticancer therapy

          -  ECOG performance status of 0-2

          -  CLIP score of equal to or less then 3

          -  Adequate bone marrow, liver and renal function as outlined in the protocol

        Exclusion Criteria:

          -  Prior treatment with any investigational drug within the preceding 4 weeks

          -  Chronic treatment with systemic steroids or another immunosuppressive agent

          -  Uncontrolled brain or leptomeningeal metastases, including patients who continue to
             require glucocorticoids for brain or leptomeningeal metastases

          -  Patients with any severe and/or uncontrolled medical conditions or other condition
             that could affect participation in the study

          -  Known history of HIV seropositivity

          -  Impairment of gastrointestinal function or gastrointestinal disease that may
             significantly alter the absorption of RAD001

          -  Active, bleeding diathesis

          -  Women who are pregnant or breast feeding

          -  Patients who have received prior treatment with an mTor inhibitor

          -  Patients with known hypersensitivity to RAD001 or other rapamycins or its excipients

          -  History of non-compliance to medical regimens

          -  Patients with a positive dipstick for urine protein (reading of 2+ or greater) will
             then undergo a 24-hour urine collection for protein. If patients have a 2g or greater
             of protein/24hr, they will be excluded from the study.
      "
NCT01542047,terminated,"
    low rate of accrual
  ",0,phase 1,"['cancer, metastatic']","[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]","['carboplatin', 'pazopanib']","['C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]', 'CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N']","
        Inclusion Criteria:

          -  18 years of age or older

          -  Histologically confirmed advanced solid tumor type that is FDA approved for treatment
             with Carboplatin.

          -  Life expectancy at least 12 wks

          -  ECOG performance status of 0-2

          -  Provide written informed

          -  Adequate organ system function

        FEMALES:

          -  Non-childbearing potential, who has had:

          -  A hysterectomy

          -  A bilateral oophorectomy (ovariectomy)

          -  A bilateral tubal ligation

          -  Is post-menopausal

          -  Complete abstinence from sexual intercourse 14 days before, during and at least 21
             days after the last dose of investigational product

          -  Oral contraceptive

          -  Injectable progestogen

          -  Implants of levonorgestrel

          -  Estrogenic vaginal ring

          -  Percutaneous contraceptive patches

          -  Intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate
             of less than 1% per year

          -  Sole male partner sterilization prior to the female subject's entry - Double barrier
             method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal
             spermicidal agent (foam/ gel/ film/cream/suppository)

          -  If lactating: discontinue nursing prior to the first dose, during and for 14 days
             following the last dose of study drug

        Exclusion Criteria:

          -  History or clinical evidence of central nervous system (CNS) metastases or
             leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS
             metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure
             medication for 6 months prior to first dose of study drug.

          -  Screening with CNS imaging studies (computed tomography [CT] or magnetic resonance
             imaging [MRI]) is required only if clinically indicated or if the subject has a
             history of CNS metastases.

          -  Clinically significant gastrointestinal abnormalities that may increase the risk for
             gastrointestinal bleeding including, but not limited to:

          -  Active peptic ulcer disease

          -  Known intraluminal metastatic lesion/s with risk of bleeding

          -  Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or

          -  other gastrointestinal conditions with increased risk of perforation

          -  History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess
             within 28 days prior to beginning study treatment

          -  Clinically significant gastrointestinal abnormalities that may affect absorption of
             investigational product including, but not limited to:

          -  Malabsorption syndrome

          -  Major resection of the stomach or small bowel.

          -  Presence of uncontrolled infection

          -  Corrected QT interval (QTc) > 480 msecs using Bazett's formula

          -  History of any one or more of the following cardiovascular conditions within the past
             6 months:

          -  Cardiac angioplasty or stenting

          -  Myocardial infarction

          -  Unstable angina

          -  Coronary artery bypass graft surgery

          -  Symptomatic peripheral vascular disease

          -  Class III or IV congestive heart failure, as defined by the New York Heart Association
             (NYHA)

          -  Poorly controlled hypertension [defined as systolic blood pressure (SBP) of greater
             than or equal to 140 mmHg or diastolic blood pressure (DBP) of greater than or equal
             to 90mmHg]

        Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to
        study entry.

          -  History of cerebrovascular accident including transient ischemic attack (TIA),
             pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months
             Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulating
             agents for at least 6 weeks are eligible

          -  Prior major surgery or trauma within 28 days prior to first dose of study drug and/or
             presence of any non-healing wound, fracture, or ulcer (procedures such as catheter
             placement not considered to be major)

          -  Evidence of active bleeding or bleeding diathesis

          -  Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels

          -  Hemoptysis within 8 weeks of first dose of study drug

          -  Any serious and/or unstable pre-existing medical, psychiatric, or other condition that
             could interfere with subject's safety, provision of informed consent, or compliance
             with study procedures

          -  Treatment with any of the following anti-cancer therapies:

          -  Radiation therapy, surgery or tumor embolization within 14 days prior to the first
             dose of pazopanib OR

          -  Chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal
             therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the
             first dose of pazopanib

          -  Any ongoing toxicity from prior anti-cancer therapy that is greater than Grade 1
             and/or that is progressing in severity, except alopecia
      "
NCT01723735,completed,,1,phase 1,['hypercholesterolemia'],"[""['E78.01', 'E78.00', 'Z83.42']""]","['alirocumab', 'ezetimibe', 'ezetimibe placebo', 'fenofibrate']","['Status: 503', 'Status: 503', 'Status: 503', 'Status: 503']","
        Inclusion criteria :

          -  Healthy male /or female subjects,

          -  aged 18 to 65 years old,

          -  with LDL-C > 130 mg/dL

          -  not receiving lipid lowering therapy.

        Exclusion criteria:

          -  Healthy subjects with history or presence of clinically relevant illness.

          -  Subjects currently taking statins, ezetimibe or fenofibrate.

          -  The above information is not intended to contain all considerations relevant to a
             patient's potential participation in a clinical trial.
      "
NCT00098332,completed,,1,phase 1,['lymphoma'],"[""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']""]",['forodesine hydrochloride'],['C1=C(C2=C(N1)C(=O)NC=N2)C3C(C(C(N3)CO)O)O.Cl'],"
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed cutaneous T-cell lymphoma

               -  Refractory to prior treatment

               -  Stage IIA, IIB, III, IVA, or IVB disease

          -  Measurable disease

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  At least 3 months

        Hematopoietic

          -  Not specified

        Hepatic

          -  AST and/or ALT ≤ 3 times upper limit of normal

          -  Hepatitis B and/or hepatitis C negative

        Renal

          -  Creatinine clearance ≥ 40 mL/min

        Immunologic

          -  Human T-cell lymphotrophic virus type I (HTLV-I) negative

          -  HIV negative

          -  No active serious infection not controlled by antibiotics

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No known impaired absorption of the gastrointestinal tract

          -  No other illness that would preclude study participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  More than 21 days since prior chemotherapy and recovered

        Endocrine therapy

          -  Concurrent topical corticosteroids allowed provided patient remains on a stable dose

        Radiotherapy

          -  No concurrent radiotherapy

        Surgery

          -  Not specified

        Other

          -  More than 30 days since prior investigational agents and recovered

          -  No concurrent tanning bed use

          -  No other concurrent therapy for cutaneous T-cell lymphoma
      "
NCT00403416,completed,,0,phase 1/phase 2,['kidney transplantation'],"[""['N26.2', 'Q63.0', 'Q63.2', 'Z52.4', 'I75.81', 'N19', 'N20.0']""]","['aeb071', 'mycophenolic acid']","['CN1CCN(CC1)C2=NC3=CC=CC=C3C(=N2)C4=C(C(=O)NC4=O)C5=CNC6=CC=CC=C65', 'CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)O)O']","
        Inclusion criteria

          -  Male and female patients of any race 18 years or older

          -  Adult recipients of a kidney transplant from a deceased or from a living donor

          -  Recipients of a functioning Kidney:. Graft must be functional no later than 36h after
             transplantation.

        Exclusion criteria

          -  Need for medication prohibited by the protocol

          -  Patients or donors infected with hepatitis B or C, or with HIV.

          -  Patients with a history of cancer

          -  Patients with severe systemic infections Patients with heart diseases (own or family
             history) which are associated with an increased risk for arrhythmias.

        Other protocol-defined inclusion/exclusion criteria may apply
      "
NCT00003005,completed,,0,phase 1,['leukemia'],"[""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']""]","['cordycepin', 'deoxycoformycin']","['Status: 503', 'Status: 503']","
        DISEASE CHARACTERISTICS: TdT positive acute lymphocytic leukemia or blastic chronic
        myelogenous leukemia Failed at least one standard treatment

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky greater than 70%
        Life expectancy: At least 3 months Hematopoietic: Not specified Hepatic: Bilirubin no
        greater than 2.0 mg/dL Transaminases no greater than 2.5 times normal Renal: Creatinine no
        greater than 1.5 mg/dL Creatinine clearance greater than 60 mL/min Cardiovascular: Ejection
        fraction greater than 40% Other: Not pregnant or nursing No serious concurrent illness

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 3 weeks
        since chemotherapy No concurrent chemotherapy Endocrine therapy: Not specified
        Radiotherapy: At least 3 weeks since radiation therapy Surgery: Not specified
      "
NCT00649207,completed,,1,phase 1,"['brain diseases', 'brain neoplasms', 'central nervous system diseases', 'neoplasm metastasis', 'nervous system neoplasms']","[""['G46.8', 'G94']"", ""['C71.7', 'C71.9', 'C79.31', 'D33.0', 'D33.1', 'D33.2', 'D49.6']"", ""['G37.9', 'G37.3', 'G13.1', 'G09', 'G13.8', 'G37.8']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]",['abt-888'],['CC1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N.Cl.Cl'],"
        Inclusion Criteria:

          -  Age is greater than or equal to 18 years.

          -  Histologically or cytologically confirmed non-CNS primary solid malignancy.

          -  Pathologically or radiographically confirmed metastatic disease in the brain. Subjects
             with non-measurable lesions, including leptomeningeal carcinomatosis, are eligible.

          -  WBRT is clinically indicated, with the exception of prophylactic treatment.

          -  Karnofsky Performance Status (KPS) greater than or equal to a score of 70.

          -  Adequate hematology, renal and hepatic function.

          -  Both men and women of childbearing potential must agree to use adequate contraception
             (one of the following listed below) prior to study entry, for the duration of study
             participation and up to 2 months following completion of protocol therapy.

               -  Total abstinence from sexual intercourse (minimum one complete menstrual cycle)

               -  A vasectomized partner * Hormonal contraceptives (oral, parenteral or
                  transdermal) for at least 3 months prior to study drug administration

               -  Double-barrier method (condoms, contraceptive sponge, diaphragm or vaginal ring
                  with spermicidal jellies or cream)

          -  Subject is capable of understanding and complying with parameters as outlined in the
             protocol.

          -  Subject or the subject's legally acceptable representative has voluntarily signed and
             dated the informed consent, approved by an Independent Ethics Committee
             (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or
             study-specific procedures.

        Exclusion Criteria:

          -  Brain metastases secondary to germ cell tumor or lymphoma malignancy.

          -  Primary central nervous system (CNS) neoplasm.

          -  Prior or concurrent administration of the following therapies or treatments:

               -  Prior treatment with WBRT

               -  SRS performed less than 14 days prior to WBRT D1, or is scheduled to occur within
                  30 days of the last WBRT session

               -  Last dose of chemotherapy, immunotherapy, biologic therapy, or investigational
                  therapy was less than 14 days prior to WBRT D1. Bisphosphonates, hormone
                  modification therapy, and trastuzumab are permitted without restriction

          -  Unresolved or unstable, serious toxicity from prior administration of another
             investigational drug and/or prior anti-cancer treatment.

          -  Known seizure disorder (status epileptics) that is uncontrolled, or seizures occurring
             greater than or equal to 3 times a week over the past month.

          -  If female, subject is pregnant or breast-feeding.

          -  Clinically significant and uncontrolled major cardiac, respiratory, renal, hepatic,
             gastrointestinal, hematologic or neurological/psychiatric disease or disorder,
             including but not limited to:

               -  Active uncontrolled infection

               -  Symptomatic congestive heart failure, unstable angina pectoris, or cardiac
                  arrhythmia

               -  Any other illness condition(s) that could exacerbate potential toxicities,
                  confound safety assessments, require excluded therapy for management, or limit
                  compliance with study requirements

          -  Unable to swallow and retain oral medications.

          -  Known contraindication to enhanced MRI and CT, including but not limited to:

               -  Presence of metal objects within the body such as a cardiac pacemaker, implanted
                  cardiac defibrillator, brain aneurysm clips, cochlear implant, ocular foreign
                  body, or shrapnel

               -  History of immediate or delayed hypersensitivity reaction or other
                  contraindication to contrast agents including but not limited to gadolinium and
                  iodine

          -  Previous enrollment in this study or another study involving the investigation of
             ABT-888, with the exception of receiving a single dose of study drug.

          -  Consideration by the investigator, for any reason, that the subject is an unsuitable
             candidate to receive ABT-888 and/or WBRT.
      "
NCT00633997,terminated,"
    after analysis of the existing data, it was determined that additional skin biopsy samples
    would not be required to determine study outcome.
  ",1,phase 1/phase 2,"['diabetes mellitus, type 2']","[""['E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', 'E11.44']""]","['vildagliptin', 'vildagliptin']","['C1CC(N(C1)C(=O)CNC23CC4CC(C2)CC(C4)(C3)O)C#N', 'C1CC(N(C1)C(=O)CNC23CC4CC(C2)CC(C4)(C3)O)C#N']","
        Inclusion Criteria:

          -  Healthy volunteers and patients with type 2 diabetes

          -  Non-smoking, Caucasian and African American, male and female (postmenopausal,
             surgically sterile or using double-barrier method of contraception) subjects between
             30 and 65 years of age (inclusive)

          -  Type 2 diabetics on metformin and/or sufonylurea

        Exclusion Criteria:

          -  History of type 1 diabetes or insulin use

          -  History of coagulation abnormalities

          -  History of abnormal heart conditions

          -  Pregnancy or breastfeeding

        Other protocol-defined inclusion/exclusion criteria may apply
      "
NCT01288261,completed,,1,phase 1,"['human epidermal growth factor 2 negative carcinoma of breast', 'male breast cancer', 'recurrent breast cancer', 'stage iiic breast cancer', 'stage iv breast cancer']","[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C50.021', 'C50.022', 'C50.029', 'C50.121', 'C50.122', 'C50.129', 'C50.621']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]",['paclitaxel'],['Status: 503'],"
        Inclusion Criteria:

          -  Written informed consent has been obtained

          -  Life expectancy of at least 3 months

          -  Histologically or cytologically confirmed, Her-2 negative breast cancer with evidence
             of metastatic disease

          -  Measurable or evaluable disease by Response Evaluation Criteria In Solid Tumors
             (RECIST)

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status =< 2

          -  Adequate hematologic function (absolute neutrophil count [ANC] >= 1,500 cells/uL;
             hemoglobin >= 9 g/dL; platelets >= 100,000/uL and =< 500,000/uL)

          -  Adequate renal function (serum creatinine =< 1.5 mg/dL or calculated creatinine
             clearance >= 60 ml/min)

          -  Adequate hepatic function (total or direct bilirubin =< Upper Limit of Normal (ULN),
             Alk Phos =< 4 x ULN)

          -  Prothrombin time international normalized ratio within institutional normal limits

          -  Activated partial thromboplastin time =< 1.5 x ULN

          -  New York Heart Association classification I or II

          -  Female patients must have a negative urine pregnancy test at prestudy (not applicable
             to patients with bilateral oophorectomy and/or hysterectomy or to those patients who
             are postmenopausal)

        Exclusion Criteria:

          -  Known history of bleeding diathesis or coagulopathy (e.g., von Willebrand Disease,
             Hemophilia)

          -  Any current evidence of clinically significant active bleeding

          -  Any history of significant thromboembolic events (i.e., deep vein thrombosis or
             pulmonary thromboembolism) within the last five years or requirement for ongoing
             therapy with oral or parenteral anticoagulants; central venous catheter-related
             thrombosis > 12 months ago and low dose anticoagulants to maintain patency of lines
             are allowed; patients taking anticoagulants (e.g., prophylactic heparin or enoxaparin)
             are required to observe the washout period of 1 week prior to study drug infusion on
             Study Day 1

          -  Concurrent hormone therapy (i.e., estrogen contraceptives, hormone replacement,
             anti-estrogen); patients taking concurrent hormone therapy are required to observe the
             washout period of 2 weeks prior to study drug infusion on Study Day 1

          -  Grade 2 or higher peripheral neuropathy (e.g., numbness, tingling, and/or pain in
             distal extremities)

          -  More than one prior chemotherapy regimen for metastatic disease (prior adjuvant
             chemotherapy or any number of prior hormonal therapies are allowed)

          -  Chemotherapy, immunotherapy or radiotherapy within 2 weeks of Study Day 1 or not
             having recovered from significant treatment-related side effects due to agents
             administered previously; patients who have receive nitrosoureas and mitomycin C
             therapy are required to observe the washout period of 6 weeks prior to study drug
             infusion on Study Day 1

          -  Allergy to polysorbate 80 or drugs containing polyoxyethylated castor oil (e.g.
             cyclosporine)

          -  Symptomatic or clinically active Central Nervous System (CNS) disease

          -  Major surgery within 4 weeks of Study Day 1

          -  Female patients pregnant or nursing

          -  All patients of reproductive potential must agree to use appropriate non-hormonal form
             of contraception

          -  Uncontrolled intercurrent disease (e.g., diabetes, hypertension, thyroid disease)

          -  Any history of angina pectoris, coronary artery disease or cerebrovascular accident,
             or transient ischemic attack

          -  A history of any condition requiring anti-platelet therapy (e.g., phosphodiesterase
             inhibitors, adenosine diphosphate receptor antagonists) with the exception of general
             cardiovascular prophylaxis with aspirin

          -  Cardiac arrhythmia requiring medical therapy

          -  Serious non-healing wound (including wound healing by secondary intention, ulcer, or
             bone fracture)

          -  Requirement for chronic daily steroid use

          -  Known chronic infection with Human Immunodeficiency Virus (HIV), Hepatitis B Virus
             (HBV), or Hepatitis C Virus (HCV)
      "
NCT00354419,terminated,"
    low accrual
  ",0,phase 1,['aplastic anemia'],"[""['D61.3', 'D61.9', 'D61.09', 'D61.1', 'D61.2', 'D61.89']""]","['cyclophosphamide', 'cyclosporine', 'mycophenolate mofetil']","['C1CNP(=O)(OC1)N(CCCl)CCCl', 'CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C', 'CC1=C2COC(=O)C2=C(C(=C1OC)CC=C(C)CCC(=O)OCCN3CCOCC3)O']","
        Inclusion Criteria:

          -  Life-threatening marrow failure of nonmalignant etiology meeting two of the three
             following criteria: granulocytes < 500/mm^3; a corrected reticulocyte count < 1%;
             platelet count < 20,000/mm^3

          -  Failure to respond to the best available immunosuppressive treatment protocol by 75
             days after initiation of therapy

          -  Lack of an HLA-identical family member or closely matched (9 or 10 of 10 HLA-locus
             match) unrelated marrow donor

          -  DONOR: Unrelated UCB unit matched for at least 4 of 6 loci

          -  DONOR: Related UCB unit matched for at least 3 of 6 lock

          -  Selection of the UCB unit(s) will be based upon matching or mismatching at HLA-A, B
             antigen level and DRB1 allele level typing; while HLA-C antigen/allele and HLA-DQB1
             antigen/allele level typing are not considered in the matching criteria, if available
             each may be used to optimize unit selection

          -  Multiple UCB units are allowed to provide sufficient cell dose; when multiple units
             are selected, the following rules apply: a) the UCB unit with the least HLA disparity
             will be selected first (i.e., selection priority is 6/6 match > 5/6 match > 4/6
             match), additional UCB units may be selected to increase cell dose; b) UCB units must
             be matched to each other for at least 4 of 6 loci; c) each unit must contain at least
             1.5 x 10^7 Total Nucleated Cells per kg recipient weight; d) the total cell dose of
             the combined units must be at least 3.0 x 10^7 Total Nucleated Cells per kg recipient
             weight

        Exclusion Criteria:

          -  Severe disease other than aplastic anemia that would severely limit the probability of
             survival during the graft procedure; patients who present with active fungal
             infections must be treated to resolve this problem before beginning the conditioning
             regimen

          -  HIV seropositive patients

          -  Patients who have developed clonal cytogenetic abnormalities or a myelodysplastic
             syndrome (these patients will be considered in separate protocols for myelodysplastic
             syndrome, etc.)

          -  Patients with paroxysmal nocturnal hemoglobinuria or Fanconi anemia

          -  Patients > 40 years of age

          -  Related or unrelated cord blood units with < 1.5 x 10^7 Total Nucleated Cells per kg
             recipient weight

          -  Related or unrelated cord blood units without full testing and negative results for
             hepatitis A, B, C, HIV, HTLV-1, CMV viruses
      "
NCT01106859,completed,,1,phase 1,['insomnia'],"[""['F51.01', 'F51.02', 'F51.03', 'F51.04', 'G47.00', 'G47.09', 'A81.83']""]","['zopiclone', 'zolpidem tartrate sublingual tablet', 'placebo (sublingual tablet)', 'placebo']",['CN1CCN(CC1)C(=O)OC2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl'],"
        Inclusion Criteria:

          -  Male or female subjects between the ages of 21 and 64 inclusive. For female subjects
             only: Female subjects will be included if they are post-menopausal or sterilized, or
             if they are of childbearing potential, they are not breastfeeding, their pregnancy
             test is negative, they have no intention of becoming pregnant during the course of the
             study, and are using adequate contraceptive drugs or devices. Medically acceptable
             methods of contraception that may be used by the subject and/or her partner are: oral
             contraceptives, progestin injection or implants, condom with spermicide, diaphragm
             with spermicide, IUD, vaginal spermicidal suppository, surgical sterilization or
             abstinence. Females using oral contraception must have started using the medication at
             least 4 weeks prior to screening. Surgical sterilization must have occurred at least 6
             weeks prior to screening.

          -  Good health on the basis of pre-study history and physical examination, vital signs
             and the results of blood chemistry, hematology, and urinalysis

          -  Good binocular visual acuity, corrected or uncorrected

          -  Possession of valid driver's license for 3 years or more

          -  Driving experience at least 3000 km/year

          -  Signed informed consent

        Exclusion Criteria:

          -  A history of drug addiction or drug or substance abuse, including alcohol abuse,
             within the past 12 months

          -  Has a history of restless legs syndrome, sleep apnea, narcolepsy or other primary
             sleep disorder

          -  A known hypersensitivity to zolpidem or zopiclone

          -  Has undergone oral surgery, tooth extraction or piercing of the lip/tongue within 60
             days prior to screening

          -  Has used any medication to promote sleep, including herbal medications, within 14 days
             (or 5 half-lives of the drug, whichever is longer) prior to screening

          -  Prescription medications for other health conditions are allowed as long as the
             subject has been on a stable dose at least 30 days prior to screening

          -  Has taken any drugs known to induce hepatic drug metabolism (i.e., rifampin) within 30
             days prior to screening

          -  BMI > 29 Kg/M^2

          -  Current use of medication that affects driving performance

          -  Smokes more than 10 cigarettes/day

          -  Uses tobacco products during periods of nighttime awakening

          -  Consumes more than 6 cups of coffee/day

          -  Consumes more than 21 glasses of alcohol/week

          -  Has received an investigational drug within 60 days or 5 half-lives (whichever is
             longer) prior to screening

          -  Has any additional condition(s) that in the Investigator's opinion would:

               -  Affect sleep/wake function

               -  Prohibit the subject from completing the study

               -  Not be in the best interest of the subject to participate in the study
      "
NCT01050764,terminated,"
    safety
  ",0,phase 1/phase 2,"['leukemia, acute', 'chronic myelogenous leukemia (cml)', 'myelodysplastic syndrome (mds)', 'non-hodgkin lymphoma (nhl)', 'chronic lymphocytic leukemia (cll)', 'acute myelogenous leukemia (aml)', 'acute lymphoblastic leukemia (all)']","[""['D46.Z', 'D46.9', 'C94.6', 'D46.C']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['A87.2', 'K52.832', 'D72.111', 'C91.11', 'C91.12', 'C91.10']""]","['regulatory t-cells', 'conventional t-cells', 'melphalan', 'thiotepa', 'anti-thymocyte globulin, rabbit', 'clinimacs cd34 reagent system']","['Status: 503', 'Status: 503', 'Status: 503', 'C1CN1P(=S)(N2CC2)N3CC3']","
        Inclusion Criteria

        RECIPIENT

          -  Histopathologically-confirmed:

          -  Acute leukemia (in first remission with poor risk factors and molecular prognosis)

          -  Acute myelogenous leukemia (AML) with -5,-7, t (6;9), tri8, -11

          -  Acute lymphoblastic leukemia (ALL) with Ph+ t (9;22), t (4;22), (q34;q11)

          -  Acute leukemia with refractory disease or > Complete Remission (CR) 1

          -  Chronic myelogenous leukemia (CML) (accelerated, blast or second chronic phase)

          -  Myelodysplastic syndrome (in high and high intermediate risk categories)

          -  Non-Hodgkin's lymphoma (NHL) with poor risk features and not suitable for autologous
             transplantation

          -  Refractory Chronic lymphocytic leukemia (CLL)

          -  At least 21 days from the end of most recent prior therapy to start of the transplant
             conditioning regimen

          -  Must be < 60 years old at time of registration.

          -  Karnofsky Performance Status (KPS) > 70%

        Must have related donor who is:

          -  Genotypically human leukocyte antigen (HLA) -A, B,C and DR beta 1 (DRB1), DQ loci
             haploidentical to the recipient (but differing for 2 to 3 HLA alleles on the unshared
             haplotype in the graft-versus-host disease (GvHD) direction)

          -  No HLA-matched sibling or matched-unrelated donor is identified.

          -  Adequate cardiac and pulmonary function (left ventricular ejection fraction (LVEF) >
             45%, diffusing capacity of the lungs for carbon monoxide (DLCO) >50% corrected for
             hemoglobin)

          -  Serum creatinine < 1.5 mg/dL OR Creatinine clearance > 50 mL/min for those above serum
             creatinine at least 1.5 mg/dL

          -  Serum bilirubin < 2.0 mg/dL

          -  Alanine transaminase (ALT) < 2x upper normal limit (ULN) (unless secondary to disease)

          -  No prior myeloablative therapy or hematopoietic cell transplantation

        DONOR:

          -  Age ≤ 70 years

          -  Weight ≥ 25 kg.

          -  Medical history and physical examination confirm good health status as defined by
             institutional standards

          -  Seronegative for HIV Ag within 30 days of apheresis collection for:

          -  Hepatitis B surface antigen (sAg) or polymerase chain reaction (PCR) +

          -  Hepatitis C ab or PCR+

          -  Genotypically haploidentical as determined by HLA typing

          -  Female donors (child-bearing potential) must have a negative serum or urine beta-human
             chorionic gonadotropin (HCG) test within 3 weeks of mobilization

          -  Capable of undergoing leukapheresis

          -  Has adequate venous access

          -  Willing to undergo insertion of a central catheter if leukapheresis via peripheral
             vein is inadequate

          -  Capable of agreeing to second donation of peripheral blood progenitor cell (PBPC) (or
             a bone marrow harvest) should the patient fail to demonstrate sustained engraftment
             following the transplant

          -  Institutional review board (IRB)-approved consent form signed by donor or legal
             guardian > 18 years of age

        Donor Selection in the priority order:

          -  Recipient's biological mother preferred, if available

          -  Other available haploidentical donors will be selected based upon the presence of
             natural killer (NK) alloreactivity between donor and recipient by high-resolution HLA
             typing of the C locus. An NK-alloreactive donor will be preferentially chosen.
             Recipients lacking a killer immunoglobulin-like receptor (KIR)-ligand present in the
             donor along with the corresponding KIR defines ""NK alloreactivity"".

          -  If more than one NK-alloreactive donor is available, preference is to cytomegalovirus
             (CMV)-seronegative donor

        Exclusion Criteria

        RECIPIENT:

          -  Suitable candidate for autologous transplantation or allogeneic transplantation with
             an available matched-related or matched-unrelated donor

          -  Seropositive for:

          -  HIV ab

          -  Hepatitis B sAg or PCR+

          -  Hepatitis C ab or PCR+

          -  History of invasive Aspergillosis

          -  Any active, uncontrolled bacterial, viral or fungal infection

          -  Uncontrolled central nervous system (CNS) disease involvement

          -  Lactating female

        DONOR:

          -  Evidence of active infection or viral hepatitis

          -  Factors of increased risk for complications from leukapheresis or granulocyte-colony
             stimulating factor (G-CSF) therapy

          -  Lactating female

          -  HIV-positive
      "
NCT01065467,completed,,0,phase 1,"['melanoma', 'malignant melanoma']","[""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']"", ""['C43.0', 'C43.31', 'C43.51', 'C43.9', 'C43.4', 'C43.52', 'C43.10']""]",['lbh589'],['CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO'],"
        Inclusion Criteria:

          -  Histologically or cytologically confirmed metastatic melanoma

          -  Measurable disease

          -  18 years of age or older

          -  ECOG performance status of 0, 1 or 2

          -  Normal organ and marrow function as outlined in the protocol

          -  Women of childbearing potential must have a negative serum pregnancy test within 7
             days of the first administration of study treatment and must be willing to use two
             methods of contraception during the study and for 3 months after last study drug
             administration

          -  Clinically euthyroid

          -  Biopsiable disease: Disease must be in the opinion of the treating investigator
             biopsiable such that there are minimal risks involved

        Exclusion Criteria:

          -  Chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who
             have not recovered from adverse events due to agents administered more than 4 weeks
             earlier

          -  May not be receiving any other study agents, anti-cancer therapy or radiation therapy

          -  Known brain metastases or any history of brain metastases

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to LBH589

          -  Concomitant use of drugs with a risk of causing torsades de pointes

          -  Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer

          -  Patients who will need valproic acid for any medical condition during the study or
             within 5 days prior to first LBH589 treatment

          -  Impaired cardiac function

          -  Uncontrolled hypertension

          -  Patients with unresolved diarrhea grade 2 or greater

          -  Impairment of the gastrointestinal (GI) function or GI disease that may significantly
             alter the absorption of oral LBH589

          -  Pregnant or breastfeeding women

          -  Individuals with a history of a different malignancy are ineligible except for the
             following circumstances: disease-free for at least 5 years and are deemed by the
             investigator to be at low risk for recurrence of that malignancy; individuals with the
             following cancers are eligible if diagnosed and treated within the past 5 years:
             cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.

          -  Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C

          -  Patients with any significant history of non-compliance to medical regimens or with
             inability to grant a reliable informed consent

          -  Uncontrolled and/or severe intercurrent illness including, but not limited to ongoing
             or active infection or psychiatric illness/social situations that would limit
             compliance with study requirements
      "
NCT01265875,completed,,0,phase 1/phase 2,['chronic pancreatitis'],"[""['K86.1', 'K86.0']""]",['human secretin'],['CC(C)CC(C(=O)NC(C(C)C)C(=O)N)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC2=CNC=N2)N'],"
        Inclusion Criteria:

          1. Male or female, between the ages of 18-70 years old.

          2. Documented chronic pancreatitis as determined by CT scan, endoscopic ultrasound, MRCP
             and/or pancreatic function tests.

          3. If female, and not more than 1 year post-menopausal or surgically sterile, must use
             medically acceptable form of contraception or abstain from sexual activity during the
             study. Acceptable methods of birth control are: intrauterine device, implantable
             progesterone device, progesterone intramuscular injection, oral contraceptive (started
             at least one month prior to Screening Visit 1 and continuing for the duration of the
             trial), contraceptive patch, condoms with spermicide or abstinence.

          4. If a female of reproductive potential, receive counseling on pregnancy protection and
             effective contraception within 30 days prior to dosing with secretin.

          5. Negative serum pregnancy within 72 hours of secretin administration.

          6. Use of opioid analgesics for chronic pain from CP.

          7. Willing and able to sign written informed consent.

        Exclusion Criteria:

          1. Male or female <18 or >70 years of age.

          2. Abnormal serum amylase and/or lipase indicative of acute pancreatitis within 30 days
             of study enrollment.

          3. Exhibiting signs and/or symptoms of an episode of acute pancreatitis.

          4. Severe cardiac disease (stable or unstable angina, congestive heart failure,
             uncontrolled arrhythmias, implantable defibrillator, severe valvular disease, etc).

          5. Severe pulmonary disease (COPD, severe asthma, interstitial lung disease, etc).

          6. Severe renal disease (history of acute or chronic renal failure, dialysis dependent,
             baseline creatinine >2.0 mg/dL).

          7. Previous adverse drug event to intravenous secretin.

          8. Ongoing illicit drug use or abuse.

          9. Ongoing moderate or severe alcohol use defined as greater than 8 oz beer, 8 oz wine
             and/or 1 oz liquor /day.

         10. Acute pancreatitis as defined by the Atlanta Classification definition (refer to Table
             1) within the previous two months or symptoms consistent with ongoing acute
             pancreatitis.

         11. Prior pancreatic surgery.

         12. Pregnant women, nursing mothers, or women of childbearing potential not employing
             appropriate contraception.

         13. Use of medication that can potentially cause pancreatitis, such as metronidazole,
             tetracycline, sulfonamides within 30 days prior to Visit 1.

         14. Any medical condition which, in the judgment of the investigator, renders
             participation in this study medically inadvisable.

         15. Participation in an investigational clinical study for a drug or medical device within
             30 days prior to Visit 1.

         16. Unwilling or unable to give written, informed consent.
      "
NCT01745887,completed,,1,phase 1,['dry eye syndrome'],"[""['H04.121', 'H04.122', 'H04.123', 'H04.129']""]",['ebi-005-2'],['Status: 503'],"
        Inclusion Criteria:

          -  Provide written informed consent prior to any study related procedures

          -  Are 18 years of age or older

          -  Are women of child bearing potential (WOCBP) who are non-pregnant, non-lactating and
             sexually inactive (abstinent) for 14 days prior to Visit 1

          -  Are willing and able to follow instructions and can be present for the required study
             visits for the duration of the study

          -  Have a history of Dry Eye Syndrome in both eyes supported by a previous clinical
             diagnosis

          -  Have ongoing Dry Eye Syndrome, in the same eye or both eyes, as defined by the
             following criteria:

               1. A score of ≥23 on OSDI

               2. A corneal fluorescein staining score of ≥6 (NEI scale)

          -  Have normal lid anatomy

          -  Are willing to withhold artificial tears for the duration of the study, with the
             exception of the study provided artificial tears: Refresh Plus®.

        Exclusion Criteria: Subjects may not:

          -  Have previously used an IL-1 blocker (e.g., Anakinra, Rilonacept or Ilaris).

          -  Have an OSDI score ≥90

          -  Have a corneal fluorescein staining score of 15 (NEI scale). NOTE: If one of two eyes
             has a corneal fluorescein staining score of 15, the subject may be eligible.

          -  Within 30 days prior to the screening visit (Visit 1) have taken: Topical cyclosporine
             (Restasis®) Ocular corticosteroids Autologous serum Topical ocular antibiotics Topical
             ocular antihistamines or mast cell stabilizers Topical or nasal vasoconstrictors

          -  Within 30 days prior to the screening visit (Visit 1) have altered the dose of
             tetracycline compounds (tetracycline, doxycycline or minocycline).
      "
NCT00329719,completed,,1,phase 1/phase 2,"['adult glioblastoma', 'adult gliosarcoma', 'recurrent adult brain neoplasm']","[""['C71.7', 'C71.9', 'C79.31', 'D33.0', 'D33.1', 'D33.2', 'D49.6']""]","['sorafenib tosylate', 'temsirolimus']","['CC1=CC=C(C=C1)S(=O)(=O)O.CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F', 'CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC']","
        Inclusion Criteria:

          -  Central pathology review submission; this review is mandatory prior to registration to
             confirm eligibility; it should be initiated as soon after surgery as possible

          -  =< 2 prior systemic chemotherapy regimens

          -  Histological confirmation of a grade 4 astrocytoma (glioblastoma) or gliosarcoma, at
             primary diagnosis or recurrence by World Health Organization (WHO) criteria; central
             pathology review is mandatory prior to study entry to confirm eligibility

          -  Evidence of tumor progression by magnetic resonance imaging (MRI) or computed
             tomography (CT) scan following radiation therapy (RT) or following the most recent
             anti-tumor therapy

          -  Bidimensionally measurable or evaluable disease by MRI or CT scan

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2

          -  >= 12 weeks since the completion of RT

          -  Fixed or decreasing dose of corticosteroids (or no corticosteroids) >= 1 week prior to
             registration

          -  >= 1 week from minor surgery other than venous line placement and > 3 weeks from major
             surgery (except for patients undergoing tumor tissue acquisition)

          -  >= 4 weeks since prior cytotoxic chemotherapy (>= 6 weeks for nitrosoureas)

          -  >= 2 weeks from cytostatic chemotherapy such as tamoxifen, cis-retinoic acid, or
             thalidomide (address questions regarding such agents to study chair)

          -  White blood cells (WBC) >= 3,000/mm^3

          -  Absolute neutrophil count (ANC) >= 1,500/mm^3

          -  Platelet count >= 100,000/mm^3

          -  Hemoglobin (Hgb) >= 10 gm/dL

          -  Total bilirubin =< 1.5 x upper limit of normal (ULN)

          -  Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =<
             2.5 x ULN

          -  Creatinine =< 2.0 x ULN

          -  Serum cholesterol =< 350 mg/dL

          -  Serum triglycerides =< 400 mg/dL

          -  Willingness to provide the biologic specimens as required by the protocol; (please
             note that the willingness to participate pertains only to the patient and does not
             factor in the institution?s ability to participate in any part of the translational
             component)

        Exclusion Criteria:

          -  Prior intratumoral chemotherapy (e.g., Gliadel or IL13-PE38QQR), stereotactic
             radiosurgery, or interstitial brachytherapy unless there is a separate lesion on MRI
             which is not part of the previous treatment field or there is proof of recurrent
             disease based on biopsy, MRI spectroscopy, or positron emission tomography (PET) scan

          -  Prior CCI-779, sorafenib, or other agents specifically targeting mammalian target of
             rapamycin (mTOR) or raf; patients receiving prior agents inhibiting VEGF or VEGF
             receptor (R) (prior anti-VEGF group) are eligible but: 1) must be at least four weeks
             from last treatment with the agent(s); and 2) must have recovered from any clinically
             relevant toxicities attributable to this agent(s)

          -  Evidence of bleeding diathesis or coagulopathy

               -  Note: Patients on prophylactic anticoagulation therapy (e.g., low-dose warfarin)
                  are eligible provided their coagulation parameter levels are as follows:
                  prothrombin time (International Normalized Ratio [INR] of prothrombin time) < 1.1
                  x institutional upper limit of normal

               -  Note: Patients on full-dose anticoagulants (e.g., warfarin) are eligible provided
                  that both of the following criteria are met: a) the patient has an in-range INR
                  (usually between 2 and 3) on a stable dose of oral anticoagulant or on a stable
                  dose of low molecular weight heparin, and b) the patient has no active bleeding
                  or pathological condition that carries a high risk of bleeding (e.g., tumor
                  involving major vessels or known varices)

          -  International normalized ration (INR) > 1.5 (unless the patient is on full-dose
             warfarin)

          -  Receiving enzyme-inducing antiepileptic drugs (EIAEDs; e.g., phenytoin, fosphenytoin,
             carbamazepine, phenobarbital, or primidone) or any other potent cytochrome P450,
             family 3, subfamily A, polypeptide 4 (CYP3A4) inducer, such as rifampin or St. John?s
             wort

          -  Any condition (e.g., gastrointestinal tract disease resulting in an inability to take
             oral medication or a requirement for IV alimentation, prior surgical procedures
             affecting absorption, or active peptic ulcer disease) that impairs their ability to
             swallow pills

          -  Hypertension with systolic blood pressure of > 140 mmHg or diastolic pressure > 90
             mmHg; however, patients with well-controlled hypertension are eligible

          -  Uncontrolled infection

          -  Pregnant women

          -  Nursing women

          -  Men or women of childbearing potential who are unwilling to employ adequate
             contraception

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for
             the duration of study participation; should a woman become pregnant or suspect she is
             pregnant while participating in this study, she should inform her treating physician
             immediately

          -  Known hypersensitivity to any of the components of CCI-779 or sorafenib

          -  Other active malignancy

          -  Uncontrolled intercurrent illness, including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, psychiatric illness/social situation that would preclude study compliance
             with study requirements

          -  Immunocompromised patients (other than that related to the use of corticosteroids)
             including patients known to be human immunodeficiency virus (HIV) positive;
             HIV-positive patients on combination antiretroviral therapy are ineligible

          -  Receiving any investigational agents other than CCI-779 and sorafenib

          -  Significant intratumoral, intracerebral, or subarachnoid hemorrhage on baseline MRI or
             CT, or other history of significant intratumoral, intracerebral, or subarachnoid
             hemorrhage
      "
NCT00852709,terminated,"
    lack of accrual
  ",0,phase 1,"['myelodysplastic syndrome', 'acute myeloid leukemia', 'myeloproliferative disorders', 'acute lymphocytic leukemia', 'acute promyelocytic leukemia', 'acute leukemia', 'chronic myelogenous leukemia', 'myelofibrosis', 'chronic myelomonocytic leukemia', 'juvenile myelomonocytic leukemia']","[""['D46.9', 'D46.C', 'D46.Z']"", ""['C92.A1', 'C92.A2', 'C92.61', 'C92.62', 'C92.A0', 'C92.60']"", ""['D47.1']"", ""['A87.2', 'K52.832', 'D72.111', 'C91.11', 'C91.12', 'C91.10']"", ""['C92.41', 'C92.42', 'C92.40']"", ""['C91.01', 'C91.02', 'C92.01', 'C92.02', 'C92.41', 'C92.42', 'C92.51']"", ""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']"", ""['D75.81', 'C94.41', 'C94.42', 'C94.40']"", ""['C93.11', 'C93.12', 'C93.10']"", ""['C93.31', 'C93.32', 'C93.30']""]","['clofarabine', 'cyclophosphamide']","['C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)F)Cl)N', 'C1CNP(=O)(OC1)N(CCCl)CCCl']","
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 for
             adolescent/young adult patients.

          -  Lansky Performance Index > 50 for pediatric patients less than age 10 years.

          -  Laboratory values obtained < 7 days prior to receiving study treatment:

          -  Total bilirubin < 1.5 mg/dL unless elevated due to hemolysis. The conjugated serum
             bilirubin prior to study entry must be within the normal range.

          -  Aspartate transaminase (AST) and alanine transaminase (ALT) < 2.5 × upper limit of
             normal (ULN)

          -  Serum creatinine < 1.0 mg/dL in adolescent/young adults (patients 12 to 17 years of
             age). For pediatric patients with serum creatinine above the ULN, creatinine clearance
             > 90 ml/min/1.73m2 calculated using the Schwartz formula may be enrolled. Collected
             creatinine clearance may be substituted.

        Patients 18 years and older (Adult population): Serum creatinine <1.0 mg/dL; if serum
        creatinine >1.0 mg/dL, then the estimated glomerular filtration rate (GFR) must be >60
        mL/min/1.73 m2

          -  Cardiac function must be normal per the institution normal as measured by
             echocardiogram (ECHO) within 7 days.

          -  Patients should have no evidence of myositis as detected by abnormal serum creatine
             kinase and/or myoglobin.

        Exclusion Criteria:

          -  No chemotherapy, radiation, or major surgery within 2 weeks prior to first dose of
             study drug except for 5-azacytidine, thalidomide, hydroxyurea, imatinib (Gleevec), and
             interferon which must be discontinued at least 3 days before study entry and the
             patient should have recovered from the toxic side effects of such therapy. In the
             instance of progressive disease, anti-leukemia therapy may have been administered
             within the 2-week period as long but the subject should have recovered from the toxic
             effects of that therapy. Also, intrathecal therapy may be administered within the
             2-week period for subjects with CNS disease.

          -  Patients who have had an allogeneic or autologous hematopoietic stem cell transplant.

          -  Patients must have discontinued all growth factors, except Procrit (epoetin), at least
             1 week before study.

          -  Patients with known HIV positive status or AIDS.

          -  Patients with known active Hepatitis B, Hepatitis C or cirrhosis.

          -  History of severe coronary artery disease, including myocardial infarction within the
             previous 3 months, arrhythmias other than atrial flutter or fibrillation requiring
             medication, or uncontrolled congestive heart failure.

          -  Patients with active uncontrolled infection, fever of infection, or evidence for
             progressive disease by CT scans of the lungs, sinuses, or abdomen. Patients who are on
             antimicrobial therapy and stable, CT scans must have been stable for 4 weeks, may be
             enrolled but there must be no evidence of an active infection. Patients with fever due
             to leukemia may be enrolled.

          -  Pregnant or lactating patients. Female patients of childbearing potential must have a
             negative serum pregnancy test within 14 days before study entry.
      "
NCT00626704,completed,,1,phase 1/phase 2,"['locally advanced or metastatic, unresectable soft tissue sarcoma', 'sarcoma', 'soft tissue sarcoma']","[""['C96.A', 'C46.9', 'C96.22', 'C46.0', 'C46.2', 'C92.31', 'C92.32']"", ""['C46.1']""]","['amg 655', 'doxorubicin']",['CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O'],"
        Inclusion Criteria:

          -  Histologically or cytologically confirmed soft tissue sarcoma

          -  Locally advanced, recurrent, or metastatic, unresectable disease

          -  Measurable disease according to modified RECIST

          -  ECOG performance status of 0 or 1

          -  Men or women at least 18 years of age

          -  Adequate hematological, renal, hepatic, and coagulation function

        Exclusion Criteria:

          -  Prior treatment with anthracyclines

          -  Uncontrolled cardiovascular disease
      "
NCT00290706,terminated,"
    closed per data monitoring committee due to lack of efficacy
  ",0,phase 1/phase 2,['lymphoma'],"[""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']""]","['bortezomib', 'gemcitabine hydrochloride']","['B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F.Cl']","
        DISEASE CHARACTERISTICS:

          -  Diagnosis of B- or T-cell non-Hodgkin's lymphoma (NHL)

               -  Intermediate histology B-cell NHL, including any of the following:

                    -  Diffuse large B-cell lymphoma

                    -  Transformed large cell lymphoma

               -  Any T-cell NHL histology

               -  Cutaneous T-cell lymphoma (CTCL) or mycosis fungoides (MF) allowed

          -  Relapsed or refractory disease, defined as disease progressed after prior complete
             remission (CR), partial remission (PR), or stable disease (SD) to last therapy OR
             failure to achieve CR, PR, or SD after completion of last therapy

          -  Must have received 1-3 prior therapeutic regimens

               -  Cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (CHOP)
                  AND cyclophosphamide, vincristine, and prednisone (CVP) OR CHOP with rituximab
                  (CHOP-R) AND CVP with rituximab (CVP-R) is considered 1 regimen

               -  Monoclonal antibody (e.g., rituximab) given as maintenance therapy is considered
                  1 regimen

               -  Salvage chemotherapy followed by an autologous stem cell transplant is considered
                  1 regimen

               -  No more than 7 prior therapeutic regimens for patients with CTCL or MF

          -  No mantle cell lymphoma

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Life expectancy > 3 months

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

               -  At least 50,000/mm^3 if documented bone marrow involvement

          -  Hemoglobin ≥ 8.0 g/dL

          -  AST and ALT ≤ 3 times upper limit of normal (ULN)

          -  Alkaline phosphatase ≤ 3 times ULN

          -  Bilirubin ≤ 2 times ULN

          -  Creatinine ≤ 2.0 mg/dL

          -  No known history of HIV infection

          -  No other active infection

          -  No uncontrolled hypertension

          -  No peripheral neuropathy ≥ grade 2 within the past 2 weeks

          -  No myocardial infarction within the past 6 months

          -  No New York Heart Association class III or IV heart failure

          -  No uncontrolled angina

          -  No severe uncontrolled ventricular arrhythmias

          -  No acute ischemia or active conduction system abnormalities by ECG

          -  No hypersensitivity to bortezomib, boron, or mannitol

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective barrier-method contraception

          -  No serious medical or psychiatric illness that would preclude study participation

        PRIOR CONCURRENT THERAPY:

          -  Prior autologous and/or allogeneic stem cell transplantation allowed

          -  More than 3 weeks since prior chemotherapy, radiotherapy, or immunotherapy

          -  More than 3 weeks since prior systemic biologic anticancer therapy

          -  More than 3 weeks since prior systemic corticosteroids (e.g., oral prednisone > 10 mg
             per day)

          -  More than 2 weeks since prior investigational drug

          -  No prior bortezomib or gemcitabine hydrochloride

          -  No other concurrent systemic cytotoxic chemotherapy or investigational agents
      "
NCT01294735,completed,,1,phase 1,"['recurrence of solid tumor', 'glioblastoma multiforme', 'melanoma']","[""['L51.0', 'L51.8', 'L51.9']"", ""['C43.0', 'C43.31', 'D03.9', 'C43.51', 'C43.9', 'D03.0', 'C43.4']""]","['mk-4827', 'temozolomide']","['Status: 503', 'Status: 503']","
        Inclusion criteria

        Part A

          -  Participants with histologically-confirmed advanced solid tumors who have failed to
             respond to standard therapy, or progressed on standard therapy, or for whom standard
             therapy does not exist.

        Part B

          -  Participants must have a histologically-confirmed recurrent glioblastoma multiforme
             (GBM) with radiographic evidence of progression/recurrence of disease, with up to two
             prior treatment regimens (not including temozolomide or bevacizumab) for their
             recurrent disease.

        OR

          -  Participants must have histologically-confirmed recurrent or metastatic melanoma for
             which the participant has received up to two prior therapies.

          -  Participants must not have received prior treatment with cytotoxic chemotherapy
             including temozolomide, dacarbazine, or PARP inhibitors.

        Part A and Part B

          -  Participants with Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or
             1.

          -  Participants must have adequate organ function.

          -  Women of childbearing potential and male participants must agree to use an adequate
             method of contraception starting with the first dose of study drug through 90 days
             after the last dose of study drugs.

          -  Participant has no history of a prior malignancy with the exception of gliomas (as
             secondary GBM is allowed), cervical intraepithelial neoplasia, basal cell carcinoma of
             the skin, or adequately treated localized prostate carcinoma with Prostate-Specific
             Antigen (PSA) < 1.0; or who has undergone potentially curative therapy with no
             evidence of that disease for five years, or who is deemed at low risk for recurrence
             by his/her treating physician.

          -  Participant has at least one measurable metastatic or recurrent lesion.

        Exclusion criteria

          -  Participant has had chemotherapy, radiotherapy, or biological therapy within four
             weeks prior to study Day 1 (six weeks for nitrosoureas and mitomycin C) or who has not
             recovered from adverse events due to agents administered more than four weeks earlier.

          -  Participants with known symptomatic or progressive Central Nervous System (CNS)
             metastases and/or carcinomatous meningitis.

          -  Participant has prior exposure to PARP inhibitors. Prior exposure to temozolomide is
             allowed only for participants with GBM, provided it was received in the adjuvant
             setting with GBM progression after completion of adjuvant temozolomide treatment and a
             treatment-free interval of ≥ 3 months.

          -  Participant has significant or uncontrolled cardiovascular disease, including New York
             Heart Association (NYHA) Class III-IV heart failure, unstable angina, or a myocardial
             infarction within the last six months.

          -  Participant is breastfeeding.

          -  Participant is known to be Human Immunodeficiency Virus (HIV)-positive.

          -  Participant has active Hepatitis B or C.

          -  Participant has symptomatic ascites or pleural effusion.

          -  Participant has a requirement for concurrent treatment with immunosuppressive agents.

          -  Participant must not have prior radiation therapy to more than 30% of hte bone marrow
             and must have recovered for at least 3 weeks from the hematologic toxicity of prior
             radiotherapy.

          -  Participant has had a prior stem cell or bone marrow transplant.
      "
NCT00301951,completed,,0,phase 1,"['leukemia', 'lymphoma', 'multiple myeloma and plasma cell neoplasm', 'myelodysplastic syndromes']","[""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['C96.20', 'C96.29', 'D47.09']"", ""['D46.9', 'D46.C', 'D46.Z']""]","['busulfan', 'fludarabine phosphate', 'mycophenolate mofetil', 'tacrolimus']","['CS(=O)(=O)OCCCCOS(=O)(=O)C', 'Status: 503', 'Status: 503', 'CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC']","
        DISEASE CHARACTERISTICS:

          -  Diagnosis of 1 of the following advanced hematologic malignancies:

               -  Acute myeloid leukemia (AML) meeting the following criteria:

                    -  Considered incurable with chemotherapy

                    -  Marrow blasts ≤ 10% (may be achieved using standard chemotherapy regimen)

                    -  Meets any of the following criteria:

                         -  High-risk cytogenetics (-7, -7q, -5, -5q, t(6,9), t(9,11), complex [≥ 3
                            abnormalities], Philadelphia chromosome positive [Ph+])

                         -  AML evolved from prior myelodysplasia

                         -  AML secondary to prior chemotherapy

                         -  Failed to achieve remission

                         -  In second or subsequent remission

                         -  Refractory relapse

               -  Myelodysplastic syndromes (MDS) meeting the following criteria:

                    -  Must have high-risk features, including any of the following:

                         -  Intermediate-2 or high risk International Prognostic Scoring System
                            (IPSS) score

                         -  Chronic myelomonocytic leukemia

                    -  Marrow blasts ≤ 20% (chemotherapy may be given to achieve target blast
                       levels)

                    -  No rapidly progressive disease

               -  Acute lymphoblastic leukemia meeting the following criteria:

                    -  Considered incurable with chemotherapy

                    -  Meets any of the following criteria:

                         -  High-risk cytogenetics (Ph+, t(4,11), 11q23 abnormalities, or monosomy
                            7)

                         -  Required > 1 induction course to achieve remission

                         -  Failed to enter remission

                         -  In second or subsequent remission

                    -  Marrow blasts ≤ 10% (chemotherapy may be given to achieve target blast
                       levels)

               -  Chronic myelogenous leukemia (CML) meeting 1 of the following criteria:

                    -  Chronic phase CML that failed imatinib mesylate therapy, as defined by
                       progressive disease or failed to achieve a major cytogenetic response at 1
                       year after initiation of therapy

                    -  Accelerated phase CML meeting 1 of the following criteria:

                         -  Failed to achieve a complete cytogenetic remission at 1 year after
                            initiation of therapy

                         -  Failed to achieve any cytogenetic response after 6 months of therapy

                         -  Progressive disease, as demonstrated by worsening cytogenetic response
                            in 2 consecutive analyses separated by 4 weeks

                    -  In blast crisis with < 10% blasts in bone marrow

               -  Multiple myeloma meeting the following criteria:

                    -  Stage I-III disease

                    -  Meets any of the following criteria:

                         -  In relapse after autologous transplantation

                         -  Refractory to ≥ 2 prior conventional myeloma therapies

                         -  Chromosome 13 abnormalities (may be enrolled at diagnosis or after
                            initial progression)

               -  Lymphoma

                    -  The following subtypes are eligible:

                         -  Diffuse large cell

                         -  Follicular large cell

                         -  Mantle cell

                         -  Peripheral T-cell

                         -  T-natural killer (T-NK) cell

                         -  Hodgkin's lymphoma

                    -  Must have progressed, recurred after prior therapy, or failed to respond to
                       primary therapy

                    -  Relapsed disease after autologous stem cell transplantation (SCT) allowed

               -  Low-grade non-Hodgkin's lymphoma meeting 1 of the following criteria:

                    -  Relapsed or refractory disease after ≥ 2 chemotherapy-based treatment
                       regimens

                    -  Relapsed after autologous SCT

               -  Chronic lymphocytic leukemia

                    -  Relapsed or refractory disease after ≥ 2 chemotherapy-based treatment
                       regimens

                    -  Relapsed after autologous SCT

          -  Meets 1 of the following criteria:

               -  Age 55-70 years

               -  Under age 55 and deemed ineligible for conventional high-dose chemotherapy, as
                  indicated by any of the following:

                    -  Poor cardiac function (i.e., LVEF < 40%)

                    -  Poor pulmonary function (i.e., DLCO < 50%)

                    -  Hepatic dysfunction

                    -  Prior myeloablative therapy

          -  Not eligible for autologous SCT or conventional therapy

          -  Umbilical cord blood donor available

               -  Matched at ≥ 4 of 6 HLA antigens (A, B, and DR)

               -  Has 1-3 units of umbilical cord blood available

               -  Must not have an HLA-identical or 1 antigen mismatched related donor or potential
                  HLA-matched unrelated donor readily available NOTE: A new classification scheme
                  for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of
                  ""indolent"" or ""aggressive"" lymphoma will replace the former terminology of ""low"",
                  ""intermediate"", or ""high"" grade lymphoma. However, this protocol uses the former
                  terminology.

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Creatinine clearance > 40 mL/min

          -  Creatinine < 2.0 mg/dL

          -  AST and alkaline phosphatase < 3 times upper limit of normal (ULN)

          -  Bilirubin < 2.0 mg/dL

          -  Hepatitis C or active hepatitis B virus (HBV) allowed if ≤ grade 2 fibrosis and/or
             inflammation by liver biopsy

               -  Patients with history of HBV infection should be tested for hepatitis B epsilon
                  (HBe) antigen, anti-HBe, and HBV DNA (quantitative)

               -  Patients with active HBV viral replication should receive antiviral therapy

          -  Ejection fraction > 30%

          -  DLCO ≥ 40%

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No active infection requiring ongoing antibiotic treatment

          -  HIV negative

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      "
NCT01165216,completed,,1,phase 1,['non-small cell lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['ipilimumab, 3 mg', 'ipilimumab, 10 mg', 'paclitaxel', 'carboplatin']","['CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C', 'C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]']","
        Key Inclusion Criteria:

          -  Histologically or cytologically documented nonsmall-cell lung cancer (NSCLC)
             presenting as stage IIIB disease without indications for definitive radiotherapy,
             stage IV disease, or recurrent disease following radiation therapy or surgical
             resection

          -  No prior chemotherapy, hormonal therapy, immunotherapy, or targeted-therapy-containing
             regimens for the treatment of NSCLC

          -  Life expectancy of at least 3 months

          -  Eastern Cooperative Oncology Group performance score of 0-1

          -  Adequate bone marrow function

          -  Hemoglobin ≥9.0 g/dL

          -  Absolute neutrophil count ≥1,500/mm^3

          -  Platelet count ≥100,000/mm^3

          -  Adequate liver function

          -  Total bilirubin level ≤2.0*the upper limit of normal (ULN)

          -  Asparate aminotransferase level ≤2.5*ULN

          -  Alanine aminotransferase level ≤2.5*ULN

          -  Adequate renal function

          -  Calculated creatinine clearance based on Cockcroft and Gault formula ≥50 mL/min.

        Key Exclusion Criteria:

          -  Symptomatic central nervous system (CNS) metastasis or active CNS metastasis requiring
             medication

          -  Malignant body cavity fluid (eg, pleural effusion, cardiac effusion, ascites) that
             recurred despite appropriate supportive care

          -  Prior radiation of ≥30% of major bone-marrow containing areas (pelvis, lumbar spine)

          -  Documented history of severe autoimmune or immune-mediated symptomatic disease that
             required prolonged (longer than 2 months) systemic immunosuppressant treatment

          -  Documented history of motor neuropathy considered of autoimmune origin (eg, Guillain
             Barré syndrome)

          -  Any concurrent malignancy other than nonmelanoma skin cancer, carcinoma in situ of the
             cervix, carcinoma in situ of the breast, carcinoma of the mucous membrane of the
             gastrointestinal tract, or superficial bladder cancer treated with systemic therapy

          -  ≥Grade 2 diarrhea

          -  History of or concurrent disease of gastrointestinal tract perforations

          -  ≥Grade 2 peripheral neuropathy (motor or sensory)

          -  Uncontrolled intercurrent illness including infection requiring systemic therapy,
             symptomatic congestive heart failure, uncontrolled hypertension, uncontrolled angina
             pectoris, uncontrolled peptic ulcer, and cardiac arrhythmia requiring medication

          -  Positive finding for human immunodeficiency virus antibody, hepatitis B surface
             antigen, or hepatitis C virus antibody.
      "
NCT01221857,completed,,1,phase 1/phase 2,"['acute lymphoblastic leukemia (all)', 'acute myelogenous leukemia (aml)', 'myelodysplastic syndrome (mds)', ""non-hodgkin's lymphoma"", ""hodgkin's disease""]","[""['D46.Z', 'D46.9', 'C94.6', 'D46.C']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']"", ""['C81.77', 'C81.97', 'C81.17', 'C81.27', 'C81.37', 'C81.47', 'C81.70']""]",['nicord®'],['Status: 503'],"
        Inclusion Criteria:

          -  Applicable disease and eligible for myeloablative SCT

          -  Patients must have two partially HLA-matched CBUs

          -  Back-up stem cell source

          -  Adequate Karnofsky Performance score or Lansky Play-Performance scale

          -  Sufficient physiological reserves

          -  Signed written informed consent

        Exclusion Criteria:

          -  HLA-matched related donor able to donate

          -  Prior allogeneic HSCT

          -  Lymphoma patients with progressive disease

          -  Other active malignancy

          -  Human immunodeficiency virus (HIV) infection

          -  Active or uncontrolled infection

          -  Active/symptoms of central nervous system (CNS) disease

          -  Pregnancy or lactation
      "
NCT00445315,completed,,1,phase 1,['hepatitis c'],"[""['B18.2', 'B17.10', 'B17.11', 'B19.20', 'B19.21', 'B15.0', 'B15.9']""]","['pf-00868554', 'pf-00868554', 'pf-00868554', 'pf-00868554', 'placebo']","['CCC1=CC(=CC(=N1)CC)CCC2(CC(=C(C(=O)O2)CC3=NN4C(=CC(=NC4=N3)C)C)O)C5CCCC5', 'CCC1=CC(=CC(=N1)CC)CCC2(CC(=C(C(=O)O2)CC3=NN4C(=CC(=NC4=N3)C)C)O)C5CCCC5', 'CCC1=CC(=CC(=N1)CC)CCC2(CC(=C(C(=O)O2)CC3=NN4C(=CC(=NC4=N3)C)C)O)C5CCCC5', 'CCC1=CC(=CC(=N1)CC)CCC2(CC(=C(C(=O)O2)CC3=NN4C(=CC(=NC4=N3)C)C)O)C5CCCC5']","
        Inclusion Criteria:

          -  HCV RNA ≥ 100,000 IU/mL at screening

          -  Genotype 1a or 1b

        Exclusion Criteria:

          -  Current or prior treatment with IFN and/or RBV

          -  Evidence of decompensated liver disease
      "
NCT01011972,completed,,1,phase 1,['neoplasm metastasis'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]",['xmt-1107'],['Status: 503'],"
        Inclusion Criteria:

          -  Patient must have a histological diagnosis of advanced solid tumor and must be
             refractory to standard therapy or have no effective therapy.

          -  Measurable or evaluable disease.

          -  At least 42 days since administration of mitomycin or nitrosoureas and 28 days since
             any other chemotherapy, investigational agent, and/or radiation therapy.

          -  Age ≥ 18 years old.

          -  Have the following laboratory values:

               -  Absolute neutrophil count (ANC) ≥ 1500 cells/mm3

               -  Platelet count ≥ 100,000 cells/mm3

               -  Hemoglobin ≥ 9 g/dL

               -  Serum creatinine ≤ 1.5 mg/dL or calculated creatinine clearance ≥ 60 mL/min
                  (Calculated by Cockroft and Gault method. Creatinine clearance (mL/min) =
                  (140-age) x weight (kg)/72 x (serum creatinine in mg/dL) = ml**/min (**for
                  females, multiply results by 0.85))

               -  Total bilirubin ≤ 1.5 mg/dL or ≤ upper limit of normal (ULN)

               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times
                  the institutional upper limit of normal (ULN) or ≤ 5 times ULN of liver
                  metastases are present

               -  Prothrombin time (PT) and partial thromboplastin time (PTT) ≤ 1.5 times the ULN

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1.

          -  Life expectancy of at least 3 months.

          -  Signed informed written consent.

        Exclusion Criteria:

          -  Known brain metastases (either currently or previously).

          -  Peripheral neuropathy ≥ Grade 2.

          -  Ataxia ≥ Grade 1.

          -  Cognitive disturbance ≥ Grade 1.

          -  History of seizures.

          -  Patients known to be human immunodeficiency virus (HIV) positive.

          -  Active infections requiring IV antibiotics or serious intercurrent illness, including
             hepatitis B or C.

          -  Unstable angina, recent myocardial infarction (within the previous 6 months), or use
             of ongoing maintenance therapy for life-threatening arrhythmia.

          -  Known hypersensitivity to this class of drugs.

          -  Pregnant or nursing women, women who are of childbearing potential and are not using
             an effective method of either barrier or hormonal contraceptives. Men who are not
             using an effective method of barrier contraceptive, or who would not be willing to
             continue to use these effective methods for the duration of the study.

          -  Patients who have had a major surgical procedure (not including mediastinoscopy), open
             biopsy, or significant traumatic injury ≤ 4 weeks prior to beginning treatment.

          -  Patients with proteinuria at screening as demonstrated by either:

               1. urine protein creatinine (UPC) ratio ≥ 1.0 at screening OR

               2. urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥ 2+ proteinuria
                  on dipstick urinalysis at baseline should undergo a 24 hour urine collection, and
                  must demonstrate ≤ 1 g of protein/24 hours to be eligible)

          -  Patients with a serious non-healing wound, active ulcer, or untreated bone fracture.

          -  Patients with history of hematemesis or hemoptysis (defined as having bright red blood
             of ½ teaspoon or more per episode) ≤ 1 month prior to study enrollment.

          -  Inadequately controlled hypertension (defined as systolic blood pressure >140 mm Hg
             and/or diastolic blood pressure > 90 mm Hg while on antihypertensive medications).
             Initiation of antihypertensive agents is permitted provided adequate control is
             documented at least 1 week prior to beginning study treatment.

          -  Significant vascular disease (e.g., aortic aneurysm requiring surgical repair, or
             recent peripheral arterial thrombosis) ≤ 6 months prior to Day 1 of treatment.

          -  History of stroke or transient ischemic attack ≤ 6 months prior to beginning
             treatment.

          -  Any prior history of hypertensive crisis or hypertensive encephalopathy.

          -  History of abdominal fistula or gastrointestinal perforation ≤ 6 months prior to Day 1
             of beginning treatment.

          -  QTc interval > 470 milliseconds as calculated by Bazett's formula.

          -  Any issue that, in the opinion of the Investigator, would render the patient
             unsuitable for study participation.
      "
NCT00003382,terminated,,0,phase 1,"['fallopian tube cancer', 'ovarian cancer', 'primary peritoneal cavity cancer']","[""['C57.00', 'C57.01', 'C57.02']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C30.0', 'Z12.81', 'D14.0', 'C14.8', 'D37.09', 'Z86.003', 'Z85.818']""]","['gemcitabine hydrochloride', 'topotecan hydrochloride']","['Status: 503', 'Status: 503']","
        DISEASE CHARACTERISTICS:

          -  Histologically documented refractory or recurrent ovarian epithelial or fallopian tube
             cancer

          -  No borderline ovarian cancer

          -  Extra-ovarian papillary serous tumors eligible

          -  Must not be eligible for any higher priority phase II or III GOG protocol

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  GOG 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Granulocyte count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  SGOT no greater than 3 times upper limit of normal (ULN)

          -  Bilirubin no greater than 1.5 mg/dL

          -  Elevated levels of alkaline phosphatase allowed

        Renal:

          -  Creatinine no greater than 1.5 mg/dL

        Cardiovascular:

          -  No angina pectoris or clinically significant multifocal uncontrolled cardiac
             dysrhythmias

          -  No uncontrolled hypertension

        Other:

          -  No other active malignancy

          -  No prior malignancy within the past 5 years except nonmelanomatous skin cancer

          -  No active infection

          -  No underlying medical problem that would prevent compliance

          -  No known hypersensitivity to E. coli-derived drug preparations

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  Must have received at least 1 prior platinum- and paclitaxel-based regimen

          -  At least 4 weeks since prior chemotherapy

          -  No prior topotecan and/or gemcitabine

          -  No prior chemotherapy for a different prior malignancy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No prior radiotherapy to more than 10% of bone marrow

          -  At least 2 weeks since limited field radiation therapy

        Surgery:

          -  Not specified
      "
NCT00074750,terminated,"
    slow accrual.
  ",0,phase 1,"['acute myelogenous leukemia', 'chronic myelomonocytic leukemia']","[""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']"", ""['C93.11', 'C93.12', 'C93.10']""]",['dtgm'],['Status: 503'],"
        Inclusion Criteria:

          -  Patients with refractory or relapsed AML ( marrow blasts > 20% ), must have failed
             induction therapy or have relapsed after CR duration < 6 months following induction
             therapy, untreated or refractory to salvage chemotherapy. Relapsed AML patients with
             CR duration > 6 months or previously untreated patients refusing chemotherapy and not
             considered for treatments of higher priority are also eligible.

          -  Patients with chronic myelomonocytic leukemia (CMML) who failed at least one course of
             chemo- or biological therapy( including trial of erythropoietin), or patients with
             relapsed CMML. Previously untreated CMML patients with HB < or = 12 g / dL, not
             eligible for protocols of higher priority or not wishing to receive chemotherapy.

          -  Patients must have an ECOG performance status of < 2.

          -  Patients must have WBC count < 10,000/mL prior to initiating the treatment. The WBC
             count must be stabilized below this level for at least three days by leukopheresis or
             hydroxyurea. Hydroxyurea must be discontinued one day prior to initiation of
             DT388GMCSF treatment.

          -  Patients must have creatinine < 1.6 times ULN: bilirubin <1.6 times ULN; SGPT < 2.6 x
             ULN; albumin > 3 gm/dl; adequate cardiac function (EF >44%), oxygen saturation > 92%
             without exogenous oxygen administered.

          -  Patients must be willing to be treated at M D Anderson Cancer Center.

          -  Women of childbearing potential and men must agree to practice contraception using
             approved methods.

          -  No chemotherapy except Hydroxyurea 2 weeks prior to entering the study and recovered
             from previous toxicity.

          -  Patients must be > 17 years old.

        Exclusion Criteria:

          -  Patients with serious concurrent medical problems. Patients with proven bacterial
             infections are not eligible until the resolution of the infection (patient afebrile
             who completed antibacterial therapy, not on steroids). Patients with active fungal
             infections are eligible only if evidence of response to antifungal medications is
             documented and fever does not exceed 38C for at least 2 days.

          -  Inability to give informed consent because of psychiatric problems or other serious
             medical problems.

          -  Pregnant or nursing women.

          -  Patients with documented CNS leukemia or leukemia with CNS symptoms.

          -  Patients who have had a myocardial infarction within the past six months.

          -  Patients with severe penicillin allergy (anaphylaxis).

          -  Not fully recovered from toxic effects of prior chemotherapy or radiation therapy.

          -  Patients who are on corticosteroid treatment for any medical condition.
      "
NCT02176525,completed,,1,phase 1,"['hepatitis c, chronic']","[""['B18.2', 'B18.0', 'B18.1', 'B18.8', 'B18.9', 'K71.3', 'K71.4']""]","['bi 207127 na', 'placebo']",['Status: 503'],"
        Inclusion Criteria:

          -  Adults from 18 - 70 years

          -  Male OR female with documented hysterectomy OR menopausal female with last menstrual
             period at least 12 months prior to screening

          -  Written informed consent consistent with International Conference on
             Harmonization/Good Clinical Practice and local legislation given prior to any study
             procedures

          -  Chronic HCV infection demonstrated by positive HCV immunoglobulin G Antibody

          -  HCV genotype 1 which has to be confirmed by central laboratory test before Visit 2

          -  For non-cirrhotic cohorts: Liver biopsy obtained within the last 36 months consistent
             with HCV infection showing minimal to mild liver fibrosis and without cirrhosis (Ishak
             or Metavir grade ≤ 2). For cirrhotic cohorts, previous liver biopsy or Fibroscan
             consistent with liver cirrhosis performed at any time before screening

          -  HCV RNA load > 100,000 IU RNA per ml serum at screening

        Exclusion Criteria:

          -  All fertile males not willing to use an adequate form of contraception (condom,
             sterilisation at least 6 months post operation) in case their partner is of
             childbearing potential and is not using an adequate form of contraception (hormonal
             contraceptives, oral or injectable/ implantable, intra-uterine device)

          -  Patients who have been treated with at least one dose of any HCV-polymerase inhibitor
             for acute or chronic hepatitis C infection

          -  Any other or additional plausible cause for chronic liver disease, including the
             presence of other viruses known or suspected to cause hepatitis

          -  Decompensated liver disease within past 12 months, as indicated by variceal bleeding,
             ascites, encephalopathy, Prothrombin or International Normalized Ratio (INR) prolonged
             to >1.7 x upper limit of normal (ULN), serum bilirubin > 2 mg/dl or albumin < 3.5 g/dl
             (i.e. Child-Pugh grade B, score > 7)

          -  For non-cirrhotic cohorts: Any previous liver biopsy consistent with cirrhosis. For
             cirrhotic cohorts: Any liver biopsy or fibroscan result from last 2 years excluding
             liver cirrhosis.

          -  Positive test for human immunodeficiency virus (HIV) or hepatitis B antigen at
             screening

          -  Current alcohol or drug abuse, or history of the same, within the past six (6) months.
             Exception: Occasional use of cannabis is not an exclusion criterion. The investigator
             must however instruct the patient that consumption of cannabis is not allowed during
             the treatment period.

          -  Any concurrent disease (cardiovascular, pulmonary, renal, haematological,
             neurological, psychiatric, immunologic, metabolic or endocrine dysfunction) if
             clinically significant based on the investigator's medical assessment at screening. A
             clinically significant disease is defined as one which in the opinion of the
             investigator may either put the patient at risk because of participation in the study
             or may influence the results of the study or the patient's ability to participate in
             the study. Exclusion is also necessary for any pre-existing cardiac abnormality by
             history.

          -  Clinically significant abnormalities at screening ECG, including but not limited to a
             QTc longer than 435 msec, Pulse Rate > 240 msec at baseline and any bundle branch
             block pattern, but not necessarily non-specific T wave abnormalities

          -  History of malignancy (except for previously cured squamous cell or basal cell
             carcinoma)

          -  Patients treated with any interferon (IFN) (approved or investigational) or Peg-IFN
             and/or Ribavirin within 3 months prior to screening

          -  Planned or concurrent usage of any other pharmacological therapy including any
             antiviral therapy or vaccination from 7 days before treatment and during treatment

          -  Usage of any investigational drug within thirty (30) days prior to enrolment or 5
             halflives, whichever is longer; or the planned usage of an investigational drug during
             the course of the current study

          -  Known hypersensitivity to drugs or excipients

          -  Patients with any one of the following laboratory values at screening:

               -  Alanine transaminase (ALT) > 3x ULN, local lab

               -  Aspartate aminotransferase (AST) > 3x ULN, local lab

               -  Total bilirubin > 1.5x ULN, local lab, unless predominantly conjugated and
                  reflecting Gilbert's disease

               -  Alkaline phosphatase > 1.5x ULN, local lab

               -  Prothrombin time (INR) > 1.5x ULN, central lab

               -  Creatinine > 1x ULN, local lab

               -  Urine protein / creatinine ratio > 0.3 g protein / g creatinine, central lab

               -  Alpha-1-microglobulin / creatinine in urine > 1x ULN, central lab

               -  Platelet count < 100,000 / mm3, central lab

               -  White Blood cell count < 2000 cells/mm3, central lab

               -  Absolute neutrophile count < 1500 cells, central lab

               -  Hemoglobin < 12 g/dL, central lab

               -  For patients with liver cirrhosis:

                    -  ALT > 5x ULN, local lab

                    -  AST > 5x ULN, local lab

                    -  Platelet count < 70,000 / mm3, central lab

          -  Patients with any clinically significant laboratory abnormalities based on the
             investigator's medical assessment at screening

          -  Positive urine test for drug abuse at screening

          -  Prior randomisation into this trial

          -  Inability to comply with the protocol

          -  Patients with ongoing or historical photosensitivity or recurrent rash

          -  Alpha fetoprotein value (AFP) > 100 ng/ml; if AFP is > 20 and ≤ 100 ng/ml, patients
             can be included if liver cancer is excluded by a current imaging study (i.e.
             ultrasound, computer tomography scan or magnetic resonance imaging)
      "
NCT00661336,withdrawn,"
    the study was withdrawn due to lack of patients.
  ",0,phase 1,['melanoma (skin)'],"[""['C43.51', 'C43.9', 'C43.52', 'D03.51', 'C43.8', 'Z85.820', 'D03.52']""]","['buthionine sulfoximine', 'melphalan']","['CCCCS(=N)(=O)CCC(C(=O)O)N', 'C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl']","
        DISEASE CHARACTERISTICS:

          -  Histologically proven primary or recurrent in-transit melanoma of the extremity

               -  Stage IIIB or IIIC disease, as determined by whole body imaging with a CT scan of
                  the chest, abdomen, and pelvis AND PET scan within the past 4 weeks

                    -  Patients with stage IIIC disease must have undergone removal of regional
                       lymph nodes

                    -  Patients with indeterminate staging must be reviewed by the study chairs
                       prior to study registration

          -  Previously treated with melphalan-based regional therapy and had persistent disease at
             3 months OR achieved a complete response but disease recurred within 6 months

          -  Disease to be treated by regional therapy must be distal to the planned site of
             tourniquet placement

          -  Bidimensionally measurable disease by caliper or a radiological method as defined by
             the RECIST criteria modified for cutaneous lesions

               -  Photo documentation required

               -  Patients with a single lesion must have archived tumor tissue available for study
                  analysis

          -  No history of tumors with clinically significant evidence of active bleeding (e.g.,
             gross hemoptysis, hematemesis, hematuria, melena, or bleeding superficial tumor)
             within the past 12 weeks

          -  No stage IV disease

          -  No cerebral metastases

        PATIENT CHARACTERISTICS:

          -  ECOG/Zubrod performance status 0-1

          -  Serum creatinine ≤ 1.5 mg/dL

          -  WBC ≥ 3,000/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 10 g/dL

          -  Bilirubin normal

          -  AST and ALT ≤ 2.5 times normal

          -  Must have a palpable femoral/axillary pulse in the affected extremity

          -  No uncontrolled seizures or clinically significant CNS disorders

          -  No psychiatric condition or diminished capacity that could preclude study compliance
             or giving informed consent

          -  No history of allergic reactions and/or hypersensitivity to melphalan

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No history of other malignancies except adequately treated basal cell or squamous cell
             carcinoma of the skin; curatively treated carcinoma in situ of the uterine cervix,
             prostate cancer, or superficial bladder cancer; or other curatively treated solid
             tumors with no evidence of disease for ≥ 5 years

          -  No stroke or other major tissue injury within the past 4 weeks

          -  No other uncontrolled serious chronic disease or condition that, in the investigator's
             opinion, could preclude study compliance or follow-up

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Recovered from prior therapy

          -  More than 4 weeks since prior major surgery

               -  Wound healing adequate since last major surgery

          -  More than 4 weeks since prior antineoplastic therapy, radiotherapy, or any other
             investigational drug

          -  More than 7 days since prior antimicrobial agents (i.e., antibiotic, antifungal, or
             antiviral agents) for active infection or infectious symptoms

          -  No drugs that are known to cause enhanced glutathione depletion (e.g., acetaminophen)
             for 7 days before, during, and for 7 days after buthionine sulfoximine (BSO)
             administration

          -  No cephalosporin antibiotics for 7 days before, during, and for 7 days after BSO
             administration
      "
NCT01536665,completed,,1,phase 1,"['diabetes', 'diabetes mellitus, type 1']","[""['E23.2', 'N25.1', 'P70.2', 'O24.92', 'Z83.3', 'Z86.32', 'E10.65']"", ""['E10.65', 'E10.9', 'E10.21', 'E10.36', 'E10.41', 'E10.42', 'E10.44']""]","['liraglutide', 'placebo']",['CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O'],"
        Inclusion Criteria:

          -  Type 1 diabetes mellitus (as diagnosed clinically) for at least 12 months prior to
             randomisation

          -  Body mass index (BMI) between 20.0 and 28.0 kg/m^2 (both inclusive)

        Exclusion Criteria:

          -  Use of liraglutide or exenatide within 3 months of randomisation

          -  Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during the last
             12 months) or hypoglycaemic unawareness as judged by the trial physician or
             hospitalisation for diabetic ketoacidosis during the previous 6 months

          -  Subject who has donated any blood or plasma in the past month or more than 500 mL
             within 3 months prior to screening
      "
NCT01451632,completed,,1,phase 1,"['colorectal cancer', 'squamous cell head and neck cancer', 'non-small cell lung cancer', 'triple negative breast cancer', 'other tumors with egfr dependence']","[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']"", ""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']""]","['mm-121', 'irinotecan', 'cetuximab']",['CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7'],"
        Inclusion Criteria:

          -  No standard options remaining

          -  Adequate liver and kidney functions

          -  18 years of age or above

        Exclusion Criteria:

          -  History of any secondary active cancer in the last 3 years.

          -  Pregnant or breast feeding

          -  History of severe allergic reactions or contraindications to cetuximab or irinotecan
      "
NCT00506805,completed,,0,phase 1,['cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]",['snx-5422'],['CC1(CC2=C(C(=O)C1)C(=NN2C3=CC(=C(C=C3)C(=O)N)NC4CCC(CC4)OC(=O)CN)C(F)(F)F)C'],"
        Inclusion Criteria:

          -  >18 years old

          -  histologically confirmed solid tumor malignancy

          -  refractory to available therapy or for which no therapy is available

          -  adequate organ function

        Exclusion Criteria:

          -  CNS malignancy

          -  significant GI disease

          -  at risk for prolonged QT interval
      "
NCT00141037,completed,,1,phase 1/phase 2,"['kidney diseases', 'kidney transplantation', 'kidney transplant', 'renal transplantation', 'renal transplant']","[""['I12.9', 'N18.9', 'Q61.9', 'I12.0', 'D63.1', 'N18.1', 'N18.5']"", ""['N26.2', 'Q63.0', 'Q63.2', 'Z52.4', 'I75.81', 'N19', 'N20.0']"", ""['T86.11', 'T86.12', 'T86.13', 'Z94.0', 'T86.10', 'T86.19', 'Z48.22']"", ""['N25.0', 'Q61.4', 'N23', 'N26.9', 'P96.0', 'Q60.0', 'Q60.1']"", ""['N25.0', 'Q61.4', 'N23', 'N26.9', 'P96.0', 'Q60.0', 'Q60.1']""]","['daclizumab', 'mycophenolate mofetil (mmf)', 'prednisone', 'tacrolimus', 'ganciclovir', 'valganciclovir', 'trimethoprim and sulfamethoxazole']","['CC12CC(=O)C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C', 'CC1CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC(=O)C(C=C(C1)C)CC=C)O)C)C(=CC4CCC(C(C4)OC)O)C)O)C)OC)OC', 'C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N', 'CC(C)C(C(=O)OCC(CO)OCN1C=NC2=C1N=C(NC2=O)N)N', 'CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N.COC1=CC(=CC(=C1OC)OC)CC2=CN=C(N=C2N)N']","
        Inclusion Criteria:

          -  Primary recipient of a kidney transplant

          -  Meets site-specific transplant criteria

          -  Panel Reactive Antibody (PRA) of 20% or less

          -  Willing to use acceptable forms of contraception

          -  Parent or guardian willing to provide informed consent, if applicable

        Exclusion Criteria:

          -  Previous treatment with steroids within 6 months prior to transplantation

          -  Received en-bloc kidney or other kidney that does not meet protocol-specified
             requirements

          -  Received an organ from an human leukocyte antigen (HLA) identical donor or a
             non-heart-beating donor

          -  Received a solid organ other than a kidney

          -  Received a bone marrow or hematopoietic stem cell transplant

          -  Received a repeat kidney transplant

          -  Currently receiving an investigational pharmacologic or biologic agent

          -  Human Immunodeficiency virus (HIV) infected or infected with another immunodeficiency
             virus

          -  Hypersensitivity to murine products or the study drugs or their formulations

          -  Inability to measure height accurately

          -  Pregnant or breastfeeding
      "
NCT01016483,completed,,0,phase 1/phase 2,['pancreatic adenocarcinoma'],"[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['pimasertib', 'gemcitabine', 'placebo']","['Status: 503', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F', 'Status: 503']","
        Inclusion Criteria:

          1. Subject has provided signed informed consent. Fully understands requirements of the
             trial and willing to comply with all trial visits and assessments.

          2. Histologically or cytologically confirmed metastatic adenocarcinoma of the pancreas
             and availability of tumor sample.

          3. Evidence of disease (not necessarily measurable disease). Complete tumor assessment
             including chest X ray, CT scan of abdomen and other scans as necessary to document all
             sites of disease performed within 28 days prior to trial entry/randomization.

          4. Age ≥ 18 years.

          5. Women of childbearing potential must have a negative blood pregnancy test at the
             screening visit. For the purposes of this trial, women of childbearing potential is
             defined as: ""All female subjects after puberty unless they are post-menopausal for at
             least two years, are surgically sterile or are sexually inactive.""

          6. Female subjects of childbearing potential and male subjects with female partners of
             childbearing potential must be willing to avoid pregnancy by using an adequate method
             of contraception for 2 weeks prior to screening, during and four weeks after the last
             dose of trial medication. Adequate contraception is defined as two barrier methods, or
             one barrier method with a spermicide, or intrauterine device. The use of hormonal
             contraceptives should be avoided in female subjects of childbearing potential due to a
             possible drug-drug interaction.

        Exclusion Criteria:

          1. Bone marrow impairment as evidenced by hemoglobin less (<) 9.0 gram per deciliter
             (g/dL), neutrophil count < 1.5 x 10^9/ liter (L), platelets < 100 x 10^9/L.

          2. Renal impairment as evidenced by serum creatinine > 1.5 x upper limit of normal (ULN),
             and/or calculated creatinine clearance < 60 mL/min.

          3. Liver function abnormality as defined by total bilirubin > 1.5 x ULN, or aspartate
             aminotransferase/ alanine aminotransferase (AST/ALT) > 2.5 x ULN, for subjects with
             liver involvement AST/ALT > 5 x ULN.

          4. Serum calcium > 1 x ULN.

          5. History of central nervous system (CNS) metastases, unless subject has been previously
             treated for CNS metastases, is stable by CT scan without evidence of cerebral edema,
             and has no requirements for corticosteroids or anticonvulsants.

          6. Eastern Cooperative Oncology Group Performance Status (ECOG PS) greater than 1.

          7. Significant cardiac conduction abnormalities, including QT interval corrected for
             heart rate (QTc) prolongation of > 480 milliseconds (ms) and/or pacemaker.

          8. Retinal degenerative disease (hereditary retinal degeneration or age-related macular
             degeneration), history of uveitis or history of retinal vein occlusion.
      "
NCT00281255,withdrawn,"
    infeasible
  ",0,phase 1/phase 2,"['cardiovascular diseases', 'cardiomyopathy, dilated', 'heart diseases', 'heart failure, congestive']","[""['A52.00', 'A52.09', 'A50.54', 'Z01.810', 'Q87.418', 'Z13.6', 'R94.30']"", ""['I11.0', 'I11.9', 'I27.1', 'I51.9', 'I09.9', 'I27.9', 'I01.8']"", ""['I50.20', 'I50.21', 'I50.22', 'I50.30', 'I50.31', 'I50.32', 'I50.40']""]","['allopurinol', 'dobutamine']","['C1=NNC2=C1C(=O)NC=N2', 'CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O']","
        Inclusion Criteria:

          -  Diagnosis of idiopathic cardiomyopathy (defined by an ejection fraction less than or
             equal to 35% that has been assessed by any method within 6 months prior to study entry
             AND no evidence of coronary artery disease, as determined by coronary angiography or
             stress perfusion imaging within 2 years prior to study entry)

          -  New York Heart Association (NYHA) Class I - II heart failure

          -  Stable heart failure medication for at least 1 month prior to study entry

          -  Able to lie flat for 45 minutes

        Exclusion Criteria:

          -  History of poorly controlled hypertension and concentric left ventricular hypertrophy
             on echocardiography suggesting hypertensive cardiomyopathy

          -  History of biopsy-proven myocarditis

          -  Peripartum cardiomyopathy

          -  Allopurinol therapy within the 6 months prior to study entry

          -  Allopurinol allergy

          -  Contraindication to allopurinol because of concomitant therapy with one of the
             following: azathioprine, cyclophosphamide, dicumarol, uricosuric agents (e.g.,
             probenecid), ampicillin, amoxicillin, chlorpropamide, or cyclosporine

          -  Acute gout

          -  Estimated creatinine clearance less than 20 ml/min

          -  Total bilirubin greater than 2 times upper limit of normal

          -  Serum aspartate AST or alanine ALT greater than 3 times the upper limit of normal

          -  White blood cell count less than 2,000

          -  Platelet count less than 80,000

          -  Hemoglobin less than 8 mg/dl

          -  Use of intravenous inotropes

          -  History of untreated symptomatic ventricular tachycardia

          -  History of sustained ventricular tachycardia induced by dobutamine

          -  Contraindication to MRI because of one of the following:

               1. Starr-Edwards pre-6000 series prosthetic valves or prosthetic valves for which
                  model can not be determined

               2. Implanted pacemaker

               3. Implanted cardioverter-defibrillator intracranial aneurysm clips

               4. Other implanted medical devices that are known to be MRI incompatible (e.g.,
                  cochlear implants and spinal stimulators)

               5. History of foundry-work that could create ocular metallic fragments

          -  Hospitalization at least 1 month prior to study entry
      "
NCT01068483,completed,,1,phase 1,"['breast cancer', 'colon cancer', 'ovarian cancer', 'endometrium cancer']","[""['C79.81', 'D24.1', 'D24.2', 'D24.9', 'D49.3', 'C44.501', 'D48.60']"", ""['C18.2', 'C18.4', 'C18.6', 'C18.7', 'C18.9', 'D12.2', 'D12.3']"", ""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]",['bkm120'],['C1COCCN1C2=NC(=NC(=C2)C3=CN=C(C=C3C(F)(F)F)N)N4CCOCC4'],"
        Inclusion Criteria:

        All patients:

          -  Histologically-confirmed advanced solid tumors

          -  Progressive, recurrent unresectable disease

          -  World Health Organization (WHO) Performance status ≤ 2

          -  No history of primary brain tumor or brain metastases

        MTD Expansion part:

          -  Histologically-confirmed advanced solid tumors

          -  Progressive, recurrent unresectable disease

          -  World Health Organization (WHO) Performance status ≤ 2

          -  No history of primary brain tumor; no brain metastases unless asymptomatic and
             clinically stable for ≥ 3 months

          -  Patients with genetic or molecular alteration of the PI3K pathway

        Exclusion Criteria:

          -  Prior treatment with a PI3K inhibitor

          -  History of or active major depressive episode, bipolar disorder, schizophrenia, or
             history of suicidal attempt or ideation

          -  No clinically manifest diabetes mellitus (treated and/or with clinical signs)

          -  No acute or chronic renal disease

          -  No acute or chronic liver disease

          -  No acute or chronic pancreatitis

          -  No unresolved diarrhea

          -  No impaired cardiac function or clinically significant cardiac diseases such as
             ventricular arrhythmia, congestive heart failure, uncontrolled hypertension

          -  No acute myocardial infarction or unstable angina pectoris within the past 3 months

          -  Not pregnant or nursing and fertile patients must use barrier contraceptives

        Other protocol-defined inclusion/exclusion criteria may apply
      "
NCT00072605,completed,,1,phase 1,"['hemorrhagic fever, ebola', 'healthy']","[""['Z76.3', 'Z76.2']""]",['vrc-ebodna012-00-vp'],['Status: 503'],"
        -  INCLUSION CRITERIA:

        A volunteer must meet all of the following inclusion criteria:

          1. 18 to 44 years old.

          2. Available for follow-up for the duration of the study (12 months).

          3. Able to provide proof of identity to the acceptance of the study clinician completing
             the enrollment process.

          4. Completion of an Assessment of Understanding prior to enrollment and verbalize
             understanding of all questions answered incorrectly.

          5. Able and willing to complete the informed consent process.

          6. Willing to receive HIV test results and willing to abide by NIH guidelines for partner
             notification of positive HIV results.

          7. Willing to donate blood for sample storage.

          8. In good general health without clinically significant medical history.

          9. Physical examination and laboratory results without clinically significant findings
             within the 28 days prior to enrollment.

             Laboratory Criteria within 28 days prior to enrollment:

         10. Hematocrit equal to 34% for women; 38% for men.

         11. Normal fibrinogen levels, D-dimer immunoassay less than 2.0 microg/mL, and RBC
             morphology without evidence of microangiopathic hemolysis.

         12. WBC count: Non-African Americans: equal to 3,300-12,000 cells/mm3, African-Americans:
             equal to 2,500 - 12,000 cells/mm3 (in the absence of clinical or pathological
             etiology).

         13. Differential either within institutional normal range or accompanied by site physician
             approval.

         14. Total lymphocyte count: Non-African Americans: equal to 800 cells/mm3, African
             Americans: equal to 650 cells/mm3 (in the absence of clinical or pathological
             etiology)

         15. Platelets within institutional normal limits.

         16. Prothrombin time and activated partial thromboplastin time (PT, PTT) within
             institutional normal range.

         17. Alanine aminotransferase (ALT) (also called SGPT) = upper limit of normal range

         18. Serum creatinine = upper limit of normal range

         19. Negative Food and Drug Administration (FDA)-approved HIV blood test

         20. Negative hepatitis B surface antigen (HbsAg)

         21. Negative antibody to hepatitis C virus (anti-HCV), or negative HCV PCR if the anti-HCV
             is positive.

         22. Normal urinalysis defined as negative glucose, negative or trace protein, and negative
             hemoglobin by dipstick.

             Female-Specific Criteria:

         23. Negative pregnancy test (urine or serum) for women presumed to be of reproductive
             potential.

         24. A female participant must meet one of the following criteria:

        No reproductive potential because of menopause (one year without menses) or because of a
        hysterectomy, bilateral oophorectomy, or tubal ligation,

        or

        Participant agrees to be heterosexually inactive at least 21 days prior to enrollment and
        throughout the duration of the study,

        or

        Participant agrees to consistently practice contraception at least 21 days prior to
        enrollment and throughout the duration of the study by one of the following methods:

          -  condoms, male or female, with or without a spermicide

          -  diaphragm or cervical cap with spermicide

          -  intrauterine device

          -  contraceptive pills or patch, Norplant, Depo-Provera or other FDA-approved
             contraceptive method

          -  male partner has previously undergone a vasectomy for which there is documentation

        EXCLUSION CRITERIA:

        A volunteer will be excluded if one or more of the following conditions apply.

        Women:

          1. Breast-feeding.

             Volunteer has received any of the following substances:

          2. Immunosuppressive or cytotoxic medications within the past six months with the
             exception of corticosteroid nasal spray for allergic rhinitis or topical
             corticosteroids for an acute uncomplicated dermatitis

          3. Blood products within 120 days prior to HIV screening.

          4. Immunoglobulin within 60 days prior to HIV screening.

          5. Live attenuated vaccines within 30 days prior to initial study injection.

          6. Investigational research agents within 30 days prior to initial study injection.

          7. Medically indicated subunit or killed vaccines, e.g. influenza, pneumococcal, or
             allergy treatment with antigen injections, within 14 days prior to initial study
             injection.

          8. Current anti-TB prophylaxis or therapy.

             Volunteer has a history of any of the following clinically significant conditions:

          9. Serious adverse reactions to vaccines, such as anaphylaxis, hives, respiratory
             difficulty, angioedema, or abdominal pain.

         10. Autoimmune disease or immunodeficiency.

         11. Asthma that is unstable or required emergent care, urgent care, hospitalization or
             intubation during the past two years or that requires the use of oral or intravenous
             corticosteroids.

         12. Diabetes mellitus (type I or II), with the exception of gestational diabetes.

         13. Thyroid disease including history of thyroidectomy and diagnoses that required
             medication within the past 12 months.

         14. Serious angioedema episodes within the previous 3 years or requiring medication in the
             previous two years.

         15. Hypertension that is not well controlled by medication or is more than 145/95 at
             enrollment.

         16. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or
             platelet disorder requiring special precautions) or significant bruising or bleeding
             difficulties with IM injections or blood draws.

         17. Malignancy that is active or treated malignancy for which there is not reasonable
             assurance of sustained cure or malignancy that is likely to recur during the period of
             the study.

         18. Seizure disorder other than: 1) febrile seizures under the age of two, 2) seizures
             secondary to alcohol withdrawal more than 3 years ago, or 3) a singular seizure not
             requiring treatment within the last 3 years.

         19. Asplenia or any condition resulting in the absence or removal of the spleen.

         20. Psychiatric condition that precludes compliance with the protocol; past or present
             psychoses; past or present bipolar disorder requiring therapy that has not been well
             controlled by medication for the past two years; disorder requiring lithium; or
             suicidal ideation occurring within five years prior to enrollment

         21. Any medical, psychiatric, or social condition, or occupational or other responsibility
             that, in the judgment of the investigator, would interfere with or serve as a
             contraindication to protocol adherence or a volunteer's ability to give informed
             consent.
      "
NCT00949026,withdrawn,"
    no accrual
  ",0,phase 1,['brain neoplasms'],"[""['C71.7', 'C71.9', 'C79.31', 'D33.0', 'D33.1', 'D33.2', 'D49.6']""]",['temsirolimus (torisel)'],['CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OC(=O)C(C)(CO)CO)C)C)O)OC)C)C)C)OC'],"
        Inclusion Criteria:

          1. Patients must be at least 18 years of age.

          2. Patients must have histologically confirmed supratentorial grade III or IV astrocytoma
             (anaplastic astrocytoma, anaplastic oligodendroglioma, glioblastoma multiforme) and
             require a stereotactic biopsy for confirmation of tumor progression or differentiation
             of tumor progression from treatment induced effects following radiation therapy ±
             chemotherapy. Patients with previous low-grade glioma who progressed after
             radiotherapy ± chemotherapy and are in need of a stereotactic biopsy to confirm the
             presence of a high-grade glioma, and this is accomplished at the time of biopsy, are
             eligible.

          3. Patients must have a Karnofsky performance status ≥ 50% (i.e. the patient must be able
             to care for himself/herself with occasional help from others).

          4. Patients must have had prior radiation therapy.

          5. The patient is a candidate for temsirolimus as the next therapy for their tumor and
             the treating physician and the patient must be planning to continue temsirolimus
             chemotherapy after receiving the one dose required for this study.

          6. Patients must have recovered from the toxicity of prior therapy. An interval of at
             least 3 months must have elapsed the since the completion of the most recent course of
             radiation therapy while at least 3 weeks must have elapsed since the completion of a
             non-nitrosourea containing chemotherapy regimen and at least six weeks since the
             completion of a nitrosourea containing chemotherapy regimen.

          7. Patients must have adequate bone marrow function (defined as an absolute neutrophil
             count of >1500 cells/mm3 and platelet count >100,000 cells/mm3), liver function with
             Total bilirubin <2.0 mg/dl and SGOT <4 times upper limit of normal, and adequate renal
             function with serum creatinine ≤ 2 mg/dl, creatinine clearance (24 hour collection)
             >50 cc/min. (Required labs must be within -7 days of catheter placement)

          8. Patients must be able to provide written informed consent.

          9. Patients with the potential for pregnancy or impregnating their partner must agree to
             follow acceptable birth control methods to avoid conception. Women of child bearing
             potential must have negative pregnancy test. The anti-proliferative activity of
             temsirolimus may be harmful to the developing fetus or nursing infant.

         10. Patients must not be allergic to temsirolimus or rapamycin.

        Exclusion Criteria:

          1. Patients with serious concurrent infection or medical illness, which would jeopardize
             the ability of the patient to receive the chemotherapy outlined in this protocol with
             reasonable safety.

          2. Patients who are pregnant or breast-feeding.

          3. Patients without MRI or CT evidence of measurable, contrast-enhancing residual disease
             are not eligible.

          4. Patients receiving concurrent chemotherapeutic or investigational agents.
      "
NCT01394055,completed,,1,phase 1,"['diabetes mellitus type 1 and 2', 'diabetes mellitus complications', 'gastroparesis', 'gastrointestinal motility disorder']","[""['E10.9', 'E11.9', 'E13.9', 'E10.8', 'E11.8', 'E13.8', 'E08.9']"", ""['K31.84']"", ""['A21.3', 'A22.2', 'B46.2', 'K92.2', 'K92.81', 'K91.0', 'P54.3']""]","['rm-131', 'placebo']",['C1CC(CNC1)C(=O)NC(CC2=CSC3=CC=CC=C32)C(=O)NC(CC4=CNC5=CC=CC=C54)C(=O)NC(CC6=CC=CC=C6)C(=O)NC7(CCNCC7)C(=O)N'],"
        Key Inclusion Criteria:

          -  Able to provide written informed consent prior to any study procedures.

          -  Diagnosis of Type 1 or 2 diabetic gastroparesis.

          -  Controlled Type 1 or 2 diabetes mellitus (HbA1c <10.1%).

          -  Stable concomitant medications defined as no changes in regimen for at least 2 weeks
             prior to Period 1 (daily adjustments of insulin doses are permitted).

          -  Body mass index of 18-40 kg/m².

        Key Exclusion Criteria:

          -  Unable or unwilling to provide informed consent or to comply with study procedures.

          -  History of gastric surgery such as fundoplication, gastrectomy, gastric pacemaker
             placement, vagotomy, bariatric procedure. (Note: history of diagnostic endoscopy is
             not exclusionary).

          -  Acute or chronic illness or history of illness, which in the opinion of the
             Investigator, could pose a threat or harm to the patient or obscure interpretation of
             laboratory test results or interpretation of study data such as frequent angina, Class
             III or IV congestive heart failure, poor renal or hepatic function, etc.

          -  Any clinically significant abnormalities on screening laboratories as determined by
             the Investigator.

          -  Abnormal 12-lead electrocardiogram (ECG), including evidence of acute myocardial or
             subendocardial ischemia and clinically significant arrhythmias or conduction
             abnormalities or blood pressure at screening except minor deviations deemed to be of
             no clinical significance by the Investigator.

          -  Poor venous access or inability to tolerate venipuncture.

          -  Acute GI illness within 48 hours of Period 1.

          -  Positive pregnancy test.

          -  Participation in a clinical study within the 30 days prior to dosing in the present
             study.

          -  Any other reason, which in the opinion of the Investigator, would confound proper
             interpretation of the study.
      "
NCT01434225,completed,,0,phase 1/phase 2,['neonatal seizures'],"[""['E71.511', 'P29.11', 'P29.12', 'P29.2', 'P37.5', 'P54.0', 'P54.1']""]",['bumetanide'],['Status: 503'],"
        Inclusion Criteria:-

          -  Male or female term baby with gestational age of 37-43 weeks and postnatal age <48
             hours

          -  One or more of the following:

          -  APGAR score < 5 at 5 mins.

          -  Umbilical cord or first arterial blood sample pH < 7.1 or base deficit >16 mmol/L.

          -  Postnatal resuscitation still required 10 minutes after birth

               -  Clinically evolving encephalopathy

               -  Received one dose of standard anticonvulsive therapy (phenobarbitone,20mg/kg) for
                  clinical or electrographic seizures.

               -  EEG: equal to or more than 3 min cumulative seizures, or 2 or more seizures of
                  >30 sec duration over 2 hr period within first 48 hr of life

               -  Written informed consent of parent or guardian.

               -  EEG monitoring has commenced within the first 48 hours of birth.

        Exclusion Criteria:

          -  Suspected or confirmed brain malformation, inborn error of metabolism,genetic
             syndrome, or major congenial malformation

          -  Congenital (in utero) infection (TORCH).

               -  Babies who have received diuretics such as furosemide or bumetanide in routine
                  clinical management within the last 24 hours.

               -  Total serum bilirubin > 15 mg/dl (255 micromol/l) at inclusion.

               -  On any other anticonvulsive medication other than phenobarbitone or bolus of
                  midazolam / pentobarbitone for intubation.

               -  Anuria/renal failure defined as serum creatinine > 200 micromol/l.

               -  Severe electrolyte depletion (Na <120 mmol/L, K <3.0 mmol/L)
      "
NCT01010243,unknown status,,1,phase 1/phase 2,['multiple myeloma'],"[""['C90.01', 'C90.02', 'C90.00']""]","['lenalidomide, pioglitazone, dexamethasone, treosulfan']",['Status: 503'],"
        Inclusion Criteria:

          -  At least 18 years of age

          -  Must be able to adhere to the study visit schedule and other protocol requirements.

          -  Must be diagnosed with multiple myeloma that is progressing or has relapsed with
             progressive disease after at least two different anti-myeloma treatments (including
             lenalidomide in one schedule for phase II part only)

          -  In case of patients that have progressive disease after complete remission during
             preceding treatment: Serum monoclonal paraprotein (M-protein) level

             ≥0.5 g/dL for IgG, IgA myeloma and ≥0.05 g/dL for IgD myeloma or urine M-protein level
             ≥ 0.2 g excreted in a 24-hour collection sample or In case of progressive disease
             without complete remission during preceding treatment: > 25% increase of serum
             monoclonal paraprotein or urine M-protein in comparison to the preceding monoclonal
             paraprotein (M-protein)nadir in serum /urine M-protein nadir in a 24 hour collection
             sample

          -  Subjects must have been previously treated with lenalidomide for the phase II part.
             Any first- and second-line treatment is allowed for the phase I part. Phase I study
             inclusion independent of pre-treatment in 1st line.

          -  Sufficient bone marrow function: neutrophils ≥ 2x109/l, hemoglobin ≥10 g/dl, and
             platelets ≥ 100x109/l

          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 (see
             Post Text Supplement 2).

          -  Subjects must discontinue all anti-myeloma drug or non-drug therapy prior to the first
             dose of study drug (at least 4 weeks).

          -  Required laboratory results:

               1. Liver function: Total bilirubin < 1.5 times of upper limit of local institution
                  (ULN), SGPT, SGOT ≤ 2.5 times of upper limit of local institution .

               2. Renal function: serum creatinine ≤ 1.5 ULN c)PT-INR/PT <1.5 ULN

          -  Normal cardiac function

          -  Patients with prior thromboembolic event with adequate anticoagulation

          -  Life expectancy at least 3 months

          -  Written informed consent of the patient prior to screening procedures

          -  Patient must be available for treatment and follow-up

          -  Any previous surgery must have taken place more than 4 weeks prior to inclusion

          -  Previous radiation therapy must have involved less than 25% of bone marrow, and must
             have been completed more than 4 weeks prior to inclusion.

          -  Able to take acetylsalicylic acid (ASA) 100 mg daily as prophylactic anticoagulation
             (patients intolerant to ASA may use low molecular weight heparin). Patients at high
             risk for thromboembolic events should receive low molecular heparin. Patients with
             history of thromboembolic event should pursue their ongoing anticoagulants (e.g.
             phenprocoumon, warfarin, heparin) or receive another adequate prophylaxis, at least
             LMWH).

          -  Female subjects of childbearing potential† must:

               -  Understand that the study medication has a teratogenic risk

               -  Agree to use, and be able to comply with, effective contraception without
                  interruption, 4 weeks before starting study drug, throughout study drug therapy
                  (including dose interruptions) and for 4 weeks after the end of study drug
                  therapy, even if she has amenorrhoea.This applies unless the subject commits to
                  absolute and continued abstinence confirmed on a monthly basis. The following are
                  effective methods of contraception*

          -  Implant**

          -  Levonorgestrel-releasing intrauterine system (IUS)**

          -  Medroxyprogesterone acetate depot

          -  Tubal sterilization

          -  Sexual intercourse with a vasectomised male partner only; vasectomy must be confirmed
             by two negative semen analyses

          -  Ovulation inhibitory progesterone-only pills (i.e., desogestrel)

               -  Because of the increased risk of venous thromboembolism in patients with multiple
                  myeloma, combined oral contraceptive pills are not recommended. If a subject was
                  using combined oral contraception, she must switch to one of the methods above.
                  The increased risk of VTE continues for 4 to 6 weeks after stopping combined oral
                  contraception.

                    -  prophylactic antibiotics should be considered at the time of insertion
                       particularly in patients with neutropenia due to risk of infection

          -  Agree to have a medically supervised pregnancy test with a minimum sensitivity of 25
             mIU/ml not more than 3 days from the start of study medication once the subject has
             been on effective contraception for at least 4 weeks. This requirement also applies to
             women of childbearing potential who practice complete and continued abstinence.

          -  Agree to have a medically supervised pregnancy test every 4 weeks including 4 weeks
             after the end of study treatment, except in the case of confirmed tubal sterilization.
             These tests should be performed not more than 3 days before the start of next
             treatment. This requirement also applies to women of childbearing potential who
             practice complete and continued abstinence

          -  Male subjects must

               -  Agree to use condoms throughout study drug therapy, during any dose interruption
                  and for one week after cessation of study therapy if their partner is pregnant or
                  is of childbearing potential and has no contraception.

               -  Agree not to donate semen during study drug therapy and for one week after end of
                  study drug therapy.

          -  All subjects must

               -  Agree to abstain from donating blood while taking study drug therapy and for one
                  week following discontinuation of study drug therapy.

               -  Agree not to share study medication with another person and to return all unused
                  study drug to the investigator † A female subject or a female partner of a male
                  subject is considered to have childbearing potential unless she meets at least
                  one of the following criteria: Age ≥50 years and naturally amenorrhoeic for ≥ 1
                  year (amenorrhoea following cancer therapy does not rule out childbearing
                  potential), premature ovarian failure confirmed by a specialist gynaecologist,
                  previous bilateral salpingo-oophorectomy or hysterectomy, XY genotype, Turner's
                  syndrome or uterine agenesis.

        Exclusion Criteria:

          -  Patients who require vitamin K antagonists except for low dose (INR ≤ 2,5)

          -  Known hypersensitivity to dexamethasone. Prior history of uncontrollable side effects
             to dexamethasone therapy.

          -  Active infection > grade 2 NCI-CTC version 3.0

          -  Known diagnosis of HIV, hepatitis B, or hepatitis C infection.

          -  Severe, unstable, or uncontrolled medical disease which would confound diagnoses or
             evaluations required by the protocol, including cardiac insufficiency (NYHA I -IV)
             uncontrolled diabetes, chronic hepatic or renal disease, active uncontrolled infection
             and chronic inflammatory intestinal disease, autoimmune diseases.

          -  Prior radiation therapy > 25% of bone marrow

          -  Regular blood transfusions

          -  Treatment with other experimental substances within 30 days before study start

          -  Participation in another clinical trial within 30 days before study start or during
             the trial

          -  Unwilling or unable to comply with the protocol

          -  Pregnant or lactating females.

          -  Patients with seizure disorders requiring medication (such as steroids or
             antiepileptics)

          -  Known hypersensitivity to one of the medications

          -  Patients with evidence or history of bleeding diathesis

          -  Patients undergoing renal dialysis

          -  Major surgery within 4 weeks prior to start of study or incomplete wound healing

          -  Drug or alcohol abuse

          -  Psychological or social conditions that may interfere with the patients participation
             in the study or evaluation of the study results

          -  Known (at time of entry) gastrointestinal disorder, including malabsorption or active
             gastric ulcer, present to the extent that it might interfere with oral intake and
             absorption of study medication

          -  Any previous or concurrent malignancy or any cancer unless curatively treated > 3
             years prior to study entry except cervical carcinoma in situ or adequately treated
             basal cell carcinoma

          -  Neuropathy > Grade 2

          -  Patients with bladder cancer or bladder cancer in their medical history

          -  Macrohematuria of unknown origin

          -  Patients with risk factors for bladder cancer (such as exposure to aromatic amines or
             heavy tobacco smokers)
      "
NCT01302145,completed,,1,phase 1,['type 2 diabetes mellitus'],"[""['E11.65', 'E11.9', 'E11.21', 'E11.36', 'E11.41', 'E11.42', 'E11.44']""]","['asp1941', 'metformin', 'placebo']","['C1=CC=C2C(=C1)C=C(S2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)F', 'CN(C)C(=N)N=C(N)N']","
        Inclusion Criteria:

          -  Subjects with type 2 diabetes

          -  Stable disease under metformin monotherapy (between 1500-3000

        mg/day) or dual therapy with metformin (1500-3000 mg/day) and a Sulfonylureum Derivative
        (SUD) for at least 3 months

          -  Fasting Serum Glucose: 7-11.5 mmol/l (after wash-out)

          -  Stable Fasting Blood Glucose (FBG) at the end of wash-out

          -  BMI between 18.5 and 40.0 kg/m2, inclusive

        Exclusion Criteria:

          -  Subjects with type 1 diabetes

          -  Any diabetes related macro-complications, painful diabetic neuropathy, diabetic
             macular edema or diabetic proliferative retinopathy

          -  Clinical significant renal disease (CLcr <60 ml/min as assessed during a 24h
             creatinine clearance on Day-2

          -  Recent evidence (e.g. within the last 6 months) of severe hypoglycemia, for example
             plasma glucose <3 mmol/l (<55 mg/dl) or requiring hospitalization

          -  Pulse <40 or >90; Systolic Blood Pressure >160 mmHg; Diastolic Blood Pressure > 100
             mmHg
      "
NCT00623064,completed,,1,phase 1,"['bladder cancer', 'transitional cell cancer of the renal pelvis and ureter']","[""['D30.3', 'C67.5', 'C67.9', 'C79.11', 'C67.0', 'C67.1', 'D41.4']""]","['cisplatin', 'gemcitabine hydrochloride', 'lapatinib ditosylate']","['N.N.Cl[Pt]Cl', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F.Cl', 'CC1=CC=C(C=C1)S(=O)(=O)O.CC1=CC=C(C=C1)S(=O)(=O)O.CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl']","
        DISEASE CHARACTERISTICS:

          -  Histologically proven transitional cell carcinoma of the urothelial tract

               -  Metastatic or locally advanced disease

          -  Measurable disease according to RECIST

               -  Involvement of at least one target not in previously irradiated fields

          -  Overexpressing HER1 and/or HER2 receptors (HER2 3+ by IHC OR HER2 FISH or CISH
             positive)

          -  No clinical signs of CNS involvement

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0-1

          -  ANC ≥ 1,500/mm³

          -  Thrombocytes > 100,000/mm³

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  AST/ALT ≤ 3 times ULN

          -  Creatinine clearance ≥ 60 mL/min

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective double-barrier contraception during and for 3
             months after completion of study treatment

          -  Cardiac ejection fraction normal

          -  Normal 12 lead ECG

          -  No serious cardiac illness or medical condition within the past 6 months including,
             but not limited to, any of the following:

               -  Documented congestive heart failure

               -  High-risk uncontrolled arrhythmias

               -  Angina pectoris requiring antianginal medication

               -  Clinically significant valvular heart disease

               -  Evidence of transmural infarction on ECG

               -  Poorly controlled hypertension (e.g., systolic blood pressure [BP] > 180 mm Hg or
                  diastolic BP > 100 mm Hg)

          -  No peripheral neuropathy > grade 1

          -  Able to swallow and retain oral medication

          -  No other malignancy within the past 3 years except basal cell or squamous cell
             carcinoma of the skin or carcinoma in situ of the cervix

          -  No active or uncontrolled infections, serious illnesses, malabsorption syndrome or
             medical conditions, hepatitis, HIV, and/or cirrhosis

          -  No psychological, familial, sociological, or geographical condition potentially
             hampering study protocol compliance or follow-up schedule

          -  No current active hepatic or biliary disease (with the exception of Gilbert's
             syndrome, asymptomatic gallstones, liver metastases or stable chronic liver metastases
             or stable chronic liver disease)

        PRIOR CONCURRENT THERAPY:

          -  Recovered from any effects of surgery

          -  Intravesicle therapy for superficial disease allowed

          -  Prior neoadjuvant or adjuvant chemotherapy allowed

               -  Must have a minimum interval of six months between the completion of neoadjuvant
                  or adjuvant chemotherapy and the diagnosis of metastatic disease

          -  No prior chemotherapy for metastatic disease

          -  No radiotherapy within the past 4 weeks

          -  No drugs and herbal inducers or inhibitors of CYP3A4 (e.g., bergamottin or glabridin)
             within 10 days prior to study treatment and while receiving lapatinib ditosylate
             therapy

          -  No other concurrent anticancer therapy or investigational agents

          -  No other concurrent anticancer agents

          -  No concurrent treatment with other investigational therapy for other diseases or
             conditions

          -  No concurrent prophylactic antibiotics

          -  No concurrent prophylactic filgrastim (G-CSF)

          -  At least 14 days since prior and no concurrent herbal or dietary supplements

          -  No concurrent consumption of grapefruit juice
      "
NCT00398086,completed,,1,phase 1/phase 2,['metastatic pancreatic cancer'],"[""['C25.3']""]","['gemcitabine', 'albumin-bound paclitaxel']",['C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F'],"
        Inclusion Criteria:

          -  Patient has histologically or cytologically confirmed metastatic adenocarcinoma of the
             pancreas. Patients with islet cell neoplasms are excluded.

          -  Male or non-pregnant and non-lactating female, and age greater or equal to 18.

               -  If a female patient is of child-bearing potential, as evidenced by regular
                  menstrual periods, she must have a negative serum pregnancy test beta-human
                  chorionic gonadotropin (B-hCG) documented within 72 hours of the first
                  administration of study drug.

               -  If sexually active, the patient must agree to use contraception considered
                  adequate and appropriate by the investigator.

          -  Patient must have received no prior therapy for the treatment of metastatic disease.
             Prior treatment with 5-fluorouracil (5-FU) or gemcitabine administered as a radiation
             sensitizer during and up to 4 weeks after radiation therapy is allowed. If a patient
             received gemcitabine in the adjuvant setting, tumor recurrence must have occurred at
             least 6 months after completing the last dose of gemcitabine.

          -  Patient has the following blood counts at baseline

               -  Absolute neutrophil count (ANC) equal or greater to 1.5 x 10^9/L;

               -  Platelets equal or greater to 100 x 10^9/L

               -  Hemoglobin equal or greater to 9 g/dL.

               -  Patient has the following blood chemistry levels at baseline:

               -  Aspartate aminotransferase (SGOT), Alanine aminotransferase (SGPT) equal or less
                  than 2.5 x upper limit of normal range (ULN) is allowed

               -  Bilirubin less than or equal to ULN

               -  Serum creatinine within normal limits or calculated clearance equal or greater to
                  60 mL/min/1.73M^2 patients with serum creatinine levels above the institutional
                  normal value

          -  Patient has no clinically significant abnormalities in urinalysis results

          -  Patient has acceptable coagulation status as indicated by a prothrombin time (PT)
             within normal limits (plus or minus 15%) and partial thromboplastin time (PTT) within
             normal limits (plus or minus 15%).

          -  Patient has a Karnofsky performance status (KPS) greater or equal to 70 (Eastern
             Cooperative Oncology Group [ECOG] PS 0-1).

          -  Patient has one or more metastatic tumors measurable by computed tomography (CT) scan.

          -  Patient has been informed about the nature of study, and has agreed to participate in
             the study, and signed the Informed Consent form prior to participation in any
             study-related activities.

        Exclusion Criteria:

          -  Patient has known brain metastases unless previously treated and well controlled for
             at least 3 months (defined as stable clinically, no edema, no steroids and stable in
             two scans at least 4 weeks apart).

          -  Patient uses therapeutic coumadin for a history of pulmonary emboli and deep vein
             thrombosis (DVT).

          -  Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring
             systemic therapy.

          -  Patient has known infection with human immunodeficiency virus (HIV), hepatitis B,
             hepatitis C.

          -  Patient has undergone major surgery, other than diagnostic surgery i.e.-- done to
             obtain a biopsy for diagnosis without removal of an organ), with 4 weeks prior to Day
             1 of treatment in this study.

          -  Patient received radiotherapy, surgery, chemotherapy, or an investigational therapy
             within 3 weeks prior to study entry weeks (6 weeks for nitrosureas or mitomycin C).

          -  Patient has a history of allergy or hypersensitivity to the study drug.

          -  Patient has serious medical risk factors involving any of the major organ systems such
             that the investigator considers it unsafe for the patient to receive an experimental
             research drug.

          -  Patient is unwilling or unable to comply with study procedures.

          -  Patient is enrolled in any other clinical protocol or investigational trial.
      "
NCT00516828,completed,,0,phase 1/phase 2,"['leukemia', 'myelodysplastic syndromes']","[""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']"", ""['D46.9', 'D46.C', 'D46.Z']""]",['cytarabine'],['Status: 503'],"
        DISEASE CHARACTERISTICS:

          -  Diagnosis of 1 of the following:

               -  Acute myeloid leukemia (AML) by FAB criteria (By morphology and routine
                  histochemistry and confirmed, when possible, by flow cytometric analysis of
                  surface immunophenotype; co-expression of lymphoid markers permitted)

               -  High-risk myelodysplastic syndromes defined as IPSS category of intermediate-2 or
                  greater

          -  Must be considered unsuitable for intensive chemotherapy regimens

          -  No documented CNS involvement

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  AST and ALT ≤ 2 times upper limit of normal (ULN)

          -  Bilirubin normal

          -  Creatinine ≤ 1.2 times ULN OR creatinine clearance ≥ 50 mL/min

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No history of other malignancies, except adequately treated nonmelanoma skin cancer,
             curatively treated in situ carcinoma of the cervix, or other solid tumors curatively
             treated with no evidence of disease for ≥ 5 years

          -  No upper gastrointestinal or other conditions that would preclude compliance with or
             administration of oral medication

          -  No serious illness or medical condition that would not permit the patient to be
             managed according to the protocol, including any of the following:

               -  History of significant neurologic or psychiatric disorder that would impair the
                  ability to obtain consent

               -  Active, uncontrolled, serious infections

               -  Active peptic ulcer disease

               -  Evidence of bleeding diathesis

          -  No myocardial infarction within the past 6 months

          -  No congestive heart failure

          -  No unstable angina

          -  No active cardiomyopathy or unstable ventricular arrhythmia

          -  No poorly controlled hypertension (e.g., systolic BP ≥ 150 mm Hg or diastolic BP ≥ 95
             mm Hg)

          -  No known hypersensitivity to the study drugs or their components

          -  No preexisting hypothyroidism prior to enrollment unless patient is euthyroid on
             medication

          -  No neuropathy ≥ grade 2

        PRIOR CONCURRENT THERAPY:

          -  At least 2 days since prior hydroxyurea

          -  No other prior chemotherapy

          -  No concurrent therapeutic doses (≥ 2 mg/day) of anticoagulants (e.g., warfarin)

               -  Doses of up to 2 mg/day given for prophylaxis of thrombosis are accepted provided
                  INR is ≤ 1.5

          -  No other concurrent experimental drugs or anticancer therapy
      "
NCT00350844,terminated,"
    low subject accrual
  ",0,phase 1/phase 2,"['sickle cell disease', 'pulmonary hypertension']","[""['D57.1', 'D57.20', 'D57.212', 'D57.219', 'D57.211', 'D57.213', 'D57.218']"", ""['I27.0', 'I27.20', 'I27.21', 'I27.24', 'I27.29', 'P29.30', 'I27.22']""]",['hydroxyurea'],['C(=O)(N)NO'],"
        Inclusion Criteria:

          -  Age between 10 and 25 years old

          -  Sickle cell disease with hemoglobin SS, SC or S-B^0 thalassemia confirmed on
             hemoglobin electrophoresis

          -  Tricuspid regurgitant jet velocity (TRJV) equal to or greater than 2.5 m/sec on 2
             baseline Doppler echocardiograms at least 3 months apart

        Exclusion Criteria:

          -  Patients already being treated with hydroxyurea

          -  Patients on a chronic transfusion protocol

          -  Patients with evidence of hepatic (alanine aminotransferase [ALT] equal to or greater
             than 2 SD above normal) or renal dysfunction (creatinine [Cr] equal to or greater than
             2 SD above normal)

          -  Patients who are pregnant

          -  Patients with documented causes of severe pulmonary hypertension other than from SCD
      "
NCT00099086,"active, not recruiting",,1,phase 1,['prostate cancer'],"[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]","['bicalutamide', 'docetaxel', 'gnrh analog']","['CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O', 'Status: 503']","
        Inclusion Criteria:

          1. Histologically confirmed adenocarcinoma of the prostate with one of the prognostic
             factors specified in the protocol. No pelvic lymph node disease that would necessitate
             pelvic radiotherapy. No radiologic evidence of metastatic disease on bone scan or on
             CT scan or MRI of the abdomen or pelvis

          2. No prior radiation therapy, chemotherapy, immunotherapy or alternative therapy for
             prostate cancer. Greater than 4 weeks since any major surgery.

          3. Performance status 0-2

          4. Must meet criteria for acceptable lab values as outlined in the protocol.

          5. Peripheral neuropathy must be greater than or equal to 1

          6. Men of childbearing potential must be willing to consent to using effective
             contraception while on treatment and for at least 3 months thereafter.

        Exclusion Criteria:

        1. No history of severe hypersensitivity reaction to docetaxel or other drugs formulated
        with Polysorbate 80
      "
NCT01561430,terminated,"
    study terminated due to abnormal liver biochemical tests in some participants.
  ",0,phase 1/phase 2,"[""alzheimer's disease""]","[""['G30.8', 'G30.9', 'G30.0', 'G30.1']""]","['ly2886721', 'placebo']",['C1C2CSC(=NC2(CO1)C3=C(C=CC(=C3)NC(=O)C4=NC=C(C=C4)F)F)N'],"
        Inclusion Criteria:

        Meets criteria for MCI due to AD or Mild AD

        All participants will be required to undergo assessment via the Mini Mental State
        Examination (MMSE) scale at screening

          -  Participants with MMSE scores of 20 to 26, inclusive, may be enrolled provided they
             meet the criteria for mild AD, as follows:

               -  Participant meets the National Institute of Neurological and Communicative
                  Disorders and Stroke/Alzheimer's Disease and Related Disorders Association
                  (NINCDS/ADRDA) criteria for probable AD

               -  Clinical Dementia Rating Scale (CDR) score of 0.5 or 1

               -  Positive scan for the presence of amyloid beta

          -  Participants with MMSE of 27 to 30, inclusive, may be enrolled as participants with
             MCI due to AD provided they meet the following criteria:

               -  Gradual and progressive change in memory function as reported by the participant
                  or a caregiver during a period of more than 6 months

               -  Free and Cued Selective Reminding Test with Immediate Recall (FCSRT-IR): free
                  recall ≤22 and total recall ≤46

               -  Absence of dementia

               -  Preservation of functional independence

               -  Exclusion of other potential (vascular, traumatic, or medical) causes of
                  cognitive decline, where possible

               -  Positive scan for the presence of amyloid beta

          -  Women must be postmenopausal

          -  Men are required to use an approved barrier method of contraception if their partners
             are pregnant, or of childbearing potential and not using approved contraceptive
             methods

        Exclusion Criteria:

          -  Participant in another drug or device study

          -  Have a history of frontotemporal dementia, Lewy body disease, vascular dementia,
             Huntington's disease, Parkinson's disease, progressive supranuclear palsy (PSNP), or
             other movement disorder

          -  Participants are not on a stable standard of care (acetylcholinesterase inhibitors,
             memantine) initiated less than 2 months prior to entry or have less than 4 weeks of
             stable therapy. Note: Stable standard of care is allowed.

          -  Have had a serious infectious disease affecting the brain in the past 5 years

          -  Have had a serious or repeat head injury

          -  Have significant retinal impairment or disease

          -  Have had a stroke or other circulation problems that are affecting current health

          -  Have had a seizure

          -  Have major depressive disorder and are not on a stable dose of medication.
             Participants who no longer meet the Diagnostic and Statistical Manual of Mental
             Disorders, Fourth Edition-Text Revision (DSM-IV) criteria for major depression may be
             included

          -  History of schizophrenia, bipolar disorder, or severe mental illness

          -  History of alcohol or drug abuse

          -  Have asthma, chronic obstructive pulmonary disease (COPD), or other breathing disease
             that is not controlled with medicine

          -  Have human immunodeficiency virus (HIV) or syphilis

          -  Are taking blood thinners
      "
NCT00329004,completed,,1,phase 1,"['cancer', 'tumor']","[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['E88.3', 'Q85.81', 'R97.8', 'C49.A0', 'C49.A1', 'C49.A2', 'C49.A5']""]",['bms-690514'],['COC1=CC=CC(=C1)NC2=NC=NN3C2=C(C=C3)CN4CCC(C(C4)O)N'],"
        Inclusion Criteria:

          -  Men and women 18 and older

          -  Diagnosis of any solid tumor

          -  ECOG performance status score 0-1

          -  Prior chemo-therapy, immunotherapy or radiotherapy with at least 4 weeks since the
             last treatment

          -  Treatment with VEGFR2 or HER1 TKI allowed but not both (for instance Avastin or
             Tarceva, but not both)

        Exclusion Criteria:

          -  Treatment with other TKIs within the past 4 weeks

          -  Patients with brain metastasis

          -  Patients with centrally located squamous cell carcinoma of the lung

          -  Major gastrointestinal surgery which may affect absorption of the drug

          -  Any surgery within last 4 weeks

          -  History of thromboembolism

          -  Severe unmanageable diarrhea

          -  Subjects in Part B will have Non-Small Cell Lung Cancer (NSCLC)

          -  Part B/Cohort I erlotinib-naive subjects

          -  Part B/Cohort II subjects who have experienced disease progression while receiving
             erlotinib (erlotinib-resistant subjects)
      "
NCT00411593,withdrawn,"
    lack of patient accrual
  ",0,phase 1/phase 2,['lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['bevacizumab', 'bortezomib']",['B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O'],"
        Inclusion Criteria:

          1. Voluntary written informed consent before performance of any study-related procedure
             not part of normal medical care, with the understanding that consent may be withdrawn
             by the subject at any time without prejudice to future medical care.

          2. Female subject is either post-menopausal (Postmenopausal women must be amenorrheic for
             at least 12 months to be considered of non-childbearing potential) or surgically
             sterilized or willing to use an acceptable method of birth control (i.e. a hormonal
             contraceptive, intra-uterine device, diaphragm with spermicide, condom with
             spermicide, or abstinence) for the duration of the study. Male subject agrees to use
             an acceptable method for contraception for the duration of the study.

          3. All patients must have an Eastern Cooperative Oncology Group (ECOG)Performance Status
             of 0 - 2

          4. Patients must have histologically or cytologically proven selected Stage IIIB (T4
             lesion due to malignant pleural or pericardial effusion) or Stage IV advanced
             non-small cell lung cancer or recurrent disease after previous surgery and/or
             radiation.

          5. No history of or active brain metastases

          6. Patients must have measurable disease documented by computed tomography (CT) or
             magnetic resonance imaging (MRI). Measurable disease must be assessed within 28 days
             prior to registration. Pleural effusions, ascites and laboratory parameters are not
             acceptable as the only evidence of disease.

          7. Recurrent or progressive cancer can be within a previously radiated site

          8. Patients must have received one or two prior systemic therapies, one of which
             contained a platinum compound. No prior Bortezomib or antiangiogenic agent is
             permitted. Prior radiation is permitted; however, at least two weeks must have elapsed
             since the completion of prior radiation therapy and patients must have recovered from
             all associated toxicities at the time of registration. At least two weeks must have
             elapsed since surgery (thoracic or other major surgeries) and patients must have
             recovered from all associated toxicities at the time of registration.

          9. Patients must have a serum creatinine </= the institutional upper limit of normal
             (i.e. 1.5 mg/dL) AND a creatinine clearance >/= 40 cc/min determined by either urine
             collection and testing or calculation using the following formula: Calculated
             Creatinine Clearance = (140 - age) * Weight(kg) * (0.85 if female)/ 72 * creatinine
             (mg/dL)

         10. Patients must have an Absolute neutrophil count (ANC)>/= 2,000/µl and platelet count
             >/= 100,000/µl obtained within 28 days prior to registration. Hemoglobin: >9.0 *
             10^9/L

         11. Patients must have adequate hepatic function documented by a serum bilirubin </=
             institutional upper limit of normal (1.0) and liver enzymes (serum glutamic
             oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT)) </= 3.0
             * the institutional upper limit of normal obtained within 28 days prior to
             registration

         12. Peripheral neuropathy, if present, must be < Grade 2 (NCI Common Terminology Criteria
             for Adverse Events Version 3.0).

         13. Patients known to be HIV-positive and taking HAART therapy are not eligible due to
             possible pharmacokinetic interactions

         14. Patients must not be planning to receive any other concomitant anticancer treatment
             including chemotherapy, radiation therapy, biologic agents or any other
             investigational drugs

         15. Patient must be >/= 18 years of age.

         16. Patients must be informed of the investigation nature of this study and must sign and
             give written informed consent in accordance with institutional and federal guidelines.

        Exclusion Criteria:

          1. Patients meeting any of the following exclusion criteria are not to be enrolled in the
             study. Participation in an experimental drug study within 4 weeks of the first
             treatment on this trial: Blood pressure > 140/90 mm Hg, History of stroke within 6
             months, Clinically significant peripheral vascular disease, Evidence of bleeding
             diathesis or coagulopathy, Presence of central nervous system or brain metastases

          2. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to Day 0, or anticipation of need for major surgical procedure during the course
             of the study.

          3. Minor surgical procedures such as fine needle aspirations or core biopsies within 7
             days prior to Day 0

          4. Urine protein: creatinine ratio >/= 1.0 at screening

          5. Serious non-healing wound, ulcer, or bone fracture

          6. Myocardial infarction within 6 months prior to enrollment or has New York Heart
             Association (NYHA) Class II or heart failure, unstable angina, severe uncontrolled
             ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active
             conduction system abnormalities. Prior to study entry, and ECG abnormality at
             Screening has to be documented by the investigator as not medically relevant

          7. Patients with squamous histology

          8. Patients with hematemesis or more than ½ teaspoon of hemoptysis within 6 months of
             study entry.

          9. Patients requiring full dose oral or parenteral anticoagulation.

         10. Abdominal fistula, GI perforation, or abdominal abscess within the last 6 months

         11. Patient has hypersensitivity to boron or mannitol

         12. Female subject is pregnant or breast-feeding. Confirmation that the subject is not
             pregnant must be established by a negative serum beta-human chorionic gonadotropin
             (beta-hCG) pregnancy test result obtained during screening. Pregnancy testing is not
             required for post-menopausal or surgically sterilized women. Patient has received
             other investigational drugs within 28 days before enrollment

         13. Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study

         14. No other prior or concurrent malignancy is allowed except for: non-melanoma skin
             cancers, in situ cervical cancer, and any cancer from which the patient has been
             disease-free for 3 years or more.

         15. Pregnant or nursing women may not participate in this trial because of the increased
             risk of fetal harm including fetal death from the chemotherapeutic agents. Women/men
             of reproductive potential may not participate unless they have agreed to use an
             effective contraceptive method.

         16. Patients requiring treatment with Nonsteroidal anti-inflammatory drugs (NSAIDS),
             antiplatelet agents, or aspirin > 325 mg/day
      "
NCT00670397,terminated,"
    safety issues
  ",0,phase 1,['head and neck cancer'],"[""['C76.0', 'C47.0', 'C49.0', 'C77.0', 'D17.0', 'D21.0', 'D36.11']""]",['hpph'],['CCCCCCOC(C)C1=C(C2=NC1=CC3=NC(=CC4=C(C5=C(CC(=C6C(C(C(=C2)N6)C)CCC(=O)O)C5=N4)O)C)C(=C3C)CC)C'],"
        DISEASE CHARACTERISTICS:

          -  Biopsy-confirmed diagnosis of 1 of the following:

               -  Mild to severe dysplasia

               -  Carcinoma in situ (CIS) of the oral cavity

                    -  Carcinoma must be less than 3mm thick

               -  Stage I (T1) squamous cell carcinoma of the oral cavity

          -  Recurrent or primary disease

          -  No T2 or greater squamous cell carcinoma, exophytic CIS, or dysplasia lesions

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Total bilirubin ≤ 2.0 mg/dL

          -  Creatinine ≤ 2.0 mg/dL

          -  Alkaline phosphatase ≤ 3 times the upper limit of normal (ULN)

          -  SGOT ≤ 3 times ULN

          -  Not pregnant

          -  Fertile patients must use effective contraception

          -  No porphyria or hypersensitivity to porphyrin or porphyrin-like compounds

        PRIOR CONCURRENT THERAPY:

          -  Prior therapy of any type allowed

          -  More than 4 weeks since prior and no concurrent chemotherapy or radiotherapy
      "
NCT00327327,completed,,1,phase 1,['pancreatic adenocarcinoma'],"[""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']""]","['imexon', 'gemcitabine']","['C1C2N1C(=O)N=C2N', 'C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F']","
        Inclusion Criteria:

          -  Inoperable cancer of the pancreas.

          -  Blood cell counts and blood chemistries in or near normal range.

          -  Able to perform the activities of daily living.

          -  A projected life expectancy of at least 2 months.

          -  If female, neither pregnant nor nursing.

          -  Willing to use contraceptives to prevent pregnancy.

          -  No other serious illnesses.

          -  No other active malignancy.

          -  No serious infections.

          -  No current other drug therapy for the cancer or steroid therapy.

          -  Prior radiation is permitted as is chemotherapy given during radiation or to prevent
             relapse after surgical removal of the disease.

        Exclusion Criteria:

          -  Prior chemotherapy for metastatic disease.

          -  Brain metastases
      "
NCT00555048,terminated,"
    low accrual
  ",0,phase 1/phase 2,"['graft versus host disease', 'leukemia', 'myelodysplastic syndromes', 'myelodysplastic/myeloproliferative diseases']","[""['D89.810', 'D89.811', 'D89.813', 'D89.812']"", ""['C95.91', 'C95.92', 'Z80.6', 'Z85.6', 'C90.11', 'C90.12', 'C91.01']"", ""['D46.9', 'D46.C', 'D46.Z']""]","['busulfan', 'cyclophosphamide', 'methotrexate', 'tacrolimus']","['Status: 503', 'Status: 503', 'Status: 503', 'Status: 503']","
        DISEASE CHARACTERISTICS:

          -  Confirmed diagnosis of one of the following:

               -  Primary acute myeloid leukemia (AML) meeting any of the following criteria:

                    -  First complete remission (CR; defined as < 5% blasts in marrow) with
                       high-risk features as defined by failure to achieve remission by day 21
                       after induction chemotherapy, or the presence of chromosomal abnormalities
                       involving any of the following:

                         -  -5/del(5q)

                         -  -7/del(7q)

                         -  Inversion 3q

                         -  Abnormalities of 11q23, 20q, 21q, del(9q),

                         -  Translocation 6;9

                         -  Translocation 9;22

                         -  Abnormalities of 17p

                         -  Complex karyotype with ≥ 3 abnormalities

                    -  Second CR or subsequent in remission

                    -  Refractory or relapsed disease

               -  Secondary AML in remission or relapse

               -  Chronic myelogenous leukemia (CML) in accelerated or blast phase meeting the
                  following criteria:

                    -  Accelerated phase is defined by any one of the following:

                         -  Blasts 10% to 19% of peripheral blood white cells or bone marrow cells

                         -  Peripheral blood basophils ≥ 20%

                         -  Persistent thrombocytopenia (< 100,000/mm³) unrelated to therapy, or
                            persistent thrombocytosis (> 1,000,000/mm³) unresponsive to therapy

                         -  Increasing spleen size and increasing WBC count unresponsive to therapy

                         -  Cytogenetic evidence of clonal evolution (i.e., the appearance of an
                            additional genetic abnormality that was not present in the initial
                            specimen at the time of diagnosis of chronic phase CML)

                    -  Blast phase is defined by any of the following:

                         -  Blasts ≥ 20% of peripheral blood white cells or bone marrow cells

                         -  Extramedullary blast proliferation

                         -  Large foci or clusters of blasts in bone marrow biopsy

               -  Primary myelodysplastic syndromes (MDS) with an IPSS score > 1.5

               -  Secondary MDS with any IPSS score

               -  Primary acute lymphoblastic leukemia meeting any of the following criteria:

                    -  First CR (< 5% blasts in marrow) with high-risk features as defined by 1 of
                       the following:

                         -  Failure to achieve remission after first induction chemotherapy

                         -  Presence of chromosomal abnormalities including hypodiploidy or
                            abnormalities of 11q23 or translocation 9;22

                    -  Second CR or subsequent in remission

                    -  Refractory or relapsed disease

          -  No patients for whom a suitable HLA genotypically identical sibling or fully matched
             HLA-A, -B, -C, and -DRB1 unrelated donor is available

          -  No active CNS involvement with disease

          -  Donors must meet the following criteria:

               -  Unrelated volunteer donors who are mismatched for more than one HLA-class I
                  alleles or antigens or for one HLA-class I antigen, but matched by
                  high-resolution typing at HLA-DRB1 and -DQB1, OR who are mismatched for one or
                  more HLA-class II alleles or antigens, but matched by high-resolution typing at
                  HLA-A, -B, and -C

                    -  No two-antigen mismatch at a single HLA-A, -B, or -C locus

                    -  No mismatching of class I and class II HLA

                    -  Matching must be based on results of high-resolution typing at HLA-A, -B,
                       -C, - DRB1, and -DQB1

        PATIENT CHARACTERISTICS:

          -  Karnofsky performance status 50-100%

          -  No symptomatic coronary artery disease or symptomatic congestive heart failure

          -  No hepatic disease with transaminases or bilirubin > 2 times upper limit of normal
             except for isolated hyperbilirubinemia attributed to Gilbert's syndrome

          -  No severe hypoxemia with room air P_AO_2 < 70, supplemental oxygen-dependence, or DLCO
             < 60% predicted

          -  No impaired renal function with creatinine > 2 times upper limit of normal or
             creatinine clearance < 50% normal

          -  Not HIV seropositive

          -  Not pregnant or breast-feeding

          -  Fertile patients must use effective contraception

          -  No active infections that are untreated or failing to respond to appropriate therapy

        PRIOR CONCURRENT THERAPY:

        Inclusion criteria:

          -  See Disease Characteristics

        Exclusion criteria:

          -  Prior allogeneic or autologous bone marrow, peripheral blood stem cell, or umbilical
             cord blood transplantation using a high-dose total-body irradiation regimen
      "
NCT01155713,completed,,1,phase 1,"['neoplasm', 'cancer', 'tumors']","[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']"", ""['E88.3', 'Q85.81', 'R97.8', 'C49.A0', 'C49.A1', 'C49.A2', 'C49.A5']""]",['tki258'],['CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=C(C5=C(C=CC=C5F)NC4=O)N'],"
        Inclusion Criteria:

          -  Patients with an advanced solid tumor which has progressed despite standard therapy,
             or for which no standard therapy exists

          -  World Health Organization (WHO) performance status ≤ 2

          -  Patient must meet protocol-specified laboratory values

        Exclusion Criteria:

          -  Patients with brain cancer

          -  Patients who have concurrent severe and/or uncontrolled medical conditions which could
             compromise participation in the study

          -  Patients who have not recovered from previous anti-cancer therapies

          -  Female patients who are pregnant, breast feeding, or not willing to use an effective
             method of birth control

        Other protocol-defined inclusion/exclusion criteria may apply
      "
NCT01244620,terminated,"
    safety issue: the trial was prematurely terminated on dec 9, 2010, due to safety concerns,
    specifically new emerging evidence of hepatic injury.
  ",0,phase 1,['pulmonary arterial hypertension'],"[""['I27.21']""]","['sitaxentan', 'tadalafil', 'sitaxsentan', 'tadalafil', 'sitaxsentan', 'sildenafil']","['CC1=CC2=C(C=C1CC(=O)C3=C(C=CS3)S(=O)(=O)NC4=C(C(=NO4)C)Cl)OCO2', 'CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36', 'CC1=CC2=C(C=C1CC(=O)C3=C(C=CS3)S(=O)(=O)NC4=C(C(=NO4)C)Cl)OCO2', 'CN1CC(=O)N2C(C1=O)CC3=C(C2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36', 'CC1=CC2=C(C=C1CC(=O)C3=C(C=CS3)S(=O)(=O)NC4=C(C(=NO4)C)Cl)OCO2', 'CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C']","
        Inclusion Criteria:

          -  Healthy male subjects and women of non-child bearing potential between the ages of 21
             and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities
             identified by a detailed medical history, full physical examination, including blood
             pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests.

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >45 kg (99 lbs).

          -  An informed consent document signed and dated by the subject or a legally acceptable
             representative.

          -  Subjects who are willing and able to comply with scheduled visits, treatment plan,
             laboratory tests, and other study procedures.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing) or clinical findings at Screening.

          -  A positive urine drug screen.

          -  Subjects with hepatic dysfunction, defined as aspartate aminotransferase (AST) and/or
             alanine aminotransferase (ALT) >1.5 times the upper limit of the normal range at
             Screening. A retest may be done if AST and/or ALT within 1.5- to 2- times the upper
             limit of the normal range at Screening, and the average of the first and repeated test
             values should be used to decide the eligibility.
      "
NCT00158886,terminated,,0,phase 1,"['carcinoma, renal cell']","[""['C22.0', 'C4A.9', 'C7B.1', 'C4A.0', 'C4A.31', 'C4A.51', 'C4A.8']""]",['topotecan'],['CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O'],"
        Inclusion Criteria:

          -  Patients with histologically confirmed rectal cancer.

          -  Candidates for preoperative radiotherapy.

          -  Primary tumor at least 3cm and clinical stage of T2, T3, or T4 and any N according to
             the Astler-Coller modification of the Dukes staging system.

          -  Eastern Cooperative Oncology Group (ECOG) performance status less than 2.

          -  Diagnosis of rectal cancer should be no more than 90 days from start of therapy.

          -  Evaluation at the H. Lee Moffitt Cancer Center.

          -  Recovery from prior surgery and life expectancy at least 3 months.

        Exclusion Criteria:

          -  A primary tumor totally excised.

          -  Recurrent rectal cancer that failed initial treatment.

          -  Exposure to topotecan, infection, immunodeficiencies, conditions of the
             gastrointestinal (GI) tract which would affect absorption, medication that maintains
             motility/gastric emptying.

          -  Any concomitant malignancy within the last five years.

          -  Severe medical problems unrelated to the malignancy which would limit compliance with
             the study.

          -  Patients of child bearing potential.

          -  Not practicing adequate contraception.

          -  Patients who are pregnant or lactating.

          -  Use of an investigational drug within 30 days or 5 half-lives of the first dose.
      "
NCT00387153,terminated,"
    last subject enrolled experienced bradycardia; study was terminated by sponsor.
  ",0,phase 1,['cancer'],"[""['C05.2', 'C10.0', 'C16.0', 'C16.4', 'C17.0', 'C17.1', 'C17.2']""]",['mpc-2130'],['Status: 503'],"
        Inclusion Criteria:

          1. Be capable of understanding the informed consent form (ICF) and complying with the
             protocol, and must sign the ICF prior to the performance of any study related
             procedures;

          2. Have cancer that is nonresponsive despite prior treatment with current standard of
             care regimens or for whom there are no available effective therapies;

          3. Have measurable or evaluable neoplastic disease;

          4. Be greater than or equal to age 18;

          5. Have and ECOG Performance Status score of less than or equal to 2;

          6. Have adequate organ function defined by:

               1. Liver function tests (AST & ALT) less than or equal to 3 times the upper limit of
                  normal (ULN);

               2. Bilirubin less than or equal to 1.5 X ULN;

               3. Serum Creatinine less than or equal to 1.5 X ULN;

               4. Hemoglobin greater than or equal to 8.0 g/dL;

          7. Have recovered or stabilized from clinically significant toxicities of prior
             chemotherapy, surgery, or radiotherapy;

          8. Have left ventricular ejection fraction (LVEF) of greater than or equal to 45% by
             multiple gated acquisition (MUGA) scan or echocardiogram.

        Exclusion Criteria:

          1. Have had a prior serious, uncontrollable hypersensitivity reaction to Cremophor EL;

          2. Be pregnant or lactating (women of childbearing potential must use appropriate birth
             control (abstinence, barrier methods, oral contraceptives and/or intrauterine devices)
             during the entire duration of the study, or the patient must be surgically sterile
             (with documentation in the patient's medical records);

          3. Receive any other anticancer treatment or investigational therapy within 14 days prior
             to day 1; or within 6 weeks after prior mitomycin C or nitrosourea. Patients with
             advanced prostate cancer may continue to receive leutinizing hormone-releasing hormone
             (LHRH) therapy while in this study;

          4. Have previously enrolled in this trial. -
      "
NCT00879619,terminated,"
    terminated due to slow accrual.
  ",0,phase 1/phase 2,"['prostate cancer', 'adenocarcinoma of the prostate', 'recurrent prostate cancer', 'stage i prostate cancer', 'stage iii prostate cancer', 'stage iv prostate cancer']","[""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']"", ""['C22.0', 'C22.1', 'C4A.9', 'C7B.1', 'D09.9', 'C4A.0', 'C4A.31']"", ""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']"", ""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']"", ""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']"", ""['C61', 'D29.1', 'D40.0', 'Z15.03', 'Z80.42', 'Z85.46', 'Z12.5']""]","['sunitinib malate', 'docetaxel', 'prednisone']","['CCN(CC)CCNC(=O)C1=C(NC(=C1C)C=C2C3=C(C=CC(=C3)F)NC2=O)C.C(C(C(=O)O)O)C(=O)O', 'CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O', 'CC12CC(=O)C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C']","
        Inclusion Criteria

          -  Subjects must have a histological diagnosis of adenocarcinoma of the prostate

          -  Age ≥ 18

          -  Subjects must have metastatic prostate cancer deemed to be unresponsive or refractory
             to hormone therapy by one or more of the following (despite androgen deprivation and
             anti-androgen withdrawal when applicable) check all that apply.

          -  Subjects may have received prior surgery. However, at least 21 days must have elapsed
             since completion of surgery and Subject must have recovered from all side effects.

          -  Subjects must have adequate hepatic function as defined by:

          -  a serum bilirubin ≤1.5 x the institutional upper limit of normal (IULN),

          -  Serum glutamic-oxaloacetic transaminase (SGOT) or serum glutamic-pyruvic transaminase
             (SGPT) ≤2.5 x the institutional upper limit of normal obtained within 14 days prior to
             start of therapy

          -  Subjects must have 2 pre-study PSA > 2ng/ml at least 1 week apart within 28 days prior
             to start of therapy

          -  Subjects must have been surgically or medically castrated. If method of castration is
             luteinizing hormone-releasing hormone (LHRH) agonist (leuprolide or goserelin), then
             the Subject should be willing to continue the use of LHRH agonists. Castration using
             LHRH agonist should not be interrupted and subjects who have stopped treatment should
             be willing to restart.

          -  Subjects must not take vitamins, herbs, or micronutrient supplement within 28 days
             prior to start of therapy.

          -  Prior external beam radiation therapy (to less than 30% of the bone marrow only) is
             allowed. This includes prior use of samarium, but subjects can not have received prior
             strontium. At least 28 days must have elapsed since the completion of radiation
             therapy and the Subject must have recovered from side effects. Soft tissue disease
             which has been radiated in the prior 2 months is not assessable as measurable disease.

          -  Subjects with a history of myocardial infarction are not eligible. Subjects must have
             a baseline EKG to rule out underlying cardiac disease within 42 days prior to
             registration. Subjects with a history of cardiac disease, specifically congestive
             heart failure (CHF) are ineligible unless their disease is well-controlled. Subjects
             with history of cardiovascular accident (CVA) or atrial fibrillation are ineligible.

          -  Subjects with a history of brain metastases or who currently have treated or untreated
             brain metastases are not eligible. Subjects with clinical evidence of brain metastases
             must have a brain CT or MRI negative for metastatic disease within 56 days prior to
             registration.

             *Liver function tests should be evaluated prior to each treatment.

          -  Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status
             0-2.

          -  Subjects must have an adequate renal function as defined by:

          -  a serum creatinine ≤1.5 x the institutional upper limit of normal obtained within 14
             days prior to start of therapy and a urine protein: creatinine (UPC) ratio of ≤ 1.0.

          -  Subjects must have the following hematological criteria (minimal values):

          -  Absolute neutrophil count ≥ 1,500/mm³

          -  Hemoglobin of ≥ 8.0gm/dL,

          -  White blood cell count ≥ 2500,

          -  Platelets ≥ 75,000/mm³

          -  Subjects must be able to take oral medications

        Exclusion Criteria

          -  Subjects must not have received chemotherapy, biologic therapy or any other
             investigational drug for any reason within 28 days prior to start of therapy and must
             have recovered from toxicities of prior therapy to grade 1 or less with the exception
             of alopecia.

          -  Subjects may not have ongoing problems with bowel obstruction or short bowel syndrome
             characterized by grade 2 or greater diarrhea or malabsorptive disorders.

          -  Men of child bearing potential must be willing to consent to using effective
             contraception while on treatment and for at least 3 months thereafter.

          -  Subjects with a history of severe hypersensitivity reaction to docetaxel or other
             drugs formulated with polysorbate 80 will be excluded

          -  Subjects should not have psychological, familial, sociological, or geographical
             conditions that do not permit medical follow-up or compliance with the study protocol.

          -  Subjects should not have any medical life-threatening complications of their
             malignancies

          -  Subjects should not have a known severe and/or uncontrolled concurrent medical disease
             (e.g., uncontrolled diabetes, uncontrolled chronic renal or liver disease, active
             uncontrolled infection, or HIV).

          -  Subjects should not have current, recent (within 4 weeks of the first infusion of this
             study), or planned participation in an experimental drug study.

          -  Baseline blood pressure of < or equal to 150/100 mmHg. Subjects with a blood pressure
             reading above this level should be initiated on anti-hypertensive therapy and may be
             considered for protocol treatment when their blood pressure is adequately controlled.

          -  Subjects with New York Heart Association (NYHA) Grade II or greater congestive heart
             failure are not eligible. Subjects must have a baseline multiple gated acquisition
             scan (MUGA) or Echocardiogram with a calculated ejection fraction > or equal to 50%.

          -  Subjects with clinically significant peripheral vascular disease are not eligible.

          -  Subjects with evidence of bleeding diathesis or coagulopathy are not eligible.

          -  Subjects with central nervous system or brain metastases are not eligible.

          -  Subjects who had major surgical procedure, open biopsy, or significant traumatic
             injury within 28 days prior to Day 0, anticipation of need for major surgical
             procedure during the course of the study are not eligible.

          -  Subjects with minor surgical procedures, fine needle aspirations or core biopsies
             within 7 days prior to Day 0 are not eligible.

          -  Subjects with history of abdominal fistula, gastrointestinal perforation, or
             intra-abdominal abscess are not eligible.

          -  Subjects with serious, non-healing wound, ulcer, or bone fracture are not eligible.

          -  Subjects who are diagnosed of any other malignancy except non-melanomatous skin cancer
             in the past 5 years are not eligible.

          -  Subjects receiving anticoagulation therapy (e.g. Coumadin) prior to registration are
             not eligible. Subjects are permitted to have prior Coumadin for prophylaxis against
             agents that might produce blood clots. Subjects with low dose Aspirin (86mg) are
             acceptable.

          -  Subjects with active thrombophlebitis or hypercoagulability are not eligible. Subjects
             with known history of pulmonary embolus are not eligible.

          -  All Subjects must be informed and must sign and give written informed consent in
             accordance with institutional and federal guidelines. Subjects who are unable to
             comply with study and/or follow-up procedures are not eligible.
      "
NCT01105247,completed,,1,phase 1/phase 2,"['b-cell chronic lymphocytic leukemia', 'small lymphocytic lymphoma']","[""['C91.11', 'C91.12', 'C91.10']"", ""['S33.110S', 'S33.111S', 'S33.120S', 'S33.121S', 'S33.130S', 'S33.131S', 'S33.140S']""]",['pci-32765'],['C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N'],"
        Inclusion Criteria:

          1. FOR TREATMENT-NAIVE GROUP ONLY: Men and women ≥ 65 years of age with confirmed
             diagnosis of CLL/SLL, who require treatment per NCI or International Working Group
             guidelines 15-18

          2. FOR RELAPSED/REFRACTORY GROUP ONLY: Men and women ≥ 18 years of age with a confirmed
             diagnosis of relapsed/refractory CLL/SLL following previous therapy(ie, failed ≥ 2
             previous treatments for CLL/SLL and at least 1 regimen had to have had a purine analog
             [eg, fludarabine] for subjects with CLL)

          3. FOR HIGH-RISK RELAPSED/ REFRACTORYGROUP ONLY: Men and women ≥ 18 years of age with a
             confirmed diagnosis of relapsed/refractory CLL/SLL with suboptimal response to
             chemoimmunotherapy, defined as progression of disease within 24 months of initiation
             of a regimen containing at least a nucleoside analogue or bendamustine in combination
             with a monoclonal antibody or failure to respond to such a regimen. (Note: a minimum
             of 2 cycles of chemoimmunotherapy required for eligibility)

          4. ECOG performance status of ≤ 2

          5. Willing and able to participate in all required evaluations and procedures in this
             study protocol including swallowing capsules without difficulty

        Exclusion Criteria:

          1. Prior malignancy, except for adequately treated basal cell or squamous cell skin
             cancer, in situ cervical cancer, or other cancer from which the subject has been
             disease free for at least 2 years or which will not limit survival to < 2 years

          2. Any immunotherapy, chemotherapy, radiotherapy, or experimental therapy within 4 weeks
             before first dose of study drug (corticosteroids for disease-related symptoms allowed
             but require 1-week washout before study drug administration)

          3. Central nervous system (CNS) involvement by lymphoma

          4. Major surgery within 4 weeks before first dose of study drug

          5. Concomitant use of medicines known to cause QT prolongation or torsades de pointes

          6. Significant screening electrocardiogram (ECG) abnormalities including left bundle
             branch block, 2nd degree AV block type II, 3rd degree block, bradycardia, and QTc >
             470 msec

          7. Lactating or pregnant
      "
NCT00096486,completed,,0,phase 1/phase 2,['lung cancer'],"[""['C78.00', 'C78.01', 'C78.02', 'D14.30', 'D14.31', 'D14.32', 'C34.2']""]","['everolimus', 'gefitinib']","['CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC', 'COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4']","
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed non-small cell lung cancer (NSCLC) meeting 1 of the following
             stage criteria:

               -  Stage IIIB (unresectable, with malignant pleural or pericardial effusion)

               -  Stage IV disease

               -  Recurrent disease

          -  Measurable or evaluable indicator lesions

          -  Progressive disease after receiving ≥ 1 prior chemotherapy regimen that included
             cisplatin or carboplatin and docetaxel

          -  No uncontrolled brain or leptomeningeal metastases

               -  Must not require concurrent glucocorticoids for control of metastases

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Karnofsky 70-100% OR

          -  ECOG 0-2

        Life expectancy

          -  Not specified

        Hematopoietic

          -  WBC ≥ 3,000/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 9.0 g/dL

        Hepatic

          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  AST ≤ 2.5 times ULN

        Renal

          -  Creatinine ≤ 1.5 times ULN OR

          -  Creatinine clearance ≥ 60 mL/min

        Cardiovascular

          -  No congestive heart failure

          -  No New York Heart Association class III or IV heart disease

          -  No unstable angina

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No severe infection

          -  No severe malnutrition

          -  No other serious medical illness

          -  No other malignancy within the past 3 years except adequately treated basal cell or
             squamous cell skin cancer or carcinoma of the cervix

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent biologic therapy

          -  No concurrent immunotherapy

        Chemotherapy

          -  See Disease Characteristics

          -  No prior conventional chemotherapy for metastatic or recurrent NSCLC (phase II only)

          -  At least 4 weeks since prior chemotherapy

          -  No other concurrent chemotherapy

        Endocrine therapy

          -  See Disease Characteristics

          -  No concurrent oral steroids for management of skin toxicity

        Radiotherapy

          -  At least 4 weeks since prior radiotherapy

          -  No concurrent radiotherapy

        Surgery

          -  At least 4 weeks since prior major surgery

          -  No concurrent surgery for an identifiable lesion

        Other

          -  Recovered from all prior therapy

          -  No prior gefitinib, erlotinib, or other epidermal growth factor tyrosine kinase
             inhibitor

          -  No concurrent cytotoxic therapy (e.g., methotrexate for rheumatoid arthritis)

          -  No other concurrent oncolytic agents
      "
